[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "alpaca-7b_response": "Acrokeratosis paraneoplastica is also known as \"Bazex's disease\" or \"Bazex syndrome\". It is a rare, chronic, and progressive skin disorder characterized by thickening and hardening of the skin on the palms and soles, as well as on other areas of the body. It is often associated with cancer, particularly breast cancer. Other symptoms may include skin lesions, nail changes, and hair loss. Treatment includes topical and systemic medications, phototherapy, and surgery.",
    "alpaca-7b_fact_raw": "1. Acrokeratosis paraneoplastica is also known as \"Bazex's disease.\"\n2. Acrokeratosis paraneoplastica is also referred to as \"Bazex syndrome.\"\n3. The disorder is characterized by thickening and hardening of the skin on the palms and soles.\n4. Acrokeratosis paraneoplastica is often associated with cancer, particularly breast cancer.\n5. Treatment for Acrokeratosis paraneoplastica may include topical and systemic medications, phototherapy, and surgery.",
    "alpaca-7b_fact": [
      "Acrokeratosis paraneoplastica is also known as \"Bazex's disease.\"",
      "Acrokeratosis paraneoplastica is also referred to as \"Bazex syndrome.\"",
      "The disorder is characterized by thickening and hardening of the skin on the palms and soles.",
      "Acrokeratosis paraneoplastica is often associated with cancer, particularly breast cancer.",
      "Treatment for Acrokeratosis paraneoplastica may include topical and systemic medications, phototherapy, and surgery."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Acrokeratosis paraneoplastica is often associated with cancer, particularly squamous cell carcinomas of the upper aerodigestive tract.\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "alpaca-7b_response": "Yes, Weaver syndrome is similar to Sotos, as both are disorders that affect the development of the cerebellum and result in various physical and intellectual disabilities. Weaver syndrome is characterized by an abnormally large cerebellum, macrocephaly, and developmental delays, while Sotos is characterized by a smaller cerebellum, microcephaly, and developmental delays. Both disorders can cause seizures, intellectual disability, and physical abnormalities such as extra fingers or toes, but Sotos is more commonly associated with heart defects and Weaver syndrome is more commonly associated with hearing loss. Both disorders are caused by genetic mutations and can be inherited.",
    "alpaca-7b_fact_raw": "1. Weaver syndrome and Sotos are disorders that affect the development of the cerebellum.\n2. Weaver syndrome is characterized by an abnormally large cerebellum, macrocephaly, and developmental delays.\n3. Sotos syndrome is characterized by a smaller cerebellum, microcephaly, and developmental delays.\n4. Sotos syndrome is more commonly associated with heart defects.\n5. Weaver syndrome is more commonly associated with hearing loss.",
    "alpaca-7b_fact": [
      "Weaver syndrome and Sotos are disorders that affect the development of the cerebellum.",
      "Weaver syndrome is characterized by an abnormally large cerebellum, macrocephaly, and developmental delays.",
      "Sotos syndrome is characterized by a smaller cerebellum, microcephaly, and developmental delays.",
      "Sotos syndrome is more commonly associated with heart defects.",
      "Weaver syndrome is more commonly associated with hearing loss."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome and Sotos syndrome are disorders that affect growth and development, but they are not specifically characterized by affecting the development of the cerebellum.\n2. FALSE [correction]: Weaver syndrome is characterized by rapid growth beginning in the prenatal period, macrocephaly (large head size), and developmental delays, but it does not specifically involve an abnormally large cerebellum.\n3. FALSE [correction]: Sotos syndrome is characterized by overgrowth and a larger head size (macrocephaly), not a smaller cerebellum and microcephaly.\n4. UNKNOWN: While individuals with Sotos syndrome may have congenital heart defects, it is not clear from the statement whether it is more commonly associated with heart defects compared to other syndromes or the general population.\n5. UNKNOWN: While hearing loss can occur in individuals with Weaver syndrome, it is not clear from the statement whether it is more commonly associated with Weaver syndrome compared to other syndromes or the general population.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "alpaca-7b_response": "The JASPAR database has been released in several versions. The current version is version 2021.0, released in April 2021. Previous versions include version 2019.0 (April 2019), version 2017.0 (April 2017), version 2015.0 (April 2015), version 2013.0 (April 2013), version 2011.0 (April 2011), version 2009.0 (April 2009), version 2007.0 (April 2007), version 2005.0 (April 2005), version 2003.0 (April 2003), and version 2001.0 (April 2001). \nThe JASPAR database is a community resource and is freely available for non-commercial use. It can be downloaded from the JASPAR website.",
    "alpaca-7b_fact_raw": "1. The current version of the JASPAR database, as of the provided information, is version 2021.0.\n2. Version 2021.0 of the JASPAR database was released in April 2021.\n3. The JASPAR database has versions dating back to 2001, with releases approximately every two years.\n4. The JASPAR database is freely available for non-commercial use.\n5. The JASPAR database can be downloaded from the JASPAR website.",
    "alpaca-7b_fact": [
      "The current version of the JASPAR database, as of the provided information, is version 2021.0.",
      "Version 2021.0 of the JASPAR database was released in April 2021.",
      "The JASPAR database has versions dating back to 2001, with releases approximately every two years.",
      "The JASPAR database is freely available for non-commercial use.",
      "The JASPAR database can be downloaded from the JASPAR website."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The current version of the JASPAR database, as of the provided information, is version 2022.0.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "alpaca-7b_response": "The viral KP4 protein is a key component of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome and is involved in the regulation of viral gene expression. It is also involved in the modulation of cell growth and cell cycle progression, as well as in the induction of cellular senescence. KP4 has also been shown to interact with cellular proteins and modulate their activity, suggesting that it may play a role in the modulation of cellular processes.",
    "alpaca-7b_fact_raw": "1. The KP4 protein is a component of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome.\n2. The KP4 protein is involved in the regulation of viral gene expression.\n3. The KP4 protein plays a role in the modulation of cell growth and cell cycle progression.\n4. The KP4 protein is involved in the induction of cellular senescence.\n5. The KP4 protein can interact with cellular proteins and modulate their activity.",
    "alpaca-7b_fact": [
      "The KP4 protein is a component of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome.",
      "The KP4 protein is involved in the regulation of viral gene expression.",
      "The KP4 protein plays a role in the modulation of cell growth and cell cycle progression.",
      "The KP4 protein is involved in the induction of cellular senescence.",
      "The KP4 protein can interact with cellular proteins and modulate their activity."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a protein known as Kaposin B, not KP4. KP4 is a viral protein from Ustilago maydis, a type of fungus.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and unknown responses are due to the fact that the KP4 protein is not a component of KSHV, but rather from a different organism. Therefore, any specific functions attributed to KP4 in the context of KSHV would be incorrect. Without additional context about the KP4 protein's functions in its correct organism, it's not possible to accurately assess statements 2 through 5.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "alpaca-7b_response": "Yes, DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. It is a potent thyroid hormone agonist that is believed to have a greater stimulatory effect on the metabolic rate than T3 or T4. DITPA is also believed to be more potent than T3 in treating hypothyroidism and has been used in some clinical studies to treat patients with hypothyroidism who have not responded to T4 or T3. DITPA has also been studied in animal models for its potential to reduce fat mass and increase lean mass. In addition, DITPA has been studied in clinical trials for its potential to improve cognitive function in patients with hypothyroidism.  It is important to note that DITPA is not currently approved for use in humans, and its use is considered experimental and investigational.  Therefore, it is important to consult with a qualified healthcare professional before using DITPA or any other experimental or investigational drug or treatment.  Additionally, it is important to understand the potential risks and benefits associated with the use of DITPA.  As with any drug or treatment, it is important to understand the potential risks and benefits associated with its use.  It is also important to understand that the safety and effectiveness of DITPA has not been established in pregnant women, nursing mothers, children, and other special populations.  Therefore, it is important to consult with a qualified healthcare professional before using DITPA or any other experimental or investigational drug or treatment.  Additionally, it is important to understand the potential risks and benefits associated with the use of DITPA.  As with any drug or treatment, it is important to understand the potential risks and benefits associated with its use.  It is also important to understand that the safety and effectiveness of DITPA has not been established in pregnant women, nursing mothers, children, and other special populations.  Therefore, it is important to consult with a qualified healthcare professional before using DITPA or any other experimental or investigational drug or treatment.  Additionally, it is important to understand the potential risks and benefits associated with the use of DITPA.  As with any drug or treatment, it is important to understand the potential risks and benefits",
    "alpaca-7b_fact_raw": "1. DITPA (3,5-diiodothyronine) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is considered to have a greater stimulatory effect on the metabolic rate than T3 or T4.\n3. DITPA has been used in clinical studies to treat patients with hypothyroidism who have not responded to T4 or T3.\n4. DITPA has been studied for its potential to reduce fat mass and increase lean mass in animal models.\n5. DITPA is not currently approved for use in humans and is considered experimental and investigational.",
    "alpaca-7b_fact": [
      "DITPA (3,5-diiodothyronine) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is considered to have a greater stimulatory effect on the metabolic rate than T3 or T4.",
      "DITPA has been used in clinical studies to treat patients with hypothyroidism who have not responded to T4 or T3.",
      "DITPA has been studied for its potential to reduce fat mass and increase lean mass in animal models.",
      "DITPA is not currently approved for use in humans and is considered experimental and investigational."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: DITPA is considered to have a less potent stimulatory effect on the metabolic rate than T3 (triiodothyronine) or T4 (thyroxine).\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "alpaca-7b_response": "The COUGER tool is a software development tool that helps developers to quickly create, debug, and optimize their software applications. It provides a graphical user interface that allows developers to easily create, debug, and optimize software applications with minimal effort. COUGER also provides an interactive debugger, a profiler, and other tools to help developers identify and fix problems in their software applications. It also provides an optimization tool that can be used to improve the performance of the software applications. COUGER also provides an automated testing tool that can be used to test software applications and identify bugs.",
    "alpaca-7b_fact_raw": "1. The COUGER tool is a software development tool.\n2. COUGER provides a graphical user interface for software development.\n3. The tool includes an interactive debugger.\n4. COUGER features a profiler to help developers identify problems.\n5. It offers an optimization tool to improve software application performance.",
    "alpaca-7b_fact": [
      "The COUGER tool is a software development tool.",
      "COUGER provides a graphical user interface for software development.",
      "The tool includes an interactive debugger.",
      "COUGER features a profiler to help developers identify problems.",
      "It offers an optimization tool to improve software application performance."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the COUGER tool, it is not possible to determine the accuracy of these statements. The term \"COUGER\" does not correspond to a widely recognized software development tool as of my knowledge cutoff date, and without additional context, the details about its features and capabilities cannot be verified.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "alpaca-7b_response": "At present, there are no drugs that have been proven to be effective in treating Tick-borne Encephalitis. The best form of treatment is prevention, by avoiding tick-infested areas and wearing protective clothing and repellents. If you do become ill, supportive care and symptomatic treatment is the best course of action. This includes rest, fluids, and medications to reduce fever and pain. In more severe cases, intensive care may be necessary.",
    "alpaca-7b_fact_raw": "1. There are no drugs proven to be effective in treating Tick-borne Encephalitis.\n2. Prevention is the best form of treatment for Tick-borne Encephalitis.\n3. Supportive care and symptomatic treatment are recommended for Tick-borne Encephalitis.\n4. Rest, fluids, and medications to reduce fever and pain are part of the symptomatic treatment for Tick-borne Encephalitis.\n5. In severe cases of Tick-borne Encephalitis, intensive care may be necessary.",
    "alpaca-7b_fact": [
      "There are no drugs proven to be effective in treating Tick-borne Encephalitis.",
      "Prevention is the best form of treatment for Tick-borne Encephalitis.",
      "Supportive care and symptomatic treatment are recommended for Tick-borne Encephalitis.",
      "Rest, fluids, and medications to reduce fever and pain are part of the symptomatic treatment for Tick-borne Encephalitis.",
      "In severe cases of Tick-borne Encephalitis, intensive care may be necessary."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: As of my knowledge cutoff in 2023, there are no specific antiviral drugs proven to be effective in treating Tick-borne Encephalitis (TBE). Treatment is mainly supportive.\n2. TRUE: Since there is no cure for TBE, prevention through vaccination and avoiding tick bites is considered the best form of treatment.\n3. TRUE: Supportive care and symptomatic treatment are indeed recommended for managing Tick-borne Encephalitis, as there is no specific cure.\n4. TRUE: Rest, fluids, and medications to reduce fever and pain are typical symptomatic treatments for many viral infections, including Tick-borne Encephalitis.\n5. TRUE: In severe cases of Tick-borne Encephalitis, which can involve central nervous system complications, intensive care may be required to manage the symptoms and support vital functions.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "alpaca-7b_response": "The Genome Browser Database for DNA shape annotations is available at the European Bioinformatics Institute (EBI). It contains a variety of data related to DNA shape, including shape features, annotations, and comparative genomics. The database is accessible through the EBI's web interface and can be used to search for and view shape features from a variety of species. It also provides tools for comparative genomics, allowing users to compare the shape features of different species. \nThe database also includes a variety of tools for analyzing and visualizing shape features. These tools allow users to view the shape features of a given species, compare them to other species, and gain insights into the evolution of DNA shape. \nIn addition, the database provides a platform for researchers to share and collaborate on shape feature data. Through the database, researchers can upload and share their own shape feature data, as well as view and download data from other researchers. This allows for a greater understanding of the diversity of DNA shape features and their evolution. \nOverall, the Genome Browser Database for DNA shape annotations provides a valuable resource for researchers to store, analyze, and visualize shape feature data. It allows for the comparison of shape features across different species and provides a platform for researchers to share and collaborate on shape feature data. It also provides tools for comparative genomics and visualization of shape features, which can be used to gain insights into the evolution of DNA shape. \n### References\nThis article was adapted from the Wikipedia article \"Genome Browser Database for DNA Shape Annotations\".",
    "alpaca-7b_fact_raw": "1. The Genome Browser Database for DNA shape annotations is available at the European Bioinformatics Institute (EBI).\n2. The database contains data related to DNA shape, including shape features, annotations, and comparative genomics.\n3. The database is accessible through the EBI's web interface.\n4. The database provides tools for comparative genomics, allowing users to compare the shape features of different species.\n5. Researchers can upload and share their own shape feature data on the database.",
    "alpaca-7b_fact": [
      "The Genome Browser Database for DNA shape annotations is available at the European Bioinformatics Institute (EBI).",
      "The database contains data related to DNA shape, including shape features, annotations, and comparative genomics.",
      "The database is accessible through the EBI's web interface.",
      "The database provides tools for comparative genomics, allowing users to compare the shape features of different species.",
      "Researchers can upload and share their own shape feature data on the database."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nWithout specific information about the Genome Browser Database for DNA shape annotations being available at the European Bioinformatics Institute (EBI), it is difficult to confirm the accuracy of statements 1, 3, and 5. While the EBI does host a variety of databases and tools for genomics research, without explicit confirmation that this particular database is hosted there, the truth of these statements cannot be determined. However, statements 2 and 4 are generally true for databases of this nature, as they typically contain such data and provide comparative genomics tools.",
    "alpaca-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "alpaca-7b_response": "Mutations in the EZH2 gene have been associated with various syndromes, including:\n- Progeria \n- Hutchinson-Gilford Progeria Syndrome \n- Wiedemann-Steiner Syndrome \n- Silver-Russell Syndrome \n- Beckwith-Wiedemann Syndrome \n- Angelman Syndrome \n- Prader-Willi Syndrome \n- Coffin-Siris Syndrome \n- Sotos Syndrome \n- Bardet-Biedl Syndrome \n- Laurence-Moon Syndrome \n- Miller-Dieker Syndrome \n- Cornelia de Lange Syndrome \n- Ocular Albinism \n- Hearing Loss \n- Developmental Delay \n- Cleft Palate \n- Hydrocephalus \n- Scoliosis \n- Renal Anomalies \n- Cardiac Anomalies \n- Cervical Rib \n- Spinal Deformity \n- Limb Reduction Defects \n- Craniofacial Abnormalities \n- Hypotonia \n- Seizures \n- Intellectual Disability \n- Autism Spectrum Disorder \n- Neurodevelopmental Delay \n- Neurological Disorder \n- Cancer Risk \n- Increased Risk of Diabetes \n- Increased Risk of Obesity \n- Increased Risk of Infertility \n- Increased Risk of Miscarriage \n- Increased Risk of Birth Defects \n- Increased Risk of Premature Aging \n- Increased Risk of Hair Loss \n- Increased Risk of Skin Discoloration \n- Increased Risk of Cataracts \n- Increased Risk of Glaucoma \n- Increased Risk of Arrhythmia \n- Increased Risk of Stroke \n- Increased Risk of Alzheimer's Disease \n- Increased Risk of Parkinson's Disease \n- Increased Risk of Autoimm",
    "alpaca-7b_fact_raw": "1. Mutations in the EZH2 gene are associated with Hutchinson-Gilford Progeria Syndrome.\n2. Mutations in the EZH2 gene are associated with Wiedemann-Steiner Syndrome.\n3. Mutations in the EZH2 gene are associated with Silver-Russell Syndrome.\n4. Mutations in the EZH2 gene are associated with Beckwith-Wiedemann Syndrome.\n5. Mutations in the EZH2 gene are associated with Angelman Syndrome.",
    "alpaca-7b_fact": [
      "Mutations in the EZH2 gene are associated with Hutchinson-Gilford Progeria Syndrome.",
      "Mutations in the EZH2 gene are associated with Wiedemann-Steiner Syndrome.",
      "Mutations in the EZH2 gene are associated with Silver-Russell Syndrome.",
      "Mutations in the EZH2 gene are associated with Beckwith-Wiedemann Syndrome.",
      "Mutations in the EZH2 gene are associated with Angelman Syndrome."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Mutations in the LMNA gene, not the EZH2 gene, are associated with Hutchinson-Gilford Progeria Syndrome.\n2. TRUE\n3. FALSE [correction]: Mutations in genes such as H19, IGF2, CDKN1C, and others are associated with Silver-Russell Syndrome, not the EZH2 gene.\n4. FALSE [correction]: Mutations in genes such as CDKN1C, IGF2, H19, and others are associated with Beckwith-Wiedemann Syndrome, not the EZH2 gene.\n5. FALSE [correction]: Mutations in the UBE3A gene are associated with Angelman Syndrome, not the EZH2 gene.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "alpaca-7b_response": "Human proteins that are known to undergo a dimer-to-tetramer transition include: actin, myosin, tubulin, collagen, and vinculin. Other proteins that have been suggested to undergo this transition include: actin-related proteins, filamin, and talin.",
    "alpaca-7b_fact_raw": "1. Actin is known to undergo a dimer-to-tetramer transition.\n2. Myosin is known to undergo a dimer-to-tetramer transition.\n3. Tubulin is known to undergo a dimer-to-tetramer transition.\n4. Collagen is known to undergo a dimer-to-tetramer transition.\n5. Vinculin is known to undergo a dimer-to-tetramer transition.",
    "alpaca-7b_fact": [
      "Actin is known to undergo a dimer-to-tetramer transition.",
      "Myosin is known to undergo a dimer-to-tetramer transition.",
      "Tubulin is known to undergo a dimer-to-tetramer transition.",
      "Collagen is known to undergo a dimer-to-tetramer transition.",
      "Vinculin is known to undergo a dimer-to-tetramer transition."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Actin is known to polymerize into long chains or filaments, not specifically a dimer-to-tetramer transition.\n2. UNKNOWN\n3. TRUE: Tubulin is known to dimerize and then further polymerize to form microtubules, but it is not typically described as undergoing a strict dimer-to-tetramer transition.\n4. FALSE [correction]: Collagen typically assembles into a triple helix structure, not a dimer-to-tetramer transition.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "alpaca-7b_response": "Bcl-2 has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein.",
    "alpaca-7b_fact_raw": "1. Bcl-2 interacts with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.",
    "alpaca-7b_fact": [
      "Bcl-2 interacts with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. TRUE",
    "alpaca-7b_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "alpaca-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. A meta-analysis of 28 randomized controlled trials found that vitamin D supplementation reduced the risk of falls by 19%, and the risk of sustaining a fracture due to a fall by 22%. The analysis also found that vitamin D supplementation had no effect on the risk of cardiovascular disease, cancer, or mortality. The authors of the analysis concluded that vitamin D supplementation is an effective and safe way to reduce the risk of falls and fractures due to falls in older people.",
    "alpaca-7b_fact_raw": "1. Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.\n2. A meta-analysis of 28 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls by 19%.\n3. The same meta-analysis found that vitamin D supplementation reduced the risk of sustaining a fracture due to a fall by 22%.\n4. The meta-analysis concluded that vitamin D supplementation had no effect on the risk of cardiovascular disease, cancer, or mortality.\n5. The authors of the analysis concluded that vitamin D supplementation is an effective and safe way to reduce the risk of falls and fractures due to falls in older people.",
    "alpaca-7b_fact": [
      "Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.",
      "A meta-analysis of 28 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls by 19%.",
      "The same meta-analysis found that vitamin D supplementation reduced the risk of sustaining a fracture due to a fall by 22%.",
      "The meta-analysis concluded that vitamin D supplementation had no effect on the risk of cardiovascular disease, cancer, or mortality.",
      "The authors of the analysis concluded that vitamin D supplementation is an effective and safe way to reduce the risk of falls and fractures due to falls in older people."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Vitamin D supplementation has been shown in various clinical trials to reduce the incidence of falls in older people.\n2. TRUE: A meta-analysis could have indicated that vitamin D supplementation reduced the risk of falls by a certain percentage, such as 19%.\n3. UNKNOWN: Without specific reference to the meta-analysis, it's unclear whether the reduction in the risk of sustaining a fracture due to a fall was 22%.\n4. UNKNOWN: The conclusion regarding vitamin D supplementation's effect on the risk of cardiovascular disease, cancer, or mortality would need to be verified with the specific meta-analysis.\n5. UNKNOWN: The authors' conclusion about the effectiveness and safety of vitamin D supplementation for reducing the risk of falls and fractures would need to be confirmed with the actual text of the analysis.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "alpaca-7b_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. miR-155 is a microRNA that is highly expressed in Th17 cells and is involved in the regulation of several genes involved in the differentiation and function of these cells. Jarid2 is a transcription factor that is also highly expressed in Th17 cells and is necessary for their differentiation. Recent studies have shown that miR-155 targets Jarid2, suggesting that the expression of both miR-155 and Jarid2 are required for the differentiation and function of Th17 cells.",
    "alpaca-7b_fact_raw": "1. miR-155 is a microRNA that is highly expressed in Th17 cells.\n2. miR-155 is involved in the regulation of genes related to the differentiation and function of Th17 cells.\n3. Jarid2 is a transcription factor that is highly expressed in Th17 cells.\n4. Jarid2 is necessary for the differentiation of Th17 cells.\n5. Recent studies have shown that miR-155 targets Jarid2, indicating a regulatory relationship between the two in Th17 cells.",
    "alpaca-7b_fact": [
      "miR-155 is a microRNA that is highly expressed in Th17 cells.",
      "miR-155 is involved in the regulation of genes related to the differentiation and function of Th17 cells.",
      "Jarid2 is a transcription factor that is highly expressed in Th17 cells.",
      "Jarid2 is necessary for the differentiation of Th17 cells.",
      "Recent studies have shown that miR-155 targets Jarid2, indicating a regulatory relationship between the two in Th17 cells."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Jarid2 is not a transcription factor; it is a component of the Polycomb Repressive Complex 2 (PRC2) that regulates transcription.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "alpaca-7b_response": "The human hoxD cluster contains 13 genes.",
    "alpaca-7b_fact_raw": "1. The human hoxD cluster contains 13 genes.",
    "alpaca-7b_fact": [
      "The human hoxD cluster contains 13 genes."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "alpaca-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "alpaca-7b_response": "Casein Kinase 1 (CK1) is a serine/threonine-specific protein kinase that plays an important role in many cellular processes such as transcription, translation, and mitosis. Phosphorylation of proteins by CK1 is often found in the N-terminal region and is usually located in the vicinity of a basic amino acid residue. The most common consensus motif for CK1-mediated phosphorylation is (T/S)PX(S/T)P, where X is any amino acid residue. Other less frequent motifs include (T/S)PX(S/T)P or (T/S)PX(S/T)P(S/T)P. CK1-mediated phosphorylation is often found in the context of a protein-protein interaction, suggesting that CK1 may be involved in the regulation of protein activity. CK1-mediated phosphorylation is also important for the regulation of gene expression and for the control of cell cycle progression.",
    "alpaca-7b_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine-specific protein kinase.\n2. CK1 plays a role in cellular processes such as transcription, translation, and mitosis.\n3. Phosphorylation by CK1 is often found in the N-terminal region of proteins.\n4. The most common consensus motif for CK1-mediated phosphorylation is (T/S)PX(S/T)P, where X is any amino acid residue.\n5. CK1-mediated phosphorylation is important for the regulation of gene expression and cell cycle progression.",
    "alpaca-7b_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine-specific protein kinase.",
      "CK1 plays a role in cellular processes such as transcription, translation, and mitosis.",
      "Phosphorylation by CK1 is often found in the N-terminal region of proteins.",
      "The most common consensus motif for CK1-mediated phosphorylation is (T/S)PX(S/T)P, where X is any amino acid residue.",
      "CK1-mediated phosphorylation is important for the regulation of gene expression and cell cycle progression."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Phosphorylation by CK1 is often found in the C-terminal region of proteins.\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "alpaca-7b_response": "The ASPH gene encodes for three different proteins or isoforms in humans: aspartate beta-hydroxylase (AspBH), aspartate beta-semialdehyde dehydrogenase (AspBSD), and aspartate beta-semialdehyde reductase (AspBSR). AspBH is responsible for the first step in the biosynthesis of the amino acid aspartate, while AspBSD and AspBSR are responsible for the second and third steps, respectively. All three isoforms are located in the inner mitochondrial membrane. AspBH is the most abundant isoform, while AspBSD and AspBSR are expressed at lower levels. AspBSD and AspBSR are also found in other species, while AspBH is only found in humans and other primates.",
    "alpaca-7b_fact_raw": "1. The ASPH gene in humans encodes for three different proteins or isoforms: aspartate beta-hydroxylase (AspBH), aspartate beta-semialdehyde dehydrogenase (AspBSD), and aspartate beta-semialdehyde reductase (AspBSR).\n2. Aspartate beta-hydroxylase (AspBH) is responsible for the first step in the biosynthesis of the amino acid aspartate.\n3. Aspartate beta-semialdehyde dehydrogenase (AspBSD) and aspartate beta-semialdehyde reductase (AspBSR) are responsible for the second and third steps in the biosynthesis of aspartate, respectively.\n4. All three isoforms encoded by the ASPH gene are located in the inner mitochondrial membrane.\n5. Aspartate beta-hydroxylase (AspBH) is only found in humans and other primates.",
    "alpaca-7b_fact": [
      "The ASPH gene in humans encodes for three different proteins or isoforms: aspartate beta-hydroxylase (AspBH), aspartate beta-semialdehyde dehydrogenase (AspBSD), and aspartate beta-semialdehyde reductase (AspBSR).",
      "Aspartate beta-hydroxylase (AspBH) is responsible for the first step in the biosynthesis of the amino acid aspartate.",
      "Aspartate beta-semialdehyde dehydrogenase (AspBSD) and aspartate beta-semialdehyde reductase (AspBSR) are responsible for the second and third steps in the biosynthesis of aspartate, respectively.",
      "All three isoforms encoded by the ASPH gene are located in the inner mitochondrial membrane.",
      "Aspartate beta-hydroxylase (AspBH) is only found in humans and other primates."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The ASPH gene in humans encodes for aspartate beta-hydroxylase (ASPH or AspBH), but not for aspartate beta-semialdehyde dehydrogenase (AspBSD) or aspartate beta-semialdehyde reductase (AspBSR). These enzymes are involved in different metabolic pathways and are not isoforms of the ASPH gene product.\n2. FALSE [correction]: Aspartate beta-hydroxylase (AspBH) is not responsible for the biosynthesis of the amino acid aspartate. Instead, it hydroxylates specific aspartyl and asparaginyl residues in epidermal growth factor-like domains of various proteins.\n3. FALSE [correction]: Aspartate beta-semialdehyde dehydrogenase (AspBSD) is involved in the biosynthesis of aspartate, but it is not an isoform encoded by the ASPH gene. Aspartate beta-semialdehyde reductase (AspBSR) is not a recognized enzyme in the biosynthesis of aspartate.\n4. FALSE [correction]: Aspartate beta-hydroxylase (AspBH) is not necessarily located in the inner mitochondrial membrane. The subcellular localization can vary, and it is often associated with the endoplasmic reticulum.\n5. FALSE [correction]: Aspartate beta-hydroxylase (AspBH) is not exclusive to humans and other primates. Homologs of this enzyme can be found in various species across different kingdoms of life.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "alpaca-7b_response": "Empagliflozin was approved by the FDA in 2014. It is indicated for the treatment of adults with type 2 diabetes. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps control blood sugar levels by causing the kidneys to remove glucose from the body through urine. It is also used in combination with other diabetes medications to improve glycemic control. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes who are at high risk for cardiovascular disease.",
    "alpaca-7b_fact_raw": "1. Empagliflozin was approved by the FDA in 2014.\n2. It is indicated for the treatment of adults with type 2 diabetes.\n3. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.\n4. The drug helps control blood sugar levels by causing the kidneys to remove glucose through urine.\n5. Empagliflozin is used to reduce the risk of cardiovascular death in adults with type 2 diabetes who are at high risk for cardiovascular disease.",
    "alpaca-7b_fact": [
      "Empagliflozin was approved by the FDA in 2014.",
      "It is indicated for the treatment of adults with type 2 diabetes.",
      "Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.",
      "The drug helps control blood sugar levels by causing the kidneys to remove glucose through urine.",
      "Empagliflozin is used to reduce the risk of cardiovascular death in adults with type 2 diabetes who are at high risk for cardiovascular disease."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "alpaca-7b_response": "The loss of the protein Lon1 in the plant Arabidopsis results in a decrease in the levels of several proteins, including those involved in the response to stress and in the maintenance of cell structure. It also leads to an increase in the levels of reactive oxygen species, which can cause cell damage. Additionally, the mutant plants are more susceptible to bacterial and fungal pathogens.",
    "alpaca-7b_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis decreases the levels of proteins involved in stress response.\n2. Loss of the protein Lon1 in Arabidopsis decreases the levels of proteins involved in the maintenance of cell structure.\n3. Loss of the protein Lon1 in Arabidopsis leads to an increase in the levels of reactive oxygen species.\n4. Arabidopsis plants without Lon1 are more susceptible to bacterial pathogens.\n5. Arabidopsis plants without Lon1 are more susceptible to fungal pathogens.",
    "alpaca-7b_fact": [
      "Loss of the protein Lon1 in Arabidopsis decreases the levels of proteins involved in stress response.",
      "Loss of the protein Lon1 in Arabidopsis decreases the levels of proteins involved in the maintenance of cell structure.",
      "Loss of the protein Lon1 in Arabidopsis leads to an increase in the levels of reactive oxygen species.",
      "Arabidopsis plants without Lon1 are more susceptible to bacterial pathogens.",
      "Arabidopsis plants without Lon1 are more susceptible to fungal pathogens."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Loss of the protein Lon1 in Arabidopsis can decrease the levels of proteins involved in stress response, as Lon1 is involved in the regulation of various cellular processes including the degradation of misfolded and damaged proteins which can be crucial in stress responses.\n2. TRUE: Loss of the protein Lon1 in Arabidopsis may decrease the levels of proteins involved in the maintenance of cell structure, as Lon1 is implicated in protein quality control and the removal of damaged proteins that could include those involved in maintaining cell structure.\n3. TRUE: Loss of the protein Lon1 in Arabidopsis can lead to an increase in the levels of reactive oxygen species (ROS), as Lon1 is involved in mitochondrial function and the degradation of damaged proteins, which, if accumulated, can lead to increased oxidative stress and ROS production.\n4. TRUE: Arabidopsis plants without Lon1 can be more susceptible to bacterial pathogens, as Lon1 is involved in stress responses and immune responses, and its absence can impair the plant's ability to respond effectively to pathogen attack.\n5. TRUE: Arabidopsis plants without Lon1 can be more susceptible to fungal pathogens for the same reasons they are more susceptible to bacterial pathogens; the protein is involved in stress and immune responses, and its absence can compromise the plant's defense mechanisms.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "alpaca-7b_response": "Yes, a linker histone exists in the yeast genome. It is encoded by the gene HIR1 and is involved in the formation of nucleosomes, which are the basic units of chromatin. It is also involved in gene regulation and transcription.",
    "alpaca-7b_fact_raw": "1. A linker histone is present in the yeast genome.\n2. The gene HIR1 encodes for the linker histone in yeast.\n3. The linker histone is involved in the formation of nucleosomes.\n4. Nucleosomes are the basic units of chromatin.\n5. The linker histone plays a role in gene regulation and transcription in yeast.",
    "alpaca-7b_fact": [
      "A linker histone is present in the yeast genome.",
      "The gene HIR1 encodes for the linker histone in yeast.",
      "The linker histone is involved in the formation of nucleosomes.",
      "Nucleosomes are the basic units of chromatin.",
      "The linker histone plays a role in gene regulation and transcription in yeast."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Yeast, specifically Saccharomyces cerevisiae, does not have a canonical linker histone. Instead, it has histone H1-related proteins.\n2. FALSE [correction]: The gene HIR1 in yeast does not encode for a linker histone. HIR1 is a gene that encodes a histone regulatory protein, but not a histone itself.\n3. TRUE: In organisms that have linker histones, they are indeed involved in the formation of nucleosomes by binding to the DNA between nucleosomes and helping to compact the chromatin structure.\n4. TRUE: Nucleosomes are the basic repeating units of chromatin, consisting of a segment of DNA wound around a core of histone proteins.\n5. UNKNOWN: While linker histones in organisms that possess them do play a role in gene regulation and transcription, the statement is vague regarding yeast, which does not have a canonical linker histone. Yeast has H1-related proteins that may have roles in chromatin structure and function, but the specific role in gene regulation and transcription can vary and may not be equivalent to that of canonical linker histones.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "alpaca-7b_response": "Yes, there is evidence that tomato juice can lower cholesterol levels. In a study conducted in 2012, participants who drank 240 milliliters of tomato juice daily for three months had a significant decrease in total cholesterol and LDL cholesterol levels. The researchers attributed the beneficial effects of tomato juice to its high content of lycopene, an antioxidant that has been linked to lower cholesterol levels. In addition, other studies have found that tomato juice may have anti-inflammatory and anti-atherosclerotic effects, which can also help to reduce the risk of cardiovascular disease. \nOverall, the evidence suggests that tomato juice can be beneficial for lowering cholesterol levels and reducing the risk of cardiovascular disease. However, more research is needed to better understand the effects of tomato juice on cholesterol levels and other health outcomes.",
    "alpaca-7b_fact_raw": "1. A study conducted in 2012 found that drinking 240 milliliters of tomato juice daily for three months led to a significant decrease in total cholesterol and LDL cholesterol levels.\n2. The study attributed the cholesterol-lowering effects of tomato juice to its high content of lycopene.\n3. Lycopene, an antioxidant found in tomato juice, has been linked to lower cholesterol levels.\n4. Tomato juice may have anti-inflammatory and anti-atherosclerotic effects.\n5. Consuming tomato juice can potentially reduce the risk of cardiovascular disease.",
    "alpaca-7b_fact": [
      "A study conducted in 2012 found that drinking 240 milliliters of tomato juice daily for three months led to a significant decrease in total cholesterol and LDL cholesterol levels.",
      "The study attributed the cholesterol-lowering effects of tomato juice to its high content of lycopene.",
      "Lycopene, an antioxidant found in tomato juice, has been linked to lower cholesterol levels.",
      "Tomato juice may have anti-inflammatory and anti-atherosclerotic effects.",
      "Consuming tomato juice can potentially reduce the risk of cardiovascular disease."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN (The statement provides specific details about a study, but without access to the study or additional information, the truth of the statement cannot be verified.)\n2. UNKNOWN (Similar to statement 1, the attribution of cholesterol-lowering effects to lycopene in tomato juice is specific to the study mentioned, and without access to that study, the truth of the statement cannot be verified.)\n3. TRUE (Lycopene is indeed an antioxidant found in tomatoes and tomato products, and it has been linked to various health benefits, including lower cholesterol levels.)\n4. TRUE (Tomato juice contains various bioactive compounds, including lycopene, which have been studied for their anti-inflammatory and anti-atherosclerotic effects.)\n5. TRUE (Given that tomato juice contains compounds like lycopene that have been linked to health benefits such as lower cholesterol levels and anti-inflammatory effects, it is plausible that consuming tomato juice could potentially reduce the risk of cardiovascular disease. However, it should be noted that this is a potential benefit and individual results may vary.)",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "alpaca-7b_response": "Hsp70 and Hsp110 are two members of the heat shock protein family that are involved in the regulation of mRNA stability. Hsp70 binds to the 3' untranslated region (3'UTR) of mRNAs and promotes their stability by preventing their degradation. Hsp110 binds to the 5'UTR of mRNAs and promotes their stability by increasing their translation rate. Both Hsp70 and Hsp110 are also involved in the regulation of mRNA translation and can modulate the activity of certain mRNAs. Overall, Hsp70 and Hsp110 are important factors in the regulation of mRNA stability and translation.",
    "alpaca-7b_fact_raw": "1. Hsp70 and Hsp110 are members of the heat shock protein family.\n2. Hsp70 binds to the 3' untranslated region (3'UTR) of mRNAs.\n3. Hsp70 promotes mRNA stability by preventing degradation.\n4. Hsp110 binds to the 5' untranslated region (5'UTR) of mRNAs.\n5. Hsp110 promotes mRNA stability by increasing their translation rate.",
    "alpaca-7b_fact": [
      "Hsp70 and Hsp110 are members of the heat shock protein family.",
      "Hsp70 binds to the 3' untranslated region (3'UTR) of mRNAs.",
      "Hsp70 promotes mRNA stability by preventing degradation.",
      "Hsp110 binds to the 5' untranslated region (5'UTR) of mRNAs.",
      "Hsp110 promotes mRNA stability by increasing their translation rate."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 typically binds to nascent polypeptides and partially synthesized proteins to assist in their folding, not specifically to the 3' untranslated region (3'UTR) of mRNAs.\n3. UNKNOWN: While Hsp70 has a role in protein folding and can be involved in the protection of proteins from aggregation, its direct role in promoting mRNA stability by preventing degradation is not well-established and can vary depending on the context.\n4. UNKNOWN: Hsp110 is known to function as a nucleotide exchange factor for Hsp70 and assist in protein folding, but its specific binding to the 5' untranslated region (5'UTR) of mRNAs is not a widely recognized function and would require specific context to verify.\n5. UNKNOWN: Hsp110's primary known function is to assist Hsp70 in protein folding. The claim that it promotes mRNA stability by increasing their translation rate is not a standard description of its function and would need specific context or evidence to be verified.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "alpaca-7b_response": "Skeletal muscle contains two types of deiodinases, DIO1 and DIO2. DIO1 is responsible for the conversion of T4 to T3, while DIO2 is responsible for the conversion of T4 to T2. Both enzymes are necessary for the proper functioning of the thyroid hormone system.",
    "alpaca-7b_fact_raw": "1. Skeletal muscle contains two types of deiodinases: DIO1 and DIO2.\n2. DIO1 is responsible for the conversion of T4 to T3.\n3. DIO2 is responsible for the conversion of T4 to T2.\n4. Both DIO1 and DIO2 enzymes are part of the thyroid hormone system's functioning.",
    "alpaca-7b_fact": [
      "Skeletal muscle contains two types of deiodinases: DIO1 and DIO2.",
      "DIO1 is responsible for the conversion of T4 to T3.",
      "DIO2 is responsible for the conversion of T4 to T2.",
      "Both DIO1 and DIO2 enzymes are part of the thyroid hormone system's functioning."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DIO2 is responsible for the conversion of T4 to T3, not T2.\n4. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "alpaca-7b_response": "Caspase-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, -21, -22, -23, -24, -25, -26, -27, -28, -29, -30, -31, -32, -33, -34, -35, -36, -37, -38, -39, -40, -41, -42, -43, -44, -45, -46, -47, -48, -49, -50, -51, -52, -53, -54, -55, -56, -57, -58, -59, -60, -61, -62, -63, -64, -65, -66, -67, -68, -69, -70, -71, -72, -73, -74, -75, -76, -77, -78, -79, -80, -81, -82, -83, -84, -85, -86, -87, -88, -89, -90, -91, -92, -93, -94, -95, -96, -97, -98, -99, -100, -101, -102, -103, -104, -105, -106, -107, -108, -109, -110, -111, -112, -113, -114, -115, -116, -117, -118, -119, -120, -121, -122, -123, -1",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "alpaca-7b_response": "Yes, there is a link between the aurora B kinase and the polycomb protein ring1B. The aurora B kinase is a key regulator of the mitotic spindle and is involved in the phosphorylation of several proteins, including the polycomb protein ring1B. The phosphorylation of ring1B by aurora B is important for its degradation, which is necessary for the completion of mitosis. Therefore, the aurora B kinase and the polycomb protein ring1B are closely linked and their interaction is essential for the proper functioning of the cell cycle.",
    "alpaca-7b_fact_raw": "1. Aurora B kinase is a key regulator of the mitotic spindle.\n2. Aurora B kinase is involved in the phosphorylation of several proteins, including the polycomb protein ring1B.\n3. The phosphorylation of ring1B by aurora B kinase is important for its degradation.\n4. The degradation of ring1B is necessary for the completion of mitosis.\n5. The interaction between aurora B kinase and the polycomb protein ring1B is essential for the proper functioning of the cell cycle.",
    "alpaca-7b_fact": [
      "Aurora B kinase is a key regulator of the mitotic spindle.",
      "Aurora B kinase is involved in the phosphorylation of several proteins, including the polycomb protein ring1B.",
      "The phosphorylation of ring1B by aurora B kinase is important for its degradation.",
      "The degradation of ring1B is necessary for the completion of mitosis.",
      "The interaction between aurora B kinase and the polycomb protein ring1B is essential for the proper functioning of the cell cycle."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The phosphorylation of ring1B by aurora B kinase is important for its function in chromatin compaction and gene silencing, not necessarily for its degradation.\n4. UNKNOWN\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "alpaca-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are UG, UGU, UGC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, UGGA, UGG, UGCG, UGCA, UGCU, UGCC, UGAA, U",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "alpaca-7b_response": "The event that results in the acetylation of S6K1 is the binding of the transcription factor NF-kB to the S6K1 promoter region. This binding causes the activation of S6K1, which in turn leads to the phosphorylation and acetylation of S6K1. This acetylation of S6K1 is necessary for the full activation of S6K1 and the subsequent phosphorylation of S6, leading to the activation of the mTOR pathway.",
    "alpaca-7b_fact_raw": "1. The acetylation of S6K1 is caused by the binding of the transcription factor NF-kB to the S6K1 promoter region.\n2. The activation of S6K1 leads to its phosphorylation and acetylation.\n3. Acetylation of S6K1 is necessary for its full activation.\n4. The full activation of S6K1 results in the phosphorylation of S6.\n5. The phosphorylation of S6 leads to the activation of the mTOR pathway.",
    "alpaca-7b_fact": [
      "The acetylation of S6K1 is caused by the binding of the transcription factor NF-kB to the S6K1 promoter region.",
      "The activation of S6K1 leads to its phosphorylation and acetylation.",
      "Acetylation of S6K1 is necessary for its full activation.",
      "The full activation of S6K1 results in the phosphorylation of S6.",
      "The phosphorylation of S6 leads to the activation of the mTOR pathway."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The acetylation of S6K1 is not directly caused by the binding of the transcription factor NF-kB to the S6K1 promoter region. NF-kB is a transcription factor that can regulate gene expression, but acetylation is a post-translational modification that typically occurs in the cytoplasm and is mediated by acetyltransferases.\n2. TRUE: The activation of S6K1 indeed involves its phosphorylation, and it can also be acetylated, although these are separate modifications.\n3. UNKNOWN: The necessity of acetylation for the full activation of S6K1 can depend on the cellular context and specific signaling pathways involved. Without specific information from the passage, it's difficult to determine the truth of this statement.\n4. TRUE: The full activation of S6K1 does result in the phosphorylation of ribosomal protein S6, which is one of its downstream targets.\n5. FALSE [correction]: The phosphorylation of S6 is a downstream effect of the activation of the mTOR pathway, not the cause of its activation. The mTOR pathway, when activated, leads to the phosphorylation of S6K1, which in turn phosphorylates S6.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "alpaca-7b_response": "Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene, which is located on chromosome 19. This gene provides instructions for making a protein that is part of a complex in the cell membrane that helps to regulate the amount of calcium in the cell. The mutation in the CACNA1A gene leads to an abnormal version of the protein being produced, which disrupts the normal functioning of the calcium channels and causes episodic ataxia type 6. \nThe abnormal version of the protein is thought to cause episodes of ataxia by interfering with the normal functioning of the calcium channels in the cell membrane. This affects the amount of calcium that enters the cell, which can lead to abnormal nerve signaling and cause symptoms of episodic ataxia type 6. \nThe abnormal calcium channels also affect the heart and can cause abnormal heart rhythms, which can be a serious complication of episodic ataxia type 6. \nIn summary, episodic ataxia type 6 is caused by a mutation in the CACNA1A gene, which leads to the production of an abnormal version of the protein that disrupts the normal functioning of the calcium channels and causes ataxia and abnormal heart rhythms. \nhttps://www.geneticdisorders.com/causes/2018/05/24/what-is-the-cause-of-episodic-ataxia-type-6/",
    "alpaca-7b_fact_raw": "1. Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene.\n2. The CACNA1A gene is located on chromosome 19.\n3. The mutation leads to an abnormal version of a protein that is part of a complex regulating calcium in the cell.\n4. This abnormal protein disrupts the normal functioning of calcium channels, causing episodic ataxia type 6.\n5. The abnormal calcium channels can cause abnormal heart rhythms, a serious complication of episodic ataxia type 6.",
    "alpaca-7b_fact": [
      "Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene.",
      "The CACNA1A gene is located on chromosome 19.",
      "The mutation leads to an abnormal version of a protein that is part of a complex regulating calcium in the cell.",
      "This abnormal protein disrupts the normal functioning of calcium channels, causing episodic ataxia type 6.",
      "The abnormal calcium channels can cause abnormal heart rhythms, a serious complication of episodic ataxia type 6."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While mutations in the CACNA1A gene can affect calcium channels and lead to neurological symptoms like episodic ataxia, they are not typically associated with causing abnormal heart rhythms. Abnormal heart rhythms are more commonly associated with mutations in genes that directly affect cardiac function.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "alpaca-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they are involved in a variety of important processes such as gene regulation and DNA repair. Most animals have two copies of the chromomethylase gene, one located on each of their two homologous chromosomes. In addition, many animals have a third copy of the gene located on the X chromosome. This third copy is often referred to as a \"supernumerary\" copy, as it is present in more than two copies. Animals with supernumerary copies of the chromomethylase gene include mice, rats, and humans.",
    "alpaca-7b_fact_raw": "1. Chromomethylases are enzymes that add methyl groups to DNA.\n2. Chromomethylases are involved in gene regulation and DNA repair.\n3. Most animals have two copies of the chromomethylase gene, one on each of their two homologous chromosomes.\n4. Many animals have a third copy of the chromomethylase gene located on the X chromosome.\n5. Mice, rats, and humans are examples of animals with supernumerary copies of the chromomethylase gene.",
    "alpaca-7b_fact": [
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "Chromomethylases are involved in gene regulation and DNA repair.",
      "Most animals have two copies of the chromomethylase gene, one on each of their two homologous chromosomes.",
      "Many animals have a third copy of the chromomethylase gene located on the X chromosome.",
      "Mice, rats, and humans are examples of animals with supernumerary copies of the chromomethylase gene."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The number of copies of the chromomethylase gene can vary widely among animals, and it is not accurate to say that most animals have two copies, one on each of their two homologous chromosomes, without specific evidence for each species.\n4. UNKNOWN: Without specific information about the chromosomal location of chromomethylase genes in many animals, it is not possible to confirm the accuracy of this statement.\n5. UNKNOWN: The statement about mice, rats, and humans having supernumerary copies of the chromomethylase gene is specific and would require genetic evidence from these species to confirm or refute.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "alpaca-7b_response": "The packages available in R/Bioconductor for transcription factor binding sites' (TFBS) analysis are: \n1. AnnotationDbi: This package provides tools for the analysis of DNase hypersensitivity and transcription factor binding site (TFBS) data. \n2. Bioconductor.v1.11: This package provides tools for the analysis of ChIP-seq and RNA-seq data. \n3. ChIPpeakAnno: This package provides tools for the analysis of ChIP-seq and RNA-seq data. \n4. DNaseTutor: This package provides tools for the analysis of DNase hypersensitivity data. \n5. FactorBinder: This package provides tools for the analysis of ChIP-seq and RNA-seq data. \n6. FactorScan: This package provides tools for the analysis of ChIP-seq and RNA-seq data. \n7. FDRBind: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n8. Fragments: This package provides tools for the analysis of RNA-seq data. \n9. GENEVE: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n10. GENEVE_D: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n11. GENEVE_R: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n12. GENEVE_D_R: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n13. GENEVE_D_R_FDR: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n14. GENEVE_D_R_FDR_S: This package provides tools for the analysis of DNase hypersensitivity and ChIP-seq data. \n15. GENEVE_D_R_FDR_S_F: This package provides tools for the analysis of DNase hypersensitivity and Ch",
    "alpaca-7b_fact_raw": "1. AnnotationDbi is a package in R/Bioconductor for the analysis of DNase hypersensitivity and transcription factor binding site (TFBS) data.\n2. Bioconductor.v1.11 is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data.\n3. ChIPpeakAnno is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data.\n4. DNaseTutor is a package in R/Bioconductor for the analysis of DNase hypersensitivity data.\n5. FactorBinder is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data.",
    "alpaca-7b_fact": [
      "AnnotationDbi is a package in R/Bioconductor for the analysis of DNase hypersensitivity and transcription factor binding site (TFBS) data.",
      "Bioconductor.v1.11 is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data.",
      "ChIPpeakAnno is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data.",
      "DNaseTutor is a package in R/Bioconductor for the analysis of DNase hypersensitivity data.",
      "FactorBinder is a package in R/Bioconductor for the analysis of ChIP-seq and RNA-seq data."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: AnnotationDbi is a package in R/Bioconductor that provides tools for annotating various types of genomic data, not specifically for the analysis of DNase hypersensitivity and transcription factor binding site (TFBS) data.\n2. FALSE [correction]: There is no package specifically named \"Bioconductor.v1.11.\" Bioconductor is a project that provides tools for the analysis of genomic data, and its versions are numbered, but they are not packages themselves.\n3. TRUE: ChIPpeakAnno is indeed a package in R/Bioconductor designed for annotating ChIP-seq data and integrating it with other types of genomic data.\n4. FALSE [correction]: There is no package named \"DNaseTutor\" in R/Bioconductor. It is possible that the statement refers to a different package or is simply incorrect.\n5. FALSE [correction]: There is no package named \"FactorBinder\" in R/Bioconductor. It is possible that the statement refers to a different package or is simply incorrect.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "alpaca-7b_response": "1. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH)\n2. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-2)\n3. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-3)\n4. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-4)\n5. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-5)\n6. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-6)\n7. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-7)\n8. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-8)\n9. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-9)\n10. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-10)\n11. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STRENGTH-11)\n12. Sarcopenia: Effects of Resistance Training and Nutritional Supplementation on Muscle Mass and Strength in Older Adults (STR",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "alpaca-7b_response": "The Database of Membrane Protein Recognition Features (MPRF) is a database of molecular recognition features in membrane proteins. It provides a comprehensive resource for the identification and analysis of membrane protein-ligand interactions. The database contains information on the structures of membrane proteins, their ligands, and the interactions between them. It also provides tools for the analysis of membrane protein-ligand interactions, such as structure-based similarity searches, clustering, and visualization. The database can be accessed at http://mprf.ucd.ie/.",
    "alpaca-7b_fact_raw": "1. The Database of Membrane Protein Recognition Features (MPRF) is a database for molecular recognition features in membrane proteins.\n2. MPRF provides resources for the identification and analysis of membrane protein-ligand interactions.\n3. The database contains information on the structures of membrane proteins and their ligands.\n4. MPRF offers tools for structure-based similarity searches, clustering, and visualization of membrane protein-ligand interactions.\n5. The database is accessible online at http://mprf.ucd.ie/.",
    "alpaca-7b_fact": [
      "The Database of Membrane Protein Recognition Features (MPRF) is a database for molecular recognition features in membrane proteins.",
      "MPRF provides resources for the identification and analysis of membrane protein-ligand interactions.",
      "The database contains information on the structures of membrane proteins and their ligands.",
      "MPRF offers tools for structure-based similarity searches, clustering, and visualization of membrane protein-ligand interactions.",
      "The database is accessible online at http://mprf.ucd.ie/."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "alpaca-7b_response": "Yes, rivaroxaban is metabolized in the kidneys. It is primarily eliminated in the urine, with less than 10% of the dose being excreted in the feces. The drug is metabolized by the cytochrome P450 enzyme system, which is primarily located in the kidneys. The metabolites of rivaroxaban are also excreted in the urine, and the half-life of the drug is increased to 11 hours in patients with renal impairment. Therefore, it is important to be aware of the potential for prolonged effects of rivaroxaban when treating patients with renal impairment.",
    "alpaca-7b_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. Rivaroxaban is primarily eliminated in the urine.\n3. Less than 10% of the dose of rivaroxaban is excreted in the feces.\n4. The cytochrome P450 enzyme system, which metabolizes rivaroxaban, is primarily located in the kidneys.\n5. The half-life of rivaroxaban is increased to 11 hours in patients with renal impairment.",
    "alpaca-7b_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "Rivaroxaban is primarily eliminated in the urine.",
      "Less than 10% of the dose of rivaroxaban is excreted in the feces.",
      "The cytochrome P450 enzyme system, which metabolizes rivaroxaban, is primarily located in the kidneys.",
      "The half-life of rivaroxaban is increased to 11 hours in patients with renal impairment."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Rivaroxaban is metabolized primarily in the liver.\n2. TRUE\n3. FALSE [correction]: Approximately one-third of the dose of rivaroxaban is excreted in the feces.\n4. FALSE [correction]: The cytochrome P450 enzyme system, which metabolizes rivaroxaban, is primarily located in the liver, not the kidneys.\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "alpaca-7b_response": "TRalpha2  is a transcription factor that binds to the DNA and regulates the expression of genes in the heart. Studies have shown that TRalpha2  binds to the promoter region of genes involved in cardiac development, hypertrophy, and remodeling, including the genes for troponin T, troponin I, myosin light chain 2, and alpha-actinin. It also binds to the promoter region of genes involved in cell cycle regulation, such as cyclin D1 and cdk4, as well as genes involved in cell death, such as Bcl-2 and Bax. In addition, TRalpha2  has been shown to regulate genes involved in metabolism, such as glucose transporters and enzymes involved in glycolysis and lipogenesis. Finally, TRalpha2  has also been shown to regulate genes involved in inflammation and remodeling, such as NF-kB and MMPs. Therefore, TRalpha2  plays an important role in the regulation of gene expression in the heart.",
    "alpaca-7b_fact_raw": "1. TRalpha2 is a transcription factor that regulates the expression of genes in the heart.\n2. TRalpha2 binds to the promoter region of genes involved in cardiac development, hypertrophy, and remodeling.\n3. The genes for troponin T, troponin I, myosin light chain 2, and alpha-actinin are among those regulated by TRalpha2 in the heart.\n4. TRalpha2 regulates the expression of genes involved in cell cycle regulation, such as cyclin D1 and cdk4.\n5. TRalpha2 also regulates genes involved in metabolism, inflammation, and remodeling, including glucose transporters, enzymes involved in glycolysis and lipogenesis, NF-kB, and MMPs.",
    "alpaca-7b_fact": [
      "TRalpha2 is a transcription factor that regulates the expression of genes in the heart.",
      "TRalpha2 binds to the promoter region of genes involved in cardiac development, hypertrophy, and remodeling.",
      "The genes for troponin T, troponin I, myosin light chain 2, and alpha-actinin are among those regulated by TRalpha2 in the heart.",
      "TRalpha2 regulates the expression of genes involved in cell cycle regulation, such as cyclin D1 and cdk4.",
      "TRalpha2 also regulates genes involved in metabolism, inflammation, and remodeling, including glucose transporters, enzymes involved in glycolysis and lipogenesis, NF-kB, and MMPs."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: TRalpha2, also known as thyroid hormone receptor alpha 2, is a transcription factor that can regulate the expression of genes, including those in the heart.\n2. TRUE: TRalpha2 can bind to the promoter region of genes, which is consistent with the role of a transcription factor involved in cardiac development, hypertrophy, and remodeling.\n3. UNKNOWN: Without specific scientific references, it is difficult to confirm whether TRalpha2 directly regulates the genes for troponin T, troponin I, myosin light chain 2, and alpha-actinin in the heart.\n4. UNKNOWN: The role of TRalpha2 in regulating cell cycle genes such as cyclin D1 and cdk4 is not specified here, and without additional context or references, the truth of this statement cannot be determined.\n5. UNKNOWN: While TRalpha2 may have a role in regulating genes involved in various biological processes, including metabolism, inflammation, and remodeling, the specific genes mentioned (glucose transporters, enzymes involved in glycolysis and lipogenesis, NF-kB, and MMPs) cannot be confirmed without further information.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "alpaca-7b_response": "1. BioASQ: A system for answering biomedical questions from the BioASQ dataset.\n2. OpenQA: A platform for developing and evaluating question answering systems.\n3. PubMedQA: A system for answering questions about medical literature from the PubMed literature database.\n4. Biocreative II: A system for answering biomedical questions from the Biocreative II dataset.\n5. Chemical Question Answering System (ChemAsk): A system for answering chemical questions from the ChemAsk dataset.\n6. Disease Prediction System (DPS): A system for predicting human diseases from the DPS dataset.\n7. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n8. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n9. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n10. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n11. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n12. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n13. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n14. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n15. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n16. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS dataset.\n17. Biomedical Question Answering System (Bio-QAS): A system for answering biomedical questions from the Bio-QAS",
    "alpaca-7b_fact_raw": "1. BioASQ is a system designed to answer biomedical questions using the BioASQ dataset.\n2. OpenQA is a platform used for developing and evaluating question answering systems.\n3. PubMedQA is a system that provides answers to questions based on the PubMed literature database.\n4. Biocreative II is a system that answers biomedical questions using the Biocreative II dataset.\n5. Chemical Question Answering System (ChemAsk) is a system for answering chemical questions using the ChemAsk dataset.",
    "alpaca-7b_fact": [
      "BioASQ is a system designed to answer biomedical questions using the BioASQ dataset.",
      "OpenQA is a platform used for developing and evaluating question answering systems.",
      "PubMedQA is a system that provides answers to questions based on the PubMed literature database.",
      "Biocreative II is a system that answers biomedical questions using the Biocreative II dataset.",
      "Chemical Question Answering System (ChemAsk) is a system for answering chemical questions using the ChemAsk dataset."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PubMedQA is a dataset, not a system, designed for biomedical question answering using abstracts from the PubMed literature database.\n4. FALSE [correction]: Biocreative II is not a system but a challenge that involves tasks such as gene mention finding and gene normalization, not specifically answering biomedical questions using a dataset.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "alpaca-7b_response": "The trancription factor that activates the betalain pathway is the red-light photoreceptor phytochrome. Phytochrome binds to a sequence in the promoter region of the betalain gene, which then activates the gene and leads to the production of betalain pigments.",
    "alpaca-7b_fact_raw": "1. The transcription factor that activates the betalain pathway is the red-light photoreceptor phytochrome.\n2. Phytochrome binds to a sequence in the promoter region of the betalain gene.\n3. The binding of phytochrome to the promoter region activates the betalain gene.\n4. Activation of the betalain gene leads to the production of betalain pigments.",
    "alpaca-7b_fact": [
      "The transcription factor that activates the betalain pathway is the red-light photoreceptor phytochrome.",
      "Phytochrome binds to a sequence in the promoter region of the betalain gene.",
      "The binding of phytochrome to the promoter region activates the betalain gene.",
      "Activation of the betalain gene leads to the production of betalain pigments."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The transcription factor that activates the betalain pathway is not specified as the red-light photoreceptor phytochrome. Transcription factors are typically proteins that bind to specific DNA sequences to control the flow (or transcription) of genetic information from DNA to mRNA, whereas phytochromes are a class of photoreceptor in plants that detect light and are involved in various signaling pathways, but they are not typically described as transcription factors themselves.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "alpaca-7b_response": "1. Ion Beam Tofu (IBT)\n2. TiO2 beads\n3. Immobilized Metal Affinity Chromatography (IMAC)\n4. Phosphopeptide Enrichment by Multidimensional Fractionation (PEM-MS)\n5. Phospho-specific Antibodies\n6. Phospho-enriched Tissue Proteins (PET)\n7. Phospho-enriched Tissue Lysates (PETL)\n8. Phospho-enriched Tissue Proteins and Lysates (PETPL)",
    "alpaca-7b_fact_raw": "1. Ion Beam Tofu (IBT) is a technology used for the enrichment of phosphorylated peptides.\n2. TiO2 beads are used for the enrichment of phosphorylated peptides.\n3. Immobilized Metal Affinity Chromatography (IMAC) is a preferred technology for the enrichment of phosphorylated peptides.\n4. Phosphopeptide Enrichment by Multidimensional Fractionation (PEM-MS) is a method used for the enrichment of phosphorylated peptides.\n5. Phospho-specific Antibodies are utilized for the enrichment of phosphorylated peptides.",
    "alpaca-7b_fact": [
      "Ion Beam Tofu (IBT) is a technology used for the enrichment of phosphorylated peptides.",
      "TiO2 beads are used for the enrichment of phosphorylated peptides.",
      "Immobilized Metal Affinity Chromatography (IMAC) is a preferred technology for the enrichment of phosphorylated peptides.",
      "Phosphopeptide Enrichment by Multidimensional Fractionation (PEM-MS) is a method used for the enrichment of phosphorylated peptides.",
      "Phospho-specific Antibodies are utilized for the enrichment of phosphorylated peptides."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Ion Beam Tofu (IBT) does not appear to be a recognized technology for the enrichment of phosphorylated peptides. It may be a typographical error or a fictional term. A known technology for this purpose is Immobilized Metal Ion Affinity Chromatography (IMAC).\n2. TRUE\n3. TRUE\n4. UNKNOWN: Phosphopeptide Enrichment by Multidimensional Fractionation (PEM-MS) is not a standard term in the literature. It could be a specific method or a combination of methods, but without additional context, it's unclear whether this is accurate.\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "alpaca-7b_response": "The Palmini classification rates disorders according to the severity of symptoms and the impact they have on a person's life. It is used to determine the level of care and support needed for a person with a mental health disorder. The classification is based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD). The Palmini classification is divided into three levels: mild, moderate, and severe. Symptoms that are present in a person's life can be rated according to the Palmini classification to determine the level of care and support needed. \nMild symptoms may include mild anxiety or depression, mild disorganization, or mild difficulty with social functioning. Moderate symptoms may include moderate anxiety or depression, moderate disorganization, or moderate difficulty with social functioning. Severe symptoms may include severe anxiety or depression, severe disorganization, or severe difficulty with social functioning. \nThe Palmini classification is used to determine the level of care and support needed for a person with a mental health disorder. It is based on the severity of symptoms and the impact they have on a person's life. The classification is used to rate symptoms according to the DSM and ICD. This helps to determine the level of care and support needed for a person with a mental health disorder. \nThe Palmini classification is used to rate symptoms according to the DSM and ICD. This helps to determine the level of care and support needed for a person with a mental health disorder. The classification is divided into three levels: mild, moderate, and severe. Symptoms that are present in a person's life can be rated according to the Palmini classification to determine the level of care and support needed. \nMild symptoms may include mild anxiety or depression, mild disorganization, or mild difficulty with social functioning. Moderate symptoms may include moderate anxiety or depression, moderate disorganization, or moderate difficulty with social functioning. Severe symptoms may include severe anxiety or depression, severe disorganization, or severe difficulty with social functioning. \nThe Palmini classification is used to rate symptoms according to",
    "alpaca-7b_fact_raw": "1. The Palmini classification is used to rate the severity of symptoms and their impact on a person's life for mental health disorders.\n2. The Palmini classification is based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD).\n3. The Palmini classification is divided into three levels of symptom severity: mild, moderate, and severe.\n4. Mild symptoms in the Palmini classification may include mild anxiety or depression, mild disorganization, or mild difficulty with social functioning.\n5. Severe symptoms in the Palmini classification may include severe anxiety or depression, severe disorganization, or severe difficulty with social functioning.",
    "alpaca-7b_fact": [
      "The Palmini classification is used to rate the severity of symptoms and their impact on a person's life for mental health disorders.",
      "The Palmini classification is based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD).",
      "The Palmini classification is divided into three levels of symptom severity: mild, moderate, and severe.",
      "Mild symptoms in the Palmini classification may include mild anxiety or depression, mild disorganization, or mild difficulty with social functioning.",
      "Severe symptoms in the Palmini classification may include severe anxiety or depression, severe disorganization, or severe difficulty with social functioning."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of symptoms for mental health disorders; it is actually used for classifying the outcomes of epilepsy surgery.\n2. FALSE [correction]: Since the Palmini classification is not for mental health disorders, it is not based on the DSM or ICD, which are used for such disorders.\n3. UNKNOWN: Without specific information about the Palmini classification, it is not possible to confirm whether it is divided into levels of symptom severity such as mild, moderate, and severe.\n4. UNKNOWN: As the Palmini classification is not for mental health disorders, the statement about mild symptoms cannot be confirmed.\n5. UNKNOWN: As the Palmini classification is not for mental health disorders, the statement about severe symptoms cannot be confirmed.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "alpaca-7b_response": "No, viruses are not involved in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition of the thyroid gland caused by viral infection or autoimmune processes. It is rare for viruses to be involved in the etiology of human diseases, and there is no evidence that viruses are involved in the etiology of subacute thyroiditis. The most common cause of subacute thyroiditis is an autoimmune process, where the body's own immune system attacks the thyroid gland. Other causes include viral infection, trauma, and radiation exposure. Treatment of subacute thyroiditis includes pain relievers, anti-inflammatories, and hormone replacement therapy.",
    "alpaca-7b_fact_raw": "1. Subacute thyroiditis is an inflammatory condition of the thyroid gland.\n2. Subacute thyroiditis can be caused by viral infection or autoimmune processes.\n3. The most common cause of subacute thyroiditis is an autoimmune process.\n4. Other causes of subacute thyroiditis include trauma and radiation exposure.\n5. Treatment options for subacute thyroiditis include pain relievers, anti-inflammatories, and hormone replacement therapy.",
    "alpaca-7b_fact": [
      "Subacute thyroiditis is an inflammatory condition of the thyroid gland.",
      "Subacute thyroiditis can be caused by viral infection or autoimmune processes.",
      "The most common cause of subacute thyroiditis is an autoimmune process.",
      "Other causes of subacute thyroiditis include trauma and radiation exposure.",
      "Treatment options for subacute thyroiditis include pain relievers, anti-inflammatories, and hormone replacement therapy."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The most common cause of subacute thyroiditis is believed to be a viral infection, not an autoimmune process.\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "alpaca-7b_response": "Yes, STAT3 is involved in EIF2AK2-dependent suppression of autophagy. STAT3 is a transcription factor that is activated by various stimuli and plays a critical role in cell growth and survival. In particular, STAT3 has been shown to negatively regulate autophagy by binding to and inhibiting the activity of the EIF2AK2 protein. This binding leads to the degradation of the EIF2AK2 protein, which in turn reduces the activity of the ULK1-ATG13 complex and the initiation of the autophagy process. Thus, STAT3 is an important regulator of autophagy and its dysregulation can lead to various diseases.",
    "alpaca-7b_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. STAT3 is a transcription factor that is activated by various stimuli.\n3. STAT3 negatively regulates autophagy by binding to and inhibiting the activity of the EIF2AK2 protein.\n4. The binding of STAT3 leads to the degradation of the EIF2AK2 protein.\n5. The degradation of EIF2AK2 protein reduces the activity of the ULK1-ATG13 complex and the initiation of the autophagy process.",
    "alpaca-7b_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "STAT3 is a transcription factor that is activated by various stimuli.",
      "STAT3 negatively regulates autophagy by binding to and inhibiting the activity of the EIF2AK2 protein.",
      "The binding of STAT3 leads to the degradation of the EIF2AK2 protein.",
      "The degradation of EIF2AK2 protein reduces the activity of the ULK1-ATG13 complex and the initiation of the autophagy process."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: STAT3 does not negatively regulate autophagy by binding to and inhibiting the activity of the EIF2AK2 protein. Instead, it is involved in the suppression of autophagy through mechanisms that may involve different proteins and pathways, but not directly inhibiting EIF2AK2.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The statements regarding the specific molecular interactions and effects of STAT3 on autophagy and EIF2AK2 are highly technical and would require specific scientific evidence to confirm. Without access to the relevant scientific literature or data, the responses to statements 4 and 5 are unknown.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "alpaca-7b_response": "Theatre is a software tool for genomic analysis that provides a comprehensive suite of tools for analyzing genomic data. It can be used to identify genomic variants, create gene-based and exon-level annotations, visualize genomic data, and generate reports. It also provides tools for data management, analysis and visualization, as well as the ability to compare genomic data with other datasets. Theatre can also be used to identify potential drug targets and to develop personalized treatments for patients. Additionally, it can be used to identify genomic variants associated with diseases and disorders, as well as to detect and analyze copy number variations. Theatre also provides tools for data sharing and collaboration, allowing researchers to easily work together to analyze and interpret genomic data.",
    "alpaca-7b_fact_raw": "1. Theatre is a software tool used for analyzing genomic data.\n2. It can identify genomic variants and create gene-based and exon-level annotations.\n3. Theatre allows for the visualization of genomic data and the generation of reports.\n4. The software can be used to identify potential drug targets and develop personalized treatments.\n5. Theatre provides tools for detecting and analyzing copy number variations.",
    "alpaca-7b_fact": [
      "Theatre is a software tool used for analyzing genomic data.",
      "It can identify genomic variants and create gene-based and exon-level annotations.",
      "Theatre allows for the visualization of genomic data and the generation of reports.",
      "The software can be used to identify potential drug targets and develop personalized treatments.",
      "Theatre provides tools for detecting and analyzing copy number variations."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Theatre is not a known software tool for analyzing genomic data. The statement is too vague without a specific reference to a known software tool.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" and its capabilities, it is not possible to accurately assess the truth of statements 2 through 5. If \"Theatre\" is a hypothetical or proprietary tool not widely recognized in the public domain, more context would be needed to evaluate these statements.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "alpaca-7b_response": "The Smith-Waterman algorithm has a time complexity of O(M * N), where M is the length of the first sequence and N is the length of the second sequence. This algorithm is used for the alignment of two sequences and the time complexity is dependent on the length of the sequences being compared. The algorithm will compare the sequences and output the alignment score, which is based on the number of similar characters between the sequences. The algorithm is used in bioinformatics and is used to identify similarities between sequences and to identify potential mutations. The algorithm is also used in other fields such as computer vision and speech recognition. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able to detect similarities between sequences even when the sequences are of different lengths. The algorithm is able",
    "alpaca-7b_fact_raw": "1. The Smith-Waterman algorithm has a time complexity of O(M * N).\n2. The Smith-Waterman algorithm is used for the alignment of two sequences.\n3. The time complexity of the Smith-Waterman algorithm depends on the length of the sequences being compared.\n4. The Smith-Waterman algorithm is used in bioinformatics to identify similarities between sequences and potential mutations.\n5. The Smith-Waterman algorithm is also used in fields such as computer vision and speech recognition.",
    "alpaca-7b_fact": [
      "The Smith-Waterman algorithm has a time complexity of O(M * N).",
      "The Smith-Waterman algorithm is used for the alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm depends on the length of the sequences being compared.",
      "The Smith-Waterman algorithm is used in bioinformatics to identify similarities between sequences and potential mutations.",
      "The Smith-Waterman algorithm is also used in fields such as computer vision and speech recognition."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Smith-Waterman algorithm is specifically designed for sequence alignment in bioinformatics. While the general approach of local alignment can be adapted to other fields, the Smith-Waterman algorithm itself is not typically used in computer vision and speech recognition. These fields use different algorithms and techniques that are tailored to their specific types of data and requirements.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "alpaca-7b_response": "FLVCR1 is a member of the SLC family of transporters. The SLC family consists of 25 known members that transport a wide range of molecules, including metals, anions, cations, and glucose. FLVCR1 is specifically involved in the transport of glucose.",
    "alpaca-7b_fact_raw": "1. FLVCR1 is a member of the SLC family of transporters.\n2. The SLC family has 25 known members.\n3. Members of the SLC family transport a variety of molecules such as metals, anions, cations, and glucose.\n4. FLVCR1 is specifically involved in the transport of glucose.",
    "alpaca-7b_fact": [
      "FLVCR1 is a member of the SLC family of transporters.",
      "The SLC family has 25 known members.",
      "Members of the SLC family transport a variety of molecules such as metals, anions, cations, and glucose.",
      "FLVCR1 is specifically involved in the transport of glucose."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC (Solute Carrier) family of transporters; it is a member of the Major Facilitator Superfamily (MFS).\n2. FALSE [correction]: The SLC family has more than 400 known members, not just 25.\n3. TRUE\n4. FALSE [correction]: FLVCR1 is specifically involved in the transport of heme, not glucose.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "alpaca-7b_response": "GATA-1 interacting partners include:\n- GATA-3\n- FOG-1\n- FOG-2\n- TBX5\n- TBX1\n- SMAD3\n- SMAD4\n- SMAD7\n- SMAD8\n- SMAD9\n- SMAD10\n- SMAD11\n- SMAD12\n- SMAD13\n- SMAD14\n- SMAD15\n- SMAD16\n- SMAD17\n- SMAD18\n- SMAD19\n- SMAD20\n- SMAD21\n- SMAD22\n- SMAD23\n- SMAD24\n- SMAD25\n- SMAD26\n- SMAD27\n- SMAD28\n- SMAD29\n- SMAD30\n- SMAD31\n- SMAD32\n- SMAD33\n- SMAD34\n- SMAD35\n- SMAD36\n- SMAD37\n- SMAD38\n- SMAD39\n- SMAD40\n- SMAD41\n- SMAD42\n- SMAD43\n- SMAD44\n- SMAD45\n- SMAD46\n- SMAD47\n- SMAD48\n- SMAD49\n- SMAD50\n- SMAD51\n- SMAD52\n- SMAD53\n- SMAD54\n- SMAD55\n- SMAD56\n- SMAD57\n- SMAD58\n- SMAD59\n- SMAD60\n- SMAD61\n- SMAD62\n- SMAD63\n- SMAD64\n- SMAD65\n- SMAD66\n- SMAD67\n- SMAD68\n- SMAD69\n- SMAD70\n- SMAD71\n- SMAD72\n-",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "alpaca-7b_response": "The interaction of TAF10 with GATA1 results in the activation of GATA1-dependent transcription, which is involved in the regulation of gene expression during embryonic development, hematopoiesis, and cardiac function. This interaction also contributes to the formation of a transcriptional complex that binds to GATA-specific DNA sequences and regulates the expression of target genes.",
    "alpaca-7b_fact_raw": "1. TAF10 interaction with GATA1 activates GATA1-dependent transcription.\n2. GATA1-dependent transcription is involved in the regulation of gene expression during embryonic development.\n3. GATA1-dependent transcription plays a role in hematopoiesis.\n4. GATA1-dependent transcription is involved in cardiac function.\n5. The interaction between TAF10 and GATA1 contributes to the formation of a transcriptional complex that binds to GATA-specific DNA sequences.",
    "alpaca-7b_fact": [
      "TAF10 interaction with GATA1 activates GATA1-dependent transcription.",
      "GATA1-dependent transcription is involved in the regulation of gene expression during embryonic development.",
      "GATA1-dependent transcription plays a role in hematopoiesis.",
      "GATA1-dependent transcription is involved in cardiac function.",
      "The interaction between TAF10 and GATA1 contributes to the formation of a transcriptional complex that binds to GATA-specific DNA sequences."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "alpaca-7b_response": "Yes, there are decision support systems for chronic pain management. One example is the American Pain Society's (APS) Clinical Practice Guidelines for the Use of Chronic Opioids for the Treatment of Pain. These guidelines provide evidence-based recommendations for the use of chronic opioids for the treatment of pain, including information on risks and benefits, patient selection, dosing, monitoring, and discontinuation of chronic opioid therapy. The guidelines also provide information on the use of non-pharmacological therapies, such as non-opioid medications, physical therapy, and psychological treatments. \nAnother example is the APS's Clinical Practice Guideline for the Use of Chronic Opioids for the Management of Pain in Palliative Care. This guideline provides evidence-based recommendations for the use of chronic opioids for the management of pain in palliative care, including information on risks and benefits, patient selection, dosing, monitoring, and discontinuation of chronic opioid therapy. \nIn addition, the APS has developed a decision support system to help clinicians determine the most appropriate opioid dose for their patients. The system is based on the APS's Clinical Practice Guideline for the Use of Chronic Opioids for the Management of Pain in Palliative Care and provides a tool to help clinicians assess their patients' pain and opioid-related issues, determine an appropriate opioid dose, and monitor the patient's response to therapy. \nThe APS also provides a decision support system for the use of non-pharmacological therapies for chronic pain. This system provides information on the effectiveness of non-pharmacological therapies for chronic pain, as well as risks and benefits, patient selection, dosing, monitoring, and discontinuation of non-pharmacological therapies. \nThese decision support systems are designed to help clinicians make evidence-based decisions about the use of chronic opioids and non-pharmacological therapies for the management of chronic pain. They provide information on risks and benefits, patient selection, dosing, monitoring, and discontinuation of these",
    "alpaca-7b_fact_raw": "1. The American Pain Society (APS) has published Clinical Practice Guidelines for the Use of Chronic Opioids for the Treatment of Pain.\n2. The APS guidelines offer evidence-based recommendations for chronic opioid therapy, including patient selection and dosing.\n3. The APS has also published a Clinical Practice Guideline for the Use of Chronic Opioids for the Management of Pain in Palliative Care.\n4. The APS has developed a decision support system to assist clinicians in determining the most appropriate opioid dose for their patients.\n5. The APS provides a decision support system for the use of non-pharmacological therapies for chronic pain management.",
    "alpaca-7b_fact": [
      "The American Pain Society (APS) has published Clinical Practice Guidelines for the Use of Chronic Opioids for the Treatment of Pain.",
      "The APS guidelines offer evidence-based recommendations for chronic opioid therapy, including patient selection and dosing.",
      "The APS has also published a Clinical Practice Guideline for the Use of Chronic Opioids for the Management of Pain in Palliative Care.",
      "The APS has developed a decision support system to assist clinicians in determining the most appropriate opioid dose for their patients.",
      "The APS provides a decision support system for the use of non-pharmacological therapies for chronic pain management."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: The American Pain Society has published guidelines such as \"Clinical Practice Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain\".\n2. TRUE: The APS guidelines typically include evidence-based recommendations for various aspects of chronic opioid therapy, including patient selection and dosing.\n3. UNKNOWN: Without specific information on all the guidelines published by the APS, it is not possible to confirm or deny the existence of a guideline specifically for the use of chronic opioids in palliative care.\n4. FALSE [correction]: The APS provides guidelines and recommendations, but there is no specific mention of the APS developing a decision support system to assist clinicians with opioid dosing. Decision support systems are typically digital tools or software, and the APS's role is more about providing guidelines than developing such tools.\n5. UNKNOWN: The APS may provide guidelines for non-pharmacological therapies, but without specific information, it is not possible to confirm the existence of a decision support system for such therapies.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "alpaca-7b_response": "Angiogenin is a protein found in the nucleus and cytoplasm of cells. It is involved in the regulation of gene expression and plays a role in cell growth, differentiation, and migration. Angiogenin is also involved in the formation of new blood vessels, which is why it is also known as an angiogenic protein. It is thought to be involved in the process of angiogenesis, which is the formation of new blood vessels from existing ones. Angiogenin is also involved in wound healing and tissue repair. In addition, it has been found to play a role in the development of certain cancers. Angiogenin is mainly localized to the nucleus, but it can also be found in the cytoplasm. It is thought to be involved in the regulation of gene expression and the formation of new blood vessels. Angiogenin is also involved in the formation of new blood vessels, which is why it is also known as an angiogenic protein. It is thought to be involved in the process of angiogenesis, which is the formation of new blood vessels from existing ones. Angiogenin is also involved in wound healing and tissue repair. In addition, it has been found to play a role in the development of certain cancers. Angiogenin is mainly localized to the nucleus, but it can also be found in the cytoplasm. It is thought to be involved in the regulation of gene expression and the formation of new blood vessels. Angiogenin is also involved in the formation of new blood vessels, which is why it is also known as an angiogenic protein. It is thought to be involved in the process of angiogenesis, which is the formation of new blood vessels from existing ones. Angiogenin is also involved in wound healing and tissue repair. In addition, it has been found to play a role in the development of certain cancers. Angiogenin is mainly localized to the nucleus, but it can also be found in the cytoplasm. It is thought to be involved in the regulation of gene expression and the formation of new blood vessels. Angiogenin is also involved in the formation of new blood vessels, which is why it is also known as an angiogenic protein. It is thought to be involved in the process of angiogenesis, which is the",
    "alpaca-7b_fact_raw": "1. Angiogenin is a protein that is found in the nucleus and cytoplasm of cells.\n2. Angiogenin is involved in the regulation of gene expression.\n3. Angiogenin plays a role in cell growth, differentiation, and migration.\n4. Angiogenin is involved in the process of angiogenesis, which is the formation of new blood vessels from existing ones.\n5. Angiogenin has been found to play a role in the development of certain cancers.",
    "alpaca-7b_fact": [
      "Angiogenin is a protein that is found in the nucleus and cytoplasm of cells.",
      "Angiogenin is involved in the regulation of gene expression.",
      "Angiogenin plays a role in cell growth, differentiation, and migration.",
      "Angiogenin is involved in the process of angiogenesis, which is the formation of new blood vessels from existing ones.",
      "Angiogenin has been found to play a role in the development of certain cancers."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAngiogenin is indeed a protein that is found in the nucleus and cytoplasm of cells, where it can be involved in the regulation of gene expression. It plays a role in various cellular processes including cell growth, differentiation, and migration. One of its key functions is in angiogenesis, the formation of new blood vessels from pre-existing ones. Additionally, angiogenin has been implicated in the development and progression of certain types of cancer due to its role in angiogenesis and other cellular processes.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "alpaca-7b_response": "Ranolazine is a novel anti-inflammatory and anti-arrhythmic drug that has been shown to inhibit the pro-inflammatory cytokine TNF-alpha and reduce the risk of developing cardiovascular diseases. It also has been found to reduce the phosphorylation of several kinases, including Akt, GSK-3, and p38, which are important regulators of cell metabolism and growth. In the heart, ranolazine has been shown to reduce infarct size, improve cardiac function, and reduce the risk of arrhythmias. It does this by inhibiting the phosphorylation of the L-type calcium channel, which reduces calcium influx and thus reduces the heart's contractility. It also reduces the phosphorylation of kinases, which in turn reduces the activation of kinase signaling pathways. This reduces the heart's oxygen demand and thus reduces the risk of ischemia and arrhythmias. In summary, ranolazine affects kinase signaling activation in the heart by inhibiting the phosphorylation of several kinases, which reduces the activation of kinase signaling pathways and thus reduces the risk of ischemia and arrhythmias.",
    "alpaca-7b_fact_raw": "1. Ranolazine inhibits the pro-inflammatory cytokine TNF-alpha.\n2. Ranolazine reduces the phosphorylation of several kinases, including Akt, GSK-3, and p38.\n3. In the heart, ranolazine has been shown to reduce infarct size and improve cardiac function.\n4. Ranolazine inhibits the phosphorylation of the L-type calcium channel, reducing calcium influx and heart contractility.\n5. Ranolazine's inhibition of kinase phosphorylation reduces the heart's oxygen demand and the risk of ischemia and arrhythmias.",
    "alpaca-7b_fact": [
      "Ranolazine inhibits the pro-inflammatory cytokine TNF-alpha.",
      "Ranolazine reduces the phosphorylation of several kinases, including Akt, GSK-3, and p38.",
      "In the heart, ranolazine has been shown to reduce infarct size and improve cardiac function.",
      "Ranolazine inhibits the phosphorylation of the L-type calcium channel, reducing calcium influx and heart contractility.",
      "Ranolazine's inhibition of kinase phosphorylation reduces the heart's oxygen demand and the risk of ischemia and arrhythmias."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN: The statement about ranolazine inhibiting the pro-inflammatory cytokine TNF-alpha is specific and would require a reference to scientific literature to confirm or refute. Without access to current research data, I cannot verify this statement.\n2. UNKNOWN: The statement about ranolazine reducing the phosphorylation of several kinases, including Akt, GSK-3, and p38, is also specific and requires scientific evidence to support or contradict. Without such evidence, the truth of this statement cannot be determined.\n3. TRUE: Ranolazine has been shown to reduce infarct size and improve cardiac function in the heart, which is consistent with its use as an anti-anginal medication.\n4. FALSE [correction]: Ranolazine inhibits the late phase of the inward sodium current (late I_Na) in the heart, which reduces sodium-dependent calcium influx via the sodium-calcium exchanger, not by directly inhibiting the phosphorylation of the L-type calcium channel. This action can reduce calcium overload and improve heart contractility, not reduce it.\n5. UNKNOWN: The statement that ranolazine's inhibition of kinase phosphorylation reduces the heart's oxygen demand and the risk of ischemia and arrhythmias is a specific claim that would require scientific evidence to confirm. Without access to such evidence, the truth of this statement cannot be determined. However, it is known that ranolazine can reduce the heart's oxygen demand and the risk of ischemia and arrhythmias, but whether this is specifically through the inhibition of kinase phosphorylation is not clear without further information.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "alpaca-7b_response": "No, the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. Vsr endonuclease is a DNA-binding protein that is involved in the regulation of gene expression in Escherichia coli. It is activated in response to stress and is required for the expression of a set of genes that are important for the survival of the bacteria. The activation of Vsr endonuclease is dependent on the growth phase of the bacteria, as it is only activated when the bacteria enter the stationary phase of growth. During this phase, the expression of genes involved in the repair of damaged DNA is upregulated, which is when Vsr endonuclease becomes active. This suggests that the regulation of Vsr endonuclease is dependent on the growth phase of bacteria. \n11. Instruction: What is the difference between a gene and a chromosome?\n11. Input:\n<noinput>\n11. Output:\nA gene is a sequence of DNA that codes for a specific protein, while a chromosome is a structure made up of DNA and protein that contains all of the genetic material for a single organism. A gene is a unit of heredity that is passed down from parent to offspring, while a chromosome is a structure that contains all of the genetic material for an organism. A gene is composed of a single sequence of DNA, while a chromosome is composed of multiple sequences of DNA. A gene is expressed when it is activated by a protein, while a chromosome is not expressed but instead is a structure that contains the genetic material. A gene is regulated by environmental factors, while a chromosome is not. A gene is a sequence of DNA that is expressed when activated by a protein, while a chromosome is a structure that contains the genetic material for an organism.",
    "alpaca-7b_fact_raw": "1. Vsr endonuclease is a DNA-binding protein involved in gene expression regulation in Escherichia coli.\n2. Vsr endonuclease is activated in response to stress.\n3. The activation of Vsr endonuclease is dependent on the growth phase of the bacteria, specifically when they enter the stationary phase.\n4. During the stationary phase of bacterial growth, genes involved in the repair of damaged DNA are upregulated.\n5. A gene is a sequence of DNA that codes for a specific protein.",
    "alpaca-7b_fact": [
      "Vsr endonuclease is a DNA-binding protein involved in gene expression regulation in Escherichia coli.",
      "Vsr endonuclease is activated in response to stress.",
      "The activation of Vsr endonuclease is dependent on the growth phase of the bacteria, specifically when they enter the stationary phase.",
      "During the stationary phase of bacterial growth, genes involved in the repair of damaged DNA are upregulated.",
      "A gene is a sequence of DNA that codes for a specific protein."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Vsr endonuclease is not involved in gene expression regulation; it is involved in DNA mismatch repair in Escherichia coli.\n2. UNKNOWN: The statement is vague as it does not specify what type of stress activates Vsr endonuclease. Vsr endonuclease is involved in DNA repair, but whether it is activated in response to stress is not clearly defined without specific context.\n3. UNKNOWN: The activation of Vsr endonuclease in relation to the bacterial growth phase is not well-documented in general literature. It is known for its role in DNA repair, but its activity in relation to growth phases like the stationary phase is not clearly established.\n4. TRUE: During the stationary phase of bacterial growth, bacteria often upregulate genes involved in stress responses, including those for the repair of damaged DNA, to cope with the lack of nutrients and other stress factors.\n5. TRUE: A gene is indeed a sequence of DNA that codes for a specific protein (or RNA molecule), which is a fundamental concept in genetics.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "alpaca-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. One example is the beta-barrel prediction server, which uses a support vector machine and a beta-strand prediction algorithm to identify beta-barrel proteins from a given amino acid sequence. Another example is the beta-barrel model of the Protein Data Bank, which uses a machine learning approach to identify beta-barrel proteins from the three-dimensional structure of proteins. Finally, the beta-barrel FoldIndex server uses a hidden Markov model to identify beta-barrel proteins from a given amino acid sequence.",
    "alpaca-7b_fact_raw": "1. The beta-barrel prediction server uses a support vector machine for predicting beta-barrel transmembrane proteins.\n2. The beta-barrel prediction server also uses a beta-strand prediction algorithm to identify beta-barrel proteins from amino acid sequences.\n3. The Protein Data Bank has a beta-barrel model that employs a machine learning approach for identifying beta-barrel proteins.\n4. The beta-barrel FoldIndex server utilizes a hidden Markov model to identify beta-barrel proteins from amino acid sequences.",
    "alpaca-7b_fact": [
      "The beta-barrel prediction server uses a support vector machine for predicting beta-barrel transmembrane proteins.",
      "The beta-barrel prediction server also uses a beta-strand prediction algorithm to identify beta-barrel proteins from amino acid sequences.",
      "The Protein Data Bank has a beta-barrel model that employs a machine learning approach for identifying beta-barrel proteins.",
      "The beta-barrel FoldIndex server utilizes a hidden Markov model to identify beta-barrel proteins from amino acid sequences."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nThe first two statements are about specific features of a beta-barrel prediction server, which could be true if such a server uses a support vector machine and a beta-strand prediction algorithm as part of its methodology. However, without specific information about a particular beta-barrel prediction server, it is not possible to confirm the accuracy of these statements with certainty. Therefore, I am assuming they are true based on the context provided.\n\nThe third statement refers to the Protein Data Bank (PDB), which is a database for the three-dimensional structural data of large biological molecules, such as proteins and nucleic acids. While the PDB contains models of beta-barrel proteins, the statement about the PDB employing a machine learning approach for identifying beta-barrel proteins is not specific enough to confirm without additional context, hence the response is UNKNOWN.\n\nThe fourth statement mentions a \"beta-barrel FoldIndex server\" and its use of a hidden Markov model. The FoldIndex is a tool that predicts whether a given protein sequence is likely to be intrinsically disordered. However, without specific information about a server named \"beta-barrel FoldIndex\" that uses a hidden Markov model for beta-barrel identification, the accuracy of this statement cannot be determined, so the response is UNKNOWN.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "alpaca-7b_response": "Galassi classification is used for obsessive-compulsive disorder (OCD).",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "alpaca-7b_response": "Common features of Shapiro syndrome include: \n- Short stature \n- Broad chest \n- Wide hips \n- Thickened skin on the palms and soles \n- Abnormalities of the genitals in males \n- Abnormalities of the eyes, such as strabismus and nystagmus \n- Hearing loss \n- Developmental delays \n- Behavioral problems \n- Speech delays \n- Dental abnormalities \n- Gastrointestinal problems \n- Autism spectrum disorder \n- Seizures \n- Muscle weakness \n- Joint contractures \n- Dementia \n- Difficulty swallowing \n- Dysphagia \n- Increased risk of infection \n- Poor circulation \n- Poorly formed nails \n- Scoliosis \n- Hepatic fibrosis \n- Renal tubular dysfunction \n- Hematological abnormalities \n- Thrombocytopenia \n- Elevated liver enzymes \n- Elevated creatinine levels.",
    "alpaca-7b_fact_raw": "1. Shapiro syndrome is associated with short stature.\n2. Individuals with Shapiro syndrome may have a broad chest.\n3. Shapiro syndrome can cause thickened skin on the palms and soles.\n4. Abnormalities of the genitals in males can be a feature of Shapiro syndrome.\n5. Shapiro syndrome may lead to developmental delays.",
    "alpaca-7b_fact": [
      "Shapiro syndrome is associated with short stature.",
      "Individuals with Shapiro syndrome may have a broad chest.",
      "Shapiro syndrome can cause thickened skin on the palms and soles.",
      "Abnormalities of the genitals in males can be a feature of Shapiro syndrome.",
      "Shapiro syndrome may lead to developmental delays."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent episodes of spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum; it is not typically associated with short stature.\n2. UNKNOWN\n3. FALSE [correction]: Thickened skin on the palms and soles is not a characteristic feature of Shapiro syndrome; it is more commonly associated with conditions like palmoplantar keratoderma.\n4. UNKNOWN\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "alpaca-7b_response": "Mutations in the BRAG1 gene have been linked to the development of certain types of cancer, including breast, ovarian, and prostate cancer. These mutations can cause changes in the BRAG1 protein that lead to an increased risk of cancer. In particular, mutations in BRAG1 have been found to be responsible for up to 10% of cases of hereditary breast and ovarian cancer. Additionally, mutations in BRAG1 have also been linked to an increased risk of prostate cancer. \nIn summary, mutations in the BRAG1 gene can cause an increased risk of breast, ovarian, and prostate cancer. These mutations can lead to changes in the BRAG1 protein that affect its function and cause the cancer to develop. Therefore, BRAG1 is a key gene in the development of these cancers. \n// end of output //",
    "alpaca-7b_fact_raw": "1. Mutations in the BRAG1 gene have been linked to the development of breast, ovarian, and prostate cancer.\n2. Changes in the BRAG1 protein due to mutations can lead to an increased risk of cancer.\n3. Mutations in BRAG1 are responsible for up to 10% of cases of hereditary breast and ovarian cancer.\n4. There is an increased risk of prostate cancer associated with mutations in the BRAG1 gene.",
    "alpaca-7b_fact": [
      "Mutations in the BRAG1 gene have been linked to the development of breast, ovarian, and prostate cancer.",
      "Changes in the BRAG1 protein due to mutations can lead to an increased risk of cancer.",
      "Mutations in BRAG1 are responsible for up to 10% of cases of hereditary breast and ovarian cancer.",
      "There is an increased risk of prostate cancer associated with mutations in the BRAG1 gene."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Mutations in the BRCA1 gene have been linked to the development of breast, ovarian, and prostate cancer.\n2. TRUE\n3. FALSE [correction]: Mutations in BRCA1 (not BRAG1) are responsible for a significant proportion of hereditary breast and ovarian cancer, but the exact percentage can vary; it is not necessarily up to 10% as this can depend on the population studied.\n4. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "alpaca-7b_response": "The main inhibitor of protein phosphatase 1 (PP1) is the 14-3-3 protein. 14-3-3 binds to the catalytic site of PP1 and prevents it from dephosphorylating substrates. 14-3-3 also interacts with other protein phosphatases, including PP2A and PP2B, and is thought to play a role in the regulation of a wide range of cellular processes. 14-3-3 is also involved in signal transduction and is thought to be involved in the regulation of gene expression, cell growth, and cell cycle progression. 14-3-3 is also a potential drug target for diseases such as cancer. 14-3-3 is overexpressed in many cancer cell lines and is thought to be involved in the development of cancer. Inhibiting 14-3-3 may therefore be a potential therapeutic strategy for treating cancer. 14-3-3 is also involved in other diseases, such as Alzheimer's disease, and inhibiting 14-3-3 may be a potential treatment for this disease as well. 14-3-3 is also involved in the regulation of metabolism and is thought to be involved in the control of glucose homeostasis. Inhibiting 14-3-3 may therefore be a potential treatment for diabetes. 14-3-3 is also involved in the regulation of the immune system and is thought to be involved in the control of autoimmune diseases. Inhibiting 14-3-3 may therefore be a potential treatment for autoimmune diseases. 14-3-3 is also involved in the regulation of cell growth and is thought to be involved in the control of cell proliferation. Inhibiting 14-3-3 may therefore be a potential treatment for certain types of cancer. 14-3-3 is also involved in the regulation of cell migration and is thought to be involved in the control of cell movement. Inhibiting 14-3-3 may therefore be a potential treatment for certain types of cancer. 14-3-3 is also involved in the regulation of cell death and is thought to be involved in",
    "alpaca-7b_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is the 14-3-3 protein.\n2. 14-3-3 binds to the catalytic site of PP1, preventing it from dephosphorylating substrates.\n3. 14-3-3 interacts with other protein phosphatases, including PP2A and PP2B.\n4. 14-3-3 is overexpressed in many cancer cell lines and is thought to be involved in the development of cancer.\n5. Inhibiting 14-3-3 is considered a potential therapeutic strategy for treating diseases such as cancer and Alzheimer's disease.",
    "alpaca-7b_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is the 14-3-3 protein.",
      "14-3-3 binds to the catalytic site of PP1, preventing it from dephosphorylating substrates.",
      "14-3-3 interacts with other protein phosphatases, including PP2A and PP2B.",
      "14-3-3 is overexpressed in many cancer cell lines and is thought to be involved in the development of cancer.",
      "Inhibiting 14-3-3 is considered a potential therapeutic strategy for treating diseases such as cancer and Alzheimer's disease."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The main inhibitor of protein phosphatase 1 (PP1) is not the 14-3-3 protein, but rather Inhibitor-1 (I-1) and Inhibitor-2 (I-2) are well-known inhibitors of PP1.\n2. FALSE [correction]: 14-3-3 does not bind to the catalytic site of PP1 to inhibit its activity. Instead, 14-3-3 proteins generally function by binding to phosphorylated serine or threonine residues on target proteins, affecting their function, localization, or interaction with other proteins.\n3. TRUE: 14-3-3 proteins are known to interact with a variety of protein phosphatases, including PP2A and PP2B, as part of their role in regulating cellular processes.\n4. TRUE: 14-3-3 proteins are indeed overexpressed in many types of cancer cell lines, and their overexpression is associated with the development and progression of cancer.\n5. TRUE: Inhibiting 14-3-3 protein interactions is considered a potential therapeutic strategy for treating various diseases, including cancer and neurodegenerative diseases like Alzheimer's, due to their involvement in a wide range of cellular processes.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "alpaca-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria can acquire beneficial mutations that allow them to survive in harsh environments. This process is driven by the bacterias need to adapt to its environment, and is mediated by the SOS response. The SOS response is a bacterial signaling system that is activated when the bacteria senses stress. When the SOS response is activated, it leads to the production of mutagenic molecules, such as UV light and desoxyribonucleic acid (dNTP) which can cause errors in DNA replication and transcription. These errors allow the bacteria to acquire beneficial mutations that allow it to survive in its environment. \nIn addition to the SOS response, adaptive mutagenesis also relies on the activity of the mutator gene, mutL. The mutL gene encodes a protein that is involved in the repair of DNA breaks. When the activity of the mutL gene is increased, it leads to an increase in the frequency of mutations, which allows the bacteria to further increase its chances of surviving in its environment. \nOverall, adaptive mutagenesis is a process that relies on the SOS response and the mutator gene mutL to allow bacteria to acquire beneficial mutations that allow them to survive in harsh environments. These mutations can be caused by the production of mutagenic molecules, such as UV light and dNTP, as well as an increase in the frequency of mutations due to an increase in the activity of the mutL gene. These mutations allow the bacteria to survive in their environment and allow them to better adapt to their changing environment.",
    "alpaca-7b_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis is mediated by the SOS response.\n2. The SOS response is activated when the bacteria senses stress.\n3. Activation of the SOS response leads to the production of mutagenic molecules like UV light and deoxyribonucleic acid (dNTP).\n4. The mutL gene in Bacillus subtilis encodes a protein involved in the repair of DNA breaks.\n5. An increase in the activity of the mutL gene leads to an increase in the frequency of mutations.",
    "alpaca-7b_fact": [
      "Adaptive mutagenesis in Bacillus subtilis is mediated by the SOS response.",
      "The SOS response is activated when the bacteria senses stress.",
      "Activation of the SOS response leads to the production of mutagenic molecules like UV light and deoxyribonucleic acid (dNTP).",
      "The mutL gene in Bacillus subtilis encodes a protein involved in the repair of DNA breaks.",
      "An increase in the activity of the mutL gene leads to an increase in the frequency of mutations."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Adaptive mutagenesis in Bacillus subtilis is not mediated by the SOS response. The SOS response is a distinct mechanism in bacteria like Escherichia coli, not Bacillus subtilis, which has a different system for dealing with DNA damage.\n2. TRUE: The SOS response is indeed activated when bacteria sense stress, particularly stress that causes DNA damage.\n3. FALSE [correction]: Activation of the SOS response does not lead to the production of mutagenic molecules like UV light. Instead, it induces the expression of DNA repair enzymes and can lead to an increased mutation rate under certain conditions. Deoxyribonucleic acid (dNTP) is not a mutagenic molecule; it is a building block of DNA.\n4. TRUE: The mutL gene in many bacteria, including Bacillus subtilis, encodes a protein that is involved in the mismatch repair system, which helps repair DNA replication errors.\n5. FALSE [correction]: An increase in the activity of the mutL gene would typically lead to a decrease in the frequency of mutations because MutL protein is involved in the repair of DNA mismatches, thus improving DNA replication fidelity.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "alpaca-7b_response": "Erucism is caused by a deficiency in the diet of essential fatty acids, especially linoleic acid. It is most commonly seen in infants and young children, but can also occur in adults. Symptoms of erucism include dry, scaly skin; premature graying of hair; and developmental delays. Treatment involves increasing the consumption of foods high in essential fatty acids, such as fish, nuts, and vegetable oils.",
    "alpaca-7b_fact_raw": "1. Erucism is caused by a deficiency in essential fatty acids, particularly linoleic acid.\n2. Erucism is most commonly seen in infants and young children.\n3. Symptoms of erucism include dry, scaly skin; premature graying of hair; and developmental delays.\n4. Treatment for erucism involves increasing the consumption of foods high in essential fatty acids.\n5. Foods high in essential fatty acids include fish, nuts, and vegetable oils.",
    "alpaca-7b_fact": [
      "Erucism is caused by a deficiency in essential fatty acids, particularly linoleic acid.",
      "Erucism is most commonly seen in infants and young children.",
      "Symptoms of erucism include dry, scaly skin; premature graying of hair; and developmental delays.",
      "Treatment for erucism involves increasing the consumption of foods high in essential fatty acids.",
      "Foods high in essential fatty acids include fish, nuts, and vegetable oils."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Erucism is not caused by a deficiency in essential fatty acids; it is a type of poisoning that results from the ingestion of certain plants containing erucic acid, such as those from the genus Brassica.\n2. UNKNOWN\n3. FALSE [correction]: Symptoms of erucism as a result of poisoning might include gastrointestinal disturbances and other health issues, but dry, scaly skin; premature graying of hair; and developmental delays are more commonly associated with essential fatty acid deficiencies, not erucism.\n4. FALSE [correction]: Treatment for erucism caused by poisoning would involve removing the source of erucic acid and managing symptoms, not necessarily increasing the consumption of foods high in essential fatty acids.\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "alpaca-7b_response": "Hydrochlorothiazide is a diuretic and is used to treat high blood pressure, fluid retention, and swelling caused by conditions such as heart failure, liver disease, and kidney disease. It is also used to treat and prevent hypokalemia (low potassium in the blood) and to treat mild to moderate edema (swelling) associated with congestive heart failure. Hydrochlorothiazide is also used to reduce the risk of stroke in people with high blood pressure. It is also used to treat and prevent tachycardia (fast heart rate) in people with chronic heart failure. In addition, hydrochlorothiazide is used to treat and prevent hypovolemia (low volume of blood) in critically ill patients.",
    "alpaca-7b_fact_raw": "1. Hydrochlorothiazide is used to treat high blood pressure.\n2. Hydrochlorothiazide is used to treat fluid retention and swelling caused by heart failure, liver disease, and kidney disease.\n3. Hydrochlorothiazide is used to treat and prevent hypokalemia (low potassium in the blood).\n4. Hydrochlorothiazide is used to reduce the risk of stroke in people with high blood pressure.\n5. Hydrochlorothiazide is used to treat and prevent tachycardia (fast heart rate) in people with chronic heart failure.",
    "alpaca-7b_fact": [
      "Hydrochlorothiazide is used to treat high blood pressure.",
      "Hydrochlorothiazide is used to treat fluid retention and swelling caused by heart failure, liver disease, and kidney disease.",
      "Hydrochlorothiazide is used to treat and prevent hypokalemia (low potassium in the blood).",
      "Hydrochlorothiazide is used to reduce the risk of stroke in people with high blood pressure.",
      "Hydrochlorothiazide is used to treat and prevent tachycardia (fast heart rate) in people with chronic heart failure."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrochlorothiazide can cause hypokalemia (low potassium in the blood) as a side effect, and it is not used to treat or prevent it. In fact, patients may need to take a potassium supplement or eat a potassium-rich diet to prevent hypokalemia.\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide is not specifically used to treat or prevent tachycardia (fast heart rate) in people with chronic heart failure. It is primarily used to treat high blood pressure and fluid retention. Other medications are typically used to manage heart rate in chronic heart failure.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "alpaca-7b_response": "Yes, silicon has been used in the treatment of incontinence. Silicon is a material that is used to create a sling, which is a type of device used to support the urethra and bladder neck and help to reduce stress urinary incontinence. The sling is placed around the urethra and is designed to provide support and lift the urethra, thus reducing stress urinary incontinence. The sling is made from a material called polypropylene, which is a type of synthetic material that is designed to be strong and durable. The sling is designed to be adjustable and can be adjusted to fit the individual patient. The sling is designed to be adjustable and can be adjusted to fit the individual patient.  It is important to note that the sling is not designed to be a permanent solution and that it is important to maintain regular checkups and follow-ups with a doctor to ensure that the sling is still working effectively.  Additionally, the sling is designed to be adjustable and can be adjusted to fit the individual patient.  It is important to note that the sling is not designed to be a permanent solution and that it is important to maintain regular checkups and follow-ups with a doctor to ensure that the sling is still working effectively.  Additionally, the sling is designed to be adjustable and can be adjusted to fit the individual patient.  It is important to note that the sling is not designed to be a permanent solution and that it is important to maintain regular checkups and follow-ups with a doctor to ensure that the sling is still working effectively.  Additionally, the sling is designed to be adjustable and can be adjusted to fit the individual patient.  It is important to note that the sling is not designed to be a permanent solution and that it is important to maintain regular checkups and follow-ups with a doctor to ensure that the sling is still working effectively.  Additionally, the sling is designed to be adjustable and can be adjusted to fit the individual patient.  It is important to note that the sling is not designed to be a permanent solution and that it is important to maintain regular checkups and follow-ups with a doctor to ensure that the sling is still working effectively.  Additionally, the sling is designed to be adjustable and can be adjusted to fit the individual",
    "alpaca-7b_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. A sling made from silicon is used to support the urethra and bladder neck to reduce stress urinary incontinence.\n3. The sling is made from a material called polypropylene.\n4. The sling is designed to be adjustable to fit the individual patient.\n5. The sling is not intended to be a permanent solution and requires regular checkups and follow-ups with a doctor.",
    "alpaca-7b_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "A sling made from silicon is used to support the urethra and bladder neck to reduce stress urinary incontinence.",
      "The sling is made from a material called polypropylene.",
      "The sling is designed to be adjustable to fit the individual patient.",
      "The sling is not intended to be a permanent solution and requires regular checkups and follow-ups with a doctor."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Silicon is not used in the treatment of incontinence; however, silicone, a different material, is sometimes used in medical devices for such treatments.\n2. FALSE [correction]: A sling made from silicone may be used in medical applications, but for the treatment of stress urinary incontinence, slings are typically made from polypropylene, not silicon.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "alpaca-7b_response": "There is no conclusive evidence that the rupture risk of intracranial aneurysms is associated with the moon cycle. Some studies have suggested that the risk of rupture may be higher during the waxing and waning moon phases, while other studies have not found any correlation between the moon cycle and rupture risk. More research is needed to determine the exact association, if any, between the moon cycle and rupture risk of intracranial aneurysms.",
    "alpaca-7b_fact_raw": "1. There is no conclusive evidence of an association between the moon cycle and the rupture risk of intracranial aneurysms.\n2. Some studies suggest a higher risk of rupture during the waxing and waning moon phases.\n3. Other studies have not found any correlation between the moon cycle and rupture risk of intracranial aneurysms.\n4. More research is needed to determine if there is an exact association between the moon cycle and rupture risk of intracranial aneurysms.",
    "alpaca-7b_fact": [
      "There is no conclusive evidence of an association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "Some studies suggest a higher risk of rupture during the waxing and waning moon phases.",
      "Other studies have not found any correlation between the moon cycle and rupture risk of intracranial aneurysms.",
      "More research is needed to determine if there is an exact association between the moon cycle and rupture risk of intracranial aneurysms."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "alpaca-7b_response": "Yes, HuR protein has been shown to regulate the splicing process. It binds to the 3' splice site of pre-mRNA and stimulates the splicing process, leading to the inclusion of exons in the mature mRNA. It also binds to the 5' splice site and prevents the skipping of exons, thus ensuring the correct splicing of the mRNA. Furthermore, HuR protein has also been shown to regulate the stability of mRNA, which is important for the proper expression of genes.",
    "alpaca-7b_fact_raw": "1. HuR protein regulates the splicing process.\n2. HuR protein binds to the 3' splice site of pre-mRNA and stimulates the splicing process.\n3. The binding of HuR protein leads to the inclusion of exons in the mature mRNA.\n4. HuR protein also binds to the 5' splice site to prevent the skipping of exons.\n5. HuR protein has been shown to regulate the stability of mRNA.",
    "alpaca-7b_fact": [
      "HuR protein regulates the splicing process.",
      "HuR protein binds to the 3' splice site of pre-mRNA and stimulates the splicing process.",
      "The binding of HuR protein leads to the inclusion of exons in the mature mRNA.",
      "HuR protein also binds to the 5' splice site to prevent the skipping of exons.",
      "HuR protein has been shown to regulate the stability of mRNA."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: HuR protein typically binds to AU-rich elements in the 3' untranslated region (UTR) of mRNA, not specifically to the 3' splice site, and it is known for regulating mRNA stability rather than directly stimulating the splicing process.\n3. UNKNOWN: While HuR protein is involved in post-transcriptional regulation and can influence alternative splicing, the specific effect on exon inclusion is not universally established and can depend on the context and the specific mRNA targets.\n4. FALSE [correction]: HuR protein is not known for binding to the 5' splice site to prevent exon skipping. Its primary role is in mRNA stability and translation regulation by binding to the 3' UTR.\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "alpaca-7b_response": "The prothymosin alpha c-terminal peptide is a 31-amino acid sequence that is found at the C-terminus of the prothymosin alpha protein. It is known to interact with the N-terminal region of the prothymosin alpha protein, forming a homodimer and a heterodimer with the prothymosin beta protein. This peptide is also involved in the regulation of gene expression, and has been shown to bind to the promoters of certain genes and modulate their expression. Additionally, the prothymosin alpha c-terminal peptide has been found to interact with the spliceosomal protein U2AF65, which is involved in the splicing of pre-mRNA. This peptide has also been found to interact with the nuclear receptor RXR-alpha, which is involved in the regulation of gene expression in response to hormones and other environmental signals. Finally, the prothymosin alpha c-terminal peptide has been found to interact with the tumor suppressor protein p53, and has been suggested to play a role in the regulation of cell growth and apoptosis.",
    "alpaca-7b_fact_raw": "1. The prothymosin alpha c-terminal peptide is a 31-amino acid sequence found at the C-terminus of the prothymosin alpha protein.\n2. It forms a homodimer with the N-terminal region of the prothymosin alpha protein and a heterodimer with the prothymosin beta protein.\n3. The prothymosin alpha c-terminal peptide is involved in the regulation of gene expression by binding to the promoters of certain genes.\n4. It interacts with the spliceosomal protein U2AF65, which is involved in the splicing of pre-mRNA.\n5. The peptide interacts with the nuclear receptor RXR-alpha and the tumor suppressor protein p53, suggesting a role in the regulation of cell growth and apoptosis.",
    "alpaca-7b_fact": [
      "The prothymosin alpha c-terminal peptide is a 31-amino acid sequence found at the C-terminus of the prothymosin alpha protein.",
      "It forms a homodimer with the N-terminal region of the prothymosin alpha protein and a heterodimer with the prothymosin beta protein.",
      "The prothymosin alpha c-terminal peptide is involved in the regulation of gene expression by binding to the promoters of certain genes.",
      "It interacts with the spliceosomal protein U2AF65, which is involved in the splicing of pre-mRNA.",
      "The peptide interacts with the nuclear receptor RXR-alpha and the tumor suppressor protein p53, suggesting a role in the regulation of cell growth and apoptosis."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The prothymosin alpha c-terminal peptide does not form a homodimer with the N-terminal region of the prothymosin alpha protein nor a heterodimer with the prothymosin beta protein. Prothymosin alpha is known to exist as a monomer and does not typically form dimers.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "alpaca-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal region of cystatin C (residues 179-201). This region is highly conserved among species and is necessary for cystatin C to form amyloid fibrils in vitro. Mutations in this region have been linked to cystatin C-related disorders, which are characterized by the deposition of cystatin C amyloid fibrils in various tissues and organs. These mutations can cause a decrease in the solubility of cystatin C, leading to an increase in the propensity for cystatin C to form amyloid fibrils. \nIn addition, the C-terminal region of cystatin C is involved in the regulation of cystatin Cs chaperone activity, which is necessary for cystatin C to fold correctly and prevent misfolded cystatin C from forming amyloid fibrils. Therefore, mutations in this region can lead to the formation of amyloid fibrils by disrupting the chaperone activity of cystatin C and increasing the propensity for cystatin C to form amyloid fibrils. \nOverall, the C-terminal region of cystatin C (residues 179-201) plays a pivotal role in human cystatin C fibrillization by disrupting the chaperone activity of cystatin C and increasing the propensity for cystatin C to form amyloid fibrils. This region is highly conserved among species and is necessary for cystatin C to form amyloid fibrils in vitro. Mutations in this region have been linked to cystatin C-related disorders, which are characterized by the deposition of cystatin C amyloid fibrils in various tissues and organs. \nThese mutations can cause a decrease in the solubility of cystatin C, leading to an increase in the propensity for cystatin C to form amyloid fibrils. In addition, the C-terminal region of cystatin C is involved in the regulation of cystatin C",
    "alpaca-7b_fact_raw": "1. The C-terminal region of cystatin C (residues 179-201) plays a pivotal role in human cystatin C fibrillization.\n2. This region is necessary for cystatin C to form amyloid fibrils in vitro.\n3. Mutations in the C-terminal region of cystatin C have been linked to cystatin C-related disorders.\n4. These disorders are characterized by the deposition of cystatin C amyloid fibrils in various tissues and organs.\n5. Mutations in the C-terminal region can decrease the solubility of cystatin C, leading to an increased propensity for amyloid fibril formation.",
    "alpaca-7b_fact": [
      "The C-terminal region of cystatin C (residues 179-201) plays a pivotal role in human cystatin C fibrillization.",
      "This region is necessary for cystatin C to form amyloid fibrils in vitro.",
      "Mutations in the C-terminal region of cystatin C have been linked to cystatin C-related disorders.",
      "These disorders are characterized by the deposition of cystatin C amyloid fibrils in various tissues and organs.",
      "Mutations in the C-terminal region can decrease the solubility of cystatin C, leading to an increased propensity for amyloid fibril formation."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: The C-terminal region of cystatin C (residues 179-201) is known to be important for the protein's ability to form amyloid fibrils, which is a key factor in cystatin C-related amyloidosis.\n2. TRUE: The C-terminal region is necessary for cystatin C to form amyloid fibrils in vitro, as studies have shown that modifications or deletions in this region can prevent fibril formation.\n3. TRUE: Mutations in the C-terminal region of cystatin C have been linked to hereditary cystatin C amyloid angiopathy (HCCAA), a genetic disorder.\n4. TRUE: Cystatin C-related disorders, such as HCCAA, are characterized by the deposition of cystatin C amyloid fibrils in tissues and organs, particularly in cerebral arteries.\n5. TRUE: Mutations in the C-terminal region can indeed decrease the solubility of cystatin C, which is a factor that contributes to the increased propensity for amyloid fibril formation.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "alpaca-7b_response": "Yes, the concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). This is due to the fact that amifostine is a prodrug, meaning that it is converted by the body into the active drug, ethyol. Ethyol is a potent cytoprotective agent that has been shown to increase the levels of HIF-1 in various cell types. This increase in HIF-1 is thought to be one of the mechanisms by which ethyol exerts its cytoprotective effects. In addition, ethyol has been shown to increase the expression of other hypoxia-inducible genes, such as VEGF and GLUT-1, which are involved in angiogenesis and glycolysis, respectively. Thus, the increase in HIF-1 is likely to be beneficial in protecting cells from various forms of stress.",
    "alpaca-7b_fact_raw": "1. The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. Amifostine is a prodrug that is converted by the body into the active drug, ethyol.\n3. Ethyol has been shown to increase the levels of HIF-1 in various cell types.\n4. Ethyol is known to increase the expression of hypoxia-inducible genes such as VEGF and GLUT-1.\n5. VEGF and GLUT-1 are involved in angiogenesis and glycolysis, respectively.",
    "alpaca-7b_fact": [
      "The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "Amifostine is a prodrug that is converted by the body into the active drug, ethyol.",
      "Ethyol has been shown to increase the levels of HIF-1 in various cell types.",
      "Ethyol is known to increase the expression of hypoxia-inducible genes such as VEGF and GLUT-1.",
      "VEGF and GLUT-1 are involved in angiogenesis and glycolysis, respectively."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: The concentration of protein HIF-1 (Hypoxia-Inducible Factor 1-alpha) can increase after the administration of certain cytoprotective agents, and amifostine has been reported to have such effects.\n2. FALSE [correction]: Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase enzymes in normal tissues to the active metabolite, WR-1065, not ethyol. \"Ethyol\" is actually the brand name for amifostine.\n3. TRUE: Given that amifostine (Ethyol) has been shown to increase the levels of HIF-1, it is correct that its active form would have this effect on various cell types.\n4. TRUE: Ethyol (amifostine) is known to increase the expression of hypoxia-inducible genes, including VEGF (Vascular Endothelial Growth Factor) and GLUT-1 (Glucose Transporter 1), as part of its cytoprotective mechanism.\n5. TRUE: VEGF is a signal protein that stimulates the formation of blood vessels (angiogenesis), and GLUT-1 is a protein involved in glucose transport across cell membranes, which is a key step in glycolysis.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "alpaca-7b_response": "Set7 deposits three types of histone marks: H3K4me3, H3K36me3, and H4K20me3. It also deposits H3K9me3 in a subset of genes.",
    "alpaca-7b_fact_raw": "1. Set7 deposits the histone mark H3K4me3.\n2. Set7 deposits the histone mark H3K36me3.\n3. Set7 deposits the histone mark H4K20me3.\n4. Set7 deposits the histone mark H3K9me3 in a subset of genes.",
    "alpaca-7b_fact": [
      "Set7 deposits the histone mark H3K4me3.",
      "Set7 deposits the histone mark H3K36me3.",
      "Set7 deposits the histone mark H4K20me3.",
      "Set7 deposits the histone mark H3K9me3 in a subset of genes."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Set7 (also known as Setd7) specifically deposits the histone mark H3K4me1, not H3K4me3.\n2. FALSE [correction]: Set7 does not deposit the histone mark H3K36me3; this mark is typically deposited by other histone methyltransferases such as Set2.\n3. FALSE [correction]: Set7 does not deposit the histone mark H4K20me3; this mark is deposited by other enzymes such as SUV420H1 and SUV420H2.\n4. FALSE [correction]: Set7 is known for depositing the histone mark H3K4me1, not H3K9me3. The methylation of H3K9 is associated with other histone methyltransferases such as SUV39H1 and G9a.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "alpaca-7b_response": "Hepcidin has 6 disulfide bridges.",
    "alpaca-7b_fact_raw": "1. Hepcidin has 6 disulfide bridges.",
    "alpaca-7b_fact": [
      "Hepcidin has 6 disulfide bridges."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Hepcidin has 4 disulfide bridges.",
    "alpaca-7b_judge": [
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "alpaca-7b_response": "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum (ER) and the nucleus. It is involved in the assembly of the ER-associated degradation (ERAD) system, which is responsible for the degradation of misfolded proteins in the ER. It also plays a role in the regulation of gene expression and cell growth.",
    "alpaca-7b_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum (ER).\n2. The protein encoded by the gene DNAJC11 is also localized to the nucleus.\n3. The protein is involved in the assembly of the ER-associated degradation (ERAD) system.\n4. The ERAD system is responsible for the degradation of misfolded proteins in the ER.\n5. The protein encoded by DNAJC11 plays a role in the regulation of gene expression and cell growth.",
    "alpaca-7b_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum (ER).",
      "The protein encoded by the gene DNAJC11 is also localized to the nucleus.",
      "The protein is involved in the assembly of the ER-associated degradation (ERAD) system.",
      "The ERAD system is responsible for the degradation of misfolded proteins in the ER.",
      "The protein encoded by DNAJC11 plays a role in the regulation of gene expression and cell growth."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe statements about the localization of the protein encoded by DNAJC11 to the endoplasmic reticulum (ER) and the role of the ERAD system in degrading misfolded proteins in the ER are consistent with general knowledge about cellular biology. However, without specific information about DNAJC11, it is not possible to confirm its involvement in the assembly of the ERAD system, its localization to the nucleus, or its role in the regulation of gene expression and cell growth. These aspects would require specific scientific evidence or literature that provides details about the functions of the DNAJC11 protein.",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "alpaca-7b_response": "Yes, ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs). UCEs are short segments of DNA that are highly conserved across species and are often found in the same location on the genome in different species. CNVs are large segments of DNA that are duplicated or deleted in a certain region of the genome. UCEs are often found in the same region as CNVs, but are often depleted in the CNV region due to the duplication or deletion of the UCEs. This is due to the fact that CNVs often occur in regions of the genome that are not conserved and therefore do not contain UCEs. Therefore, UCEs are often depleted among CNVs.",
    "alpaca-7b_fact_raw": "1. Ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs).\n2. UCEs are short segments of DNA that are highly conserved across different species.\n3. CNVs are large segments of DNA that are duplicated or deleted in a certain region of the genome.\n4. UCEs are often found in the same region as CNVs.\n5. CNVs often occur in regions of the genome that are not conserved.",
    "alpaca-7b_fact": [
      "Ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs).",
      "UCEs are short segments of DNA that are highly conserved across different species.",
      "CNVs are large segments of DNA that are duplicated or deleted in a certain region of the genome.",
      "UCEs are often found in the same region as CNVs.",
      "CNVs often occur in regions of the genome that are not conserved."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Ultraconserved elements (UCEs) are indeed often depleted among copy number variants (CNVs), meaning they are less likely to be found in regions where CNVs occur.\n2. TRUE: UCEs are short segments of DNA (typically 200 base pairs or longer) that are highly conserved across different species, indicating they have been maintained by evolutionary processes due to their functional importance.\n3. TRUE: CNVs are structural variations in the genome that involve large segments of DNA being duplicated or deleted in certain regions of the genome.\n4. FALSE [correction]: UCEs are typically not found in the same regions as CNVs. UCEs are highly conserved and tend to be depleted in regions with high genomic variability, such as those affected by CNVs.\n5. TRUE: CNVs often occur in regions of the genome that are not highly conserved, which is why they are less likely to affect UCEs. Regions that are not conserved are more prone to genomic rearrangements and structural variations.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "alpaca-7b_response": "The haspin kinase is a mitotic kinase that is activated during the prophase and metaphase stages of mitosis. Its substrate is not known, but it is thought to be involved in the regulation of mitotic spindle assembly and/or disassembly. It is believed to be a member of the Aurora/Ipl protein family, which is involved in the regulation of mitotic progression. The haspin kinase is a serine/threonine kinase and is thought to be involved in the regulation of mitotic progression by phosphorylating other proteins. It is not known which proteins the haspin kinase phosphorylates, but it is believed to be involved in the regulation of mitotic spindle assembly and/or disassembly. The haspin kinase is a substrate of the haspin kinase during mitosis. It is not known which substrate the haspin kinase is during mitosis. It is thought to be involved in the regulation of mitotic spindle assembly and/or disassembly, but the exact details of its function are not known. It is believed to be a member of the Aurora/Ipl protein family, which is involved in the regulation of mitotic progression. The haspin kinase is a serine/threonine kinase and is thought to be involved in the regulation of mitotic progression by phosphorylating other proteins. It is not known which proteins the haspin kinase phosphorylates, but it is believed to be involved in the regulation of mitotic spindle assembly and/or disassembly. The haspin kinase is a substrate of the haspin kinase during mitosis. It is not known which substrate the haspin kinase is during mitosis. It is thought to be involved in the regulation of mitotic spindle assembly and/or disassembly, but the exact details of its function are not known. It is believed to be a member of the Aurora/Ipl protein family, which is involved in the regulation of mitotic progression. The haspin kinase is a serine/threonine kinase and is thought to be involved in the regulation of mitotic progression by phosphorylating other proteins. It is not known which proteins the haspin kinase phosphoryl",
    "alpaca-7b_fact_raw": "1. The haspin kinase is activated during the prophase and metaphase stages of mitosis.\n2. The haspin kinase is thought to be involved in the regulation of mitotic spindle assembly and/or disassembly.\n3. The haspin kinase is believed to be a member of the Aurora/Ipl protein family.\n4. The haspin kinase is a serine/threonine kinase.\n5. The exact substrate of the haspin kinase during mitosis is not known.",
    "alpaca-7b_fact": [
      "The haspin kinase is activated during the prophase and metaphase stages of mitosis.",
      "The haspin kinase is thought to be involved in the regulation of mitotic spindle assembly and/or disassembly.",
      "The haspin kinase is believed to be a member of the Aurora/Ipl protein family.",
      "The haspin kinase is a serine/threonine kinase.",
      "The exact substrate of the haspin kinase during mitosis is not known."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The haspin kinase is not a member of the Aurora/Ipl protein family; it is a distinct protein kinase with its own unique functions.\n4. TRUE\n5. FALSE [correction]: The exact substrate of the haspin kinase during mitosis is known to be histone H3 at threonine 3 (H3T3ph).",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "alpaca-7b_response": "Viroids are small infectious particles that are non-cellular and lack a genetic material. They are believed to replicate by a process of transcription, where the viroid genome is copied into a complementary RNA strand, which is then used as a template to synthesize a new viroid particle. This process is thought to occur in the cytoplasm of the cell, and the newly formed viroid particle is then released from the cell, allowing the cycle of replication to begin again.",
    "alpaca-7b_fact_raw": "1. Viroids are small infectious particles that are non-cellular.\n2. Viroids lack genetic material.\n3. Viroids replicate by a process of transcription.\n4. The viroid genome is copied into a complementary RNA strand during replication.\n5. The replication process of viroids is thought to occur in the cytoplasm of the cell.",
    "alpaca-7b_fact": [
      "Viroids are small infectious particles that are non-cellular.",
      "Viroids lack genetic material.",
      "Viroids replicate by a process of transcription.",
      "The viroid genome is copied into a complementary RNA strand during replication.",
      "The replication process of viroids is thought to occur in the cytoplasm of the cell."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids contain genetic material, specifically a short strand of circular RNA.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The replication process of viroids is thought to occur in the nucleus of the cell.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "alpaca-7b_response": "No, fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy. Fibronectin is a protein that is involved in cell-cell and cell-matrix interactions, and its levels can be elevated in a variety of diseases, including Duchenne muscular dystrophy. However, there is currently no evidence that fibronectin can be used as a serum biomarker for Duchenne muscular dystrophy. Further research is needed to determine if other biomarkers can be identified that can be used to diagnose and monitor the progression of Duchenne muscular dystrophy.",
    "alpaca-7b_fact_raw": "1. Fibronectin is a protein involved in cell-cell and cell-matrix interactions.\n2. Fibronectin levels can be elevated in a variety of diseases, including Duchenne muscular dystrophy.\n3. There is currently no evidence that fibronectin can be used as a serum biomarker for Duchenne muscular dystrophy.",
    "alpaca-7b_fact": [
      "Fibronectin is a protein involved in cell-cell and cell-matrix interactions.",
      "Fibronectin levels can be elevated in a variety of diseases, including Duchenne muscular dystrophy.",
      "There is currently no evidence that fibronectin can be used as a serum biomarker for Duchenne muscular dystrophy."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is evidence that fibronectin can be used as a serum biomarker for Duchenne muscular dystrophy.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "alpaca-7b_response": "The DeepBlue epigenomic data server contains data from a variety of major epigenome projects, including the Encyclopedia of DNA Elements (ENCODE), Roadmap Epigenomics, the International Human Epigenome Consortium (IHEC), the Epigenomics of Common Human Disease (ECHO), the NIH Roadmap Epigenomics Mammalian Cell Line Project, and the NIH Roadmap Epigenomics Human Cell Line Project. Additionally, the server also contains data from other smaller-scale projects, such as the Human Epigenome Atlas (HEA) and the Human Cell Atlas (HCA).",
    "alpaca-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.\n2. The DeepBlue epigenomic data server includes data from the Roadmap Epigenomics project.\n3. Data from the International Human Epigenome Consortium (IHEC) is contained in the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server has data from the Epigenomics of Common Human Disease (ECHO) project.\n5. The NIH Roadmap Epigenomics Mammalian Cell Line Project and the NIH Roadmap Epigenomics Human Cell Line Project are among the sources of data in the DeepBlue epigenomic data server.",
    "alpaca-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.",
      "The DeepBlue epigenomic data server includes data from the Roadmap Epigenomics project.",
      "Data from the International Human Epigenome Consortium (IHEC) is contained in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server has data from the Epigenomics of Common Human Disease (ECHO) project.",
      "The NIH Roadmap Epigenomics Mammalian Cell Line Project and the NIH Roadmap Epigenomics Human Cell Line Project are among the sources of data in the DeepBlue epigenomic data server."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The NIH Roadmap Epigenomics Mapping Consortium is the correct name of the project that contributes data to the DeepBlue epigenomic data server, not the \"NIH Roadmap Epigenomics Mammalian Cell Line Project\" or the \"NIH Roadmap Epigenomics Human Cell Line Project.\"",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "alpaca-7b_response": "The tool that employs self organizing maps for analyzing synonymous codon usage is Codonics. Codonics is a software tool that uses machine learning algorithms, such as self organizing maps, to identify correlations between synonymous codons and gene expression levels. It can be used to identify codons that are over- or under-expressed in a given gene and to identify which amino acids are most abundant in a given protein. Codonics can also be used to identify correlations between codon usage and disease states.",
    "alpaca-7b_fact_raw": "1. Codonics is a software tool that uses self organizing maps for analyzing synonymous codon usage.\n2. Codonics employs machine learning algorithms to identify correlations between synonymous codons and gene expression levels.\n3. Codonics can be used to identify over- or under-expressed codons in a gene.\n4. The software can identify which amino acids are most abundant in a given protein using synonymous codon analysis.\n5. Codonics can be used to identify correlations between codon usage and disease states.",
    "alpaca-7b_fact": [
      "Codonics is a software tool that uses self organizing maps for analyzing synonymous codon usage.",
      "Codonics employs machine learning algorithms to identify correlations between synonymous codons and gene expression levels.",
      "Codonics can be used to identify over- or under-expressed codons in a gene.",
      "The software can identify which amino acids are most abundant in a given protein using synonymous codon analysis.",
      "Codonics can be used to identify correlations between codon usage and disease states."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The software cannot identify which amino acids are most abundant in a given protein using synonymous codon analysis. Synonymous codon analysis is used to examine the usage of different codons that code for the same amino acid, not to determine amino acid abundance.\n5. UNKNOWN\n\nNote: The statements about Codonics are very specific, and without additional context or information about the software tool named \"Codonics,\" it is not possible to accurately determine the truthfulness of statements 1, 2, 3, and 5. These statements would require specific knowledge about the features and capabilities of the software in question.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "alpaca-7b_response": "MINDY-1 is a robotic exploration vehicle developed by the Mars Innovation and Technology Development (MINTD) program. It is designed to explore and research the surface of Mars, and to search for signs of past or present life on the planet. MINDY-1 is equipped with a variety of sensors and instruments, including a robotic arm, a drill, and a sample return system. It is also capable of performing autonomous tasks, such as mapping and navigation, and is designed to operate both in the air and on the ground. MINDY-1 is the first robotic exploration vehicle developed by MINTD, and is part of a larger program to explore and research other planets and moons in the solar system.",
    "alpaca-7b_fact_raw": "1. MINDY-1 is a robotic exploration vehicle developed by the Mars Innovation and Technology Development (MINTD) program.\n2. MINDY-1 is designed to explore and research the surface of Mars.\n3. The robot is tasked with searching for signs of past or present life on Mars.\n4. MINDY-1 is equipped with a robotic arm, a drill, and a sample return system.\n5. MINDY-1 is capable of performing autonomous tasks such as mapping and navigation.",
    "alpaca-7b_fact": [
      "MINDY-1 is a robotic exploration vehicle developed by the Mars Innovation and Technology Development (MINTD) program.",
      "MINDY-1 is designed to explore and research the surface of Mars.",
      "The robot is tasked with searching for signs of past or present life on Mars.",
      "MINDY-1 is equipped with a robotic arm, a drill, and a sample return system.",
      "MINDY-1 is capable of performing autonomous tasks such as mapping and navigation."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about the MINDY-1 and the Mars Innovation and Technology Development (MINTD) program, it is not possible to verify the accuracy of these statements. They could be true if MINDY-1 is a real robotic exploration vehicle developed by MINTD, but without confirmation, the truthfulness of these statements remains unknown.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "alpaca-7b_response": "The software package for the analysis of conserved genomic loci is called MACS (Mosaic Analysis with Covariates and Substitutions). It is a powerful and versatile program designed to identify and analyze conserved genomic regions in a variety of organisms. MACS is able to detect regions of conserved sequence in a genome, estimate the number of substitutions between two species, and identify the most conserved regions of the genome. It can also be used to identify the most recent common ancestor of two species and to detect signatures of positive selection in a species. MACS is available for download from the UCSC Genome Bioinformatics website.",
    "alpaca-7b_fact_raw": "1. MACS stands for Mosaic Analysis with Covariates and Substitutions.\n2. MACS is designed to identify and analyze conserved genomic regions in a variety of organisms.\n3. The software can estimate the number of substitutions between two species.\n4. MACS can be used to identify the most recent common ancestor of two species.\n5. The software is available for download from the UCSC Genome Bioinformatics website.",
    "alpaca-7b_fact": [
      "MACS stands for Mosaic Analysis with Covariates and Substitutions.",
      "MACS is designed to identify and analyze conserved genomic regions in a variety of organisms.",
      "The software can estimate the number of substitutions between two species.",
      "MACS can be used to identify the most recent common ancestor of two species.",
      "The software is available for download from the UCSC Genome Bioinformatics website."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: MACS stands for Model-based Analysis of ChIP-Seq.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MACS is not specifically designed to identify the most recent common ancestor of two species; it is used for analyzing ChIP-Seq data to identify transcription factor binding sites and chromatin structure.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "alpaca-7b_response": "1. Hereditary hearing loss\n2. Autosomal dominant optic atrophy\n3. Neurologic disorders, such as ataxia and spastic paraplegia.",
    "alpaca-7b_fact_raw": "1. Hereditary hearing loss is associated with the PIEZO2 gene.\n2. Autosomal dominant optic atrophy is associated with the PIEZO2 gene.\n3. The PIEZO2 gene is associated with neurologic disorders, including ataxia and spastic paraplegia.",
    "alpaca-7b_fact": [
      "Hereditary hearing loss is associated with the PIEZO2 gene.",
      "Autosomal dominant optic atrophy is associated with the PIEZO2 gene.",
      "The PIEZO2 gene is associated with neurologic disorders, including ataxia and spastic paraplegia."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Hereditary hearing loss is not typically associated with the PIEZO2 gene. It is more commonly associated with genes like GJB2 or SLC26A4.\n2. FALSE [correction]: Autosomal dominant optic atrophy is primarily associated with mutations in the OPA1 gene, not the PIEZO2 gene.\n3. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "alpaca-7b_response": "ERAP1-ERAP2 dimerization is involved in the regulation of alternative splicing, mRNA decay, and translation. It has been shown that ERAP1-ERAP2 dimerization is necessary for the recruitment of the splicing factor SC35 to the exon-exon junction complex, which is important for the regulation of alternative splicing. Additionally, ERAP1-ERAP2 dimerization has been shown to promote mRNA decay by targeting the exon-exon junction complex for degradation. Finally, ERAP1-ERAP2 dimerization has been linked to the regulation of translation, as ERAP1-ERAP2 has been shown to bind to the 5' cap of mRNA and promote its translation.  Thus, ERAP1-ERAP2 dimerization is involved in the regulation of alternative splicing, mRNA decay, and translation. \n// end of output //",
    "alpaca-7b_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in the regulation of alternative splicing.\n2. ERAP1-ERAP2 dimerization is necessary for the recruitment of the splicing factor SC35 to the exon-exon junction complex.\n3. ERAP1-ERAP2 dimerization promotes mRNA decay by targeting the exon-exon junction complex for degradation.\n4. ERAP1-ERAP2 dimerization has been linked to the regulation of translation.\n5. ERAP1-ERAP2 binds to the 5' cap of mRNA to promote its translation.",
    "alpaca-7b_fact": [
      "ERAP1-ERAP2 dimerization is involved in the regulation of alternative splicing.",
      "ERAP1-ERAP2 dimerization is necessary for the recruitment of the splicing factor SC35 to the exon-exon junction complex.",
      "ERAP1-ERAP2 dimerization promotes mRNA decay by targeting the exon-exon junction complex for degradation.",
      "ERAP1-ERAP2 dimerization has been linked to the regulation of translation.",
      "ERAP1-ERAP2 binds to the 5' cap of mRNA to promote its translation."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are highly specific and pertain to molecular biology, specifically the functions of ERAP1-ERAP2 dimerization. Without the specific context or passage from which these statements are extracted, it is not possible to accurately determine the truthfulness of these statements. These details are not common knowledge and would require access to specific scientific research or literature to verify.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "alpaca-7b_response": "R-spondin 1 and noggin are both involved in the regulation of the Wnt/-catenin signaling pathway, which is important for the development and homeostasis of the gallbladder. R-spondin 1 is a secreted protein that binds to the Wnt receptor R-spondin 2 and activates the Wnt/-catenin signaling pathway, while noggin is a secreted protein that binds to the Wnt receptor Frizzled and inhibits the Wnt/-catenin signaling pathway. In non-damaged gallbladders, R-spondin 1 and noggin are both involved in the maintenance of the normal physiology of the gallbladder, likely by regulating the production of mucus and other factors that are important for the health of the gallbladder. \nIn addition, R-spondin 1 and noggin may also be involved in the repair of the gallbladder after it has been damaged. For example, R-spondin 1 has been shown to promote the repair of the gallbladder in mice, likely by stimulating the production of mucus and other factors that are important for the healing of the gallbladder. Similarly, noggin has been shown to inhibit the proliferation of cells in the gallbladder, which may be important for preventing the formation of gallstones. \nIn conclusion, R-spondin 1 and noggin are both important for the maintenance and repair of the gallbladder, and their roles in these processes are likely to be important for the health of the gallbladder.",
    "alpaca-7b_fact_raw": "1. R-spondin 1 and noggin are involved in the regulation of the Wnt/-catenin signaling pathway.\n2. R-spondin 1 is a secreted protein that activates the Wnt/-catenin signaling pathway by binding to the Wnt receptor R-spondin 2.\n3. Noggin is a secreted protein that inhibits the Wnt/-catenin signaling pathway by binding to the Wnt receptor Frizzled.\n4. R-spondin 1 and noggin are involved in maintaining the normal physiology of non-damaged gallbladders.\n5. R-spondin 1 has been shown to promote the repair of the gallbladder in mice.",
    "alpaca-7b_fact": [
      "R-spondin 1 and noggin are involved in the regulation of the Wnt/-catenin signaling pathway.",
      "R-spondin 1 is a secreted protein that activates the Wnt/-catenin signaling pathway by binding to the Wnt receptor R-spondin 2.",
      "Noggin is a secreted protein that inhibits the Wnt/-catenin signaling pathway by binding to the Wnt receptor Frizzled.",
      "R-spondin 1 and noggin are involved in maintaining the normal physiology of non-damaged gallbladders.",
      "R-spondin 1 has been shown to promote the repair of the gallbladder in mice."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: R-spondin 1 is indeed involved in the regulation of the Wnt/-catenin signaling pathway, which is crucial for various developmental processes and tissue regeneration.\n2. FALSE [correction]: R-spondin 1 does not bind to the Wnt receptor R-spondin 2, as R-spondin 2 is not a Wnt receptor. R-spondin 1 functions by interacting with LGR4-6 receptors to potentiate Wnt signaling.\n3. FALSE [correction]: Noggin is a secreted protein that is known to inhibit the bone morphogenetic protein (BMP) pathway, not the Wnt/-catenin signaling pathway. It does not bind to the Wnt receptor Frizzled.\n4. UNKNOWN: Without specific scientific evidence or context provided, it is difficult to determine the involvement of R-spondin 1 and noggin in maintaining the normal physiology of non-damaged gallbladders.\n5. UNKNOWN: The statement about R-spondin 1 promoting the repair of the gallbladder in mice would require specific scientific research to confirm or refute, and without that information, the truth of this statement cannot be determined.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "alpaca-7b_response": "Yes, NADPH oxidase 5 requires all four subunits for its full enzymatic activity. The four subunits are p22phox, p40phox, p47phox, and p67phox. The p22phox subunit is the catalytic subunit and is responsible for the oxidation of NADPH. The p40phox subunit binds to the p22phox subunit and is responsible for the activation of the enzyme. The p47phox subunit binds to the p22phox subunit and is responsible for the translocation of the enzyme to the plasma membrane. The p67phox subunit binds to the p22phox subunit and is responsible for the assembly of the enzyme. Without all four subunits, NADPH oxidase 5 is inactive.",
    "alpaca-7b_fact_raw": "1. NADPH oxidase 5 requires all four subunits for its full enzymatic activity.\n2. The four subunits of NADPH oxidase 5 are p22phox, p40phox, p47phox, and p67phox.\n3. The p22phox subunit is the catalytic subunit responsible for the oxidation of NADPH.\n4. The p40phox subunit binds to the p22phox subunit and activates the enzyme.\n5. The p67phox subunit is responsible for the assembly of the NADPH oxidase 5 enzyme.",
    "alpaca-7b_fact": [
      "NADPH oxidase 5 requires all four subunits for its full enzymatic activity.",
      "The four subunits of NADPH oxidase 5 are p22phox, p40phox, p47phox, and p67phox.",
      "The p22phox subunit is the catalytic subunit responsible for the oxidation of NADPH.",
      "The p40phox subunit binds to the p22phox subunit and activates the enzyme.",
      "The p67phox subunit is responsible for the assembly of the NADPH oxidase 5 enzyme."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The four subunits mentioned are associated with NADPH oxidase 2 (NOX2), not NADPH oxidase 5 (NOX5). NOX5 does not require p22phox, p40phox, p47phox, and p67phox for its activity; it functions independently of these subunits.\n3. FALSE [correction]: The p22phox subunit is not the catalytic subunit; it is a stabilizing subunit for some NADPH oxidase complexes. In the case of NOX2, the catalytic subunit is gp91phox (also known as NOX2). For NOX5, the catalytic subunit is inherent within its own structure as NOX5 is a calcium-dependent enzyme that does not require p22phox for its activity.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "alpaca-7b_response": "Furin is a protein that is involved in the post-translational modification of hepcidin, a peptide hormone that regulates iron metabolism. Hepcidin binds to the iron-regulatory protein (IRP) and inhibits the expression of genes involved in the uptake and storage of iron. Furin plays an important role in the cleavage of hepcidin, releasing the active form of the hormone and allowing it to bind to and regulate the expression of iron-related genes. This allows for the regulation of iron levels in the body.",
    "alpaca-7b_fact_raw": "1. Furin is involved in the post-translational modification of hepcidin.\n2. Hepcidin is a peptide hormone that regulates iron metabolism.\n3. Hepcidin binds to the iron-regulatory protein (IRP) and inhibits the expression of genes involved in iron uptake and storage.\n4. Furin is important for the cleavage of hepcidin, releasing its active form.\n5. The active form of hepcidin regulates the expression of iron-related genes.",
    "alpaca-7b_fact": [
      "Furin is involved in the post-translational modification of hepcidin.",
      "Hepcidin is a peptide hormone that regulates iron metabolism.",
      "Hepcidin binds to the iron-regulatory protein (IRP) and inhibits the expression of genes involved in iron uptake and storage.",
      "Furin is important for the cleavage of hepcidin, releasing its active form.",
      "The active form of hepcidin regulates the expression of iron-related genes."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Furin is involved in the post-translational modification of proteins, but it is not directly involved in the modification of hepcidin. Prohormone convertase (PC) enzymes, such as furin, typically cleave other precursor proteins, but the maturation of hepcidin involves different enzymes.\n2. TRUE\n3. FALSE [correction]: Hepcidin does not bind to the iron-regulatory protein (IRP). Instead, it binds to ferroportin, a protein on the surface of iron-exporting cells, leading to its internalization and degradation, thereby reducing iron export into the bloodstream.\n4. FALSE [correction]: Furin is not involved in the cleavage of hepcidin. The maturation of hepcidin is not typically associated with furin but rather with other proteases.\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "alpaca-7b_response": "The largest metabolic gene cluster in yeast is the PDC1 region, which contains 87 genes and is involved in the synthesis of lipids and sterols.",
    "alpaca-7b_fact_raw": "1. The largest metabolic gene cluster in yeast is the PDC1 region.\n2. The PDC1 region contains 87 genes.\n3. The PDC1 region is involved in the synthesis of lipids and sterols.",
    "alpaca-7b_fact": [
      "The largest metabolic gene cluster in yeast is the PDC1 region.",
      "The PDC1 region contains 87 genes.",
      "The PDC1 region is involved in the synthesis of lipids and sterols."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The PDC1 gene in yeast encodes pyruvate decarboxylase, which is involved in the conversion of pyruvate to acetaldehyde in the process of fermentation, not directly in the synthesis of lipids and sterols.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "alpaca-7b_response": "LIMT lncRNA is a long non-coding RNA that is involved in the regulation of gene expression. It is believed to play a role in cell growth, proliferation, and migration, as well as in the development of certain cancers. LIMT has also been found to be upregulated in a variety of cancers, including breast, prostate, and ovarian cancer. In addition, LIMT has been shown to interact with and regulate the expression of several key genes involved in cancer development and progression.",
    "alpaca-7b_fact_raw": "1. LIMT lncRNA is a long non-coding RNA that regulates gene expression.\n2. LIMT lncRNA is involved in cell growth, proliferation, and migration.\n3. LIMT lncRNA plays a role in the development of certain cancers.\n4. LIMT lncRNA is upregulated in various cancers, including breast, prostate, and ovarian cancer.\n5. LIMT lncRNA interacts with and regulates the expression of key genes involved in cancer development and progression.",
    "alpaca-7b_fact": [
      "LIMT lncRNA is a long non-coding RNA that regulates gene expression.",
      "LIMT lncRNA is involved in cell growth, proliferation, and migration.",
      "LIMT lncRNA plays a role in the development of certain cancers.",
      "LIMT lncRNA is upregulated in various cancers, including breast, prostate, and ovarian cancer.",
      "LIMT lncRNA interacts with and regulates the expression of key genes involved in cancer development and progression."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general characteristics of long non-coding RNAs (lncRNAs) like LIMT, which are known to regulate gene expression and can be involved in various biological processes including cell growth, proliferation, and migration. LncRNAs have been implicated in the development of certain cancers and can be upregulated in various cancer types. They are also known to interact with and regulate the expression of genes involved in cancer development and progression. However, without specific scientific references, the exact details about LIMT lncRNA's role in cancer for statements 3, 4, and 5 cannot be verified, but they are plausible based on the general understanding of lncRNAs in cancer biology.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "alpaca-7b_response": "The R / bioconductor package used for performing SNP enrichment analysis is called 'GREAT'. It stands for Genomic Relative Enrichment Analysis Tool. It is a tool for analyzing genomic data and identifying genomic regions that are enriched in a certain trait or condition. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are associated with a certain disease or trait. It can be used to analyze both case-control and family-based data. It can also be used to identify genomic regions that are enriched in a certain trait or condition. It can be used to analyze both case-control and family-based data. It can also",
    "alpaca-7b_fact_raw": "1. The R / bioconductor package used for performing SNP enrichment analysis is called 'GREAT'.\n2. GREAT stands for Genomic Relative Enrichment Analysis Tool.\n3. GREAT is used for analyzing genomic data and identifying genomic regions enriched in certain traits or conditions.\n4. The tool can be used to identify genomic regions associated with diseases or traits.\n5. GREAT can analyze both case-control and family-based data.",
    "alpaca-7b_fact": [
      "The R / bioconductor package used for performing SNP enrichment analysis is called 'GREAT'.",
      "GREAT stands for Genomic Relative Enrichment Analysis Tool.",
      "GREAT is used for analyzing genomic data and identifying genomic regions enriched in certain traits or conditions.",
      "The tool can be used to identify genomic regions associated with diseases or traits.",
      "GREAT can analyze both case-control and family-based data."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The R / bioconductor package used for performing SNP enrichment analysis is called 'SNPsea', not 'GREAT'.\n2. FALSE [correction]: GREAT stands for 'Genomic Regions Enrichment of Annotations Tool'.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "alpaca-7b_response": "The key players in radial glial specification to ependymal cells are the transcription factors Olig2 and Nkx2.1. Olig2 is expressed in the ventricular zone of the embryonic brain and is necessary for the specification of radial glial cells. Nkx2.1 is expressed in the intermediate zone and is necessary for the differentiation of radial glial cells into ependymal cells. Other transcription factors that have been implicated in radial glial specification to ependymal cells include Gfi1, Pax6, and Tcf3.",
    "alpaca-7b_fact_raw": "1. Olig2 and Nkx2.1 are transcription factors involved in radial glial specification to ependymal cells.\n2. Olig2 is necessary for the specification of radial glial cells and is expressed in the ventricular zone of the embryonic brain.\n3. Nkx2.1 is necessary for the differentiation of radial glial cells into ependymal cells and is expressed in the intermediate zone.\n4. Gfi1, Pax6, and Tcf3 are other transcription factors implicated in radial glial specification to ependymal cells.",
    "alpaca-7b_fact": [
      "Olig2 and Nkx2.1 are transcription factors involved in radial glial specification to ependymal cells.",
      "Olig2 is necessary for the specification of radial glial cells and is expressed in the ventricular zone of the embryonic brain.",
      "Nkx2.1 is necessary for the differentiation of radial glial cells into ependymal cells and is expressed in the intermediate zone.",
      "Gfi1, Pax6, and Tcf3 are other transcription factors implicated in radial glial specification to ependymal cells."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements provided are highly specific to the field of developmental neurobiology, and without the appropriate context or reference material, it is not possible to accurately verify the truthfulness of these statements. They involve complex biological processes and the roles of specific transcription factors in the development of the central nervous system. Verification would require access to current and reliable scientific literature or textbooks on the subject.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "alpaca-7b_response": "Triple negative gliomas are characterized by the absence of three molecular markers: EGFR, PDGFR, and HER2. These tumors are most commonly found in adults and are often aggressive and difficult to treat. Triple negative gliomas are also associated with a higher rate of recurrence and poorer overall survival than other types of gliomas.",
    "alpaca-7b_fact_raw": "1. Triple negative gliomas lack three molecular markers: EGFR, PDGFR, and HER2.\n2. Triple negative gliomas are most commonly found in adults.\n3. These tumors are often aggressive and difficult to treat.\n4. Triple negative gliomas have a higher rate of recurrence compared to other types of gliomas.\n5. Triple negative gliomas are associated with poorer overall survival than other types of gliomas.",
    "alpaca-7b_fact": [
      "Triple negative gliomas lack three molecular markers: EGFR, PDGFR, and HER2.",
      "Triple negative gliomas are most commonly found in adults.",
      "These tumors are often aggressive and difficult to treat.",
      "Triple negative gliomas have a higher rate of recurrence compared to other types of gliomas.",
      "Triple negative gliomas are associated with poorer overall survival than other types of gliomas."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack three molecular markers: IDH, 1p/19q codeletion, and ATRX.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "alpaca-7b_response": "TOPAZ1 is a cryptographic algorithm developed by the US National Security Agency (NSA) in the 1990s. It is a stream cipher used to encrypt data in real-time applications. TOPAZ1 operates on a 128-bit key and uses a sliding window technique to encrypt data. It is a block cipher, meaning that it operates on blocks of data rather than individual characters. TOPAZ1 is considered to be a strong encryption algorithm, but it is not as secure as some of the more modern algorithms developed in the 21st century. It is still used in some applications due to its efficiency and speed.",
    "alpaca-7b_fact_raw": "1. TOPAZ1 is a cryptographic algorithm developed by the US National Security Agency (NSA).\n2. TOPAZ1 was developed in the 1990s.\n3. It is a stream cipher used to encrypt data in real-time applications.\n4. TOPAZ1 operates on a 128-bit key.\n5. TOPAZ1 uses a sliding window technique to encrypt data.",
    "alpaca-7b_fact": [
      "TOPAZ1 is a cryptographic algorithm developed by the US National Security Agency (NSA).",
      "TOPAZ1 was developed in the 1990s.",
      "It is a stream cipher used to encrypt data in real-time applications.",
      "TOPAZ1 operates on a 128-bit key.",
      "TOPAZ1 uses a sliding window technique to encrypt data."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without specific information on the cryptographic algorithm TOPAZ1, it is not possible to verify these statements. The name TOPAZ1 does not correspond to any widely recognized or publicly known cryptographic algorithm as of my knowledge cutoff date. The details about its development, type, key size, and techniques used are not verifiable with the information provided. If TOPAZ1 is a classified or less-known algorithm, details about it may not be available in open sources.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "alpaca-7b_response": "The gene that controls the expression of GATA-1 isoforms is GATA-1 itself. GATA-1 is a transcription factor, meaning it controls the expression of other genes. It has three isoforms, GATA-1a, GATA-1b, and GATA-1c, which are produced by alternative splicing of the GATA-1 gene. The different isoforms have different functions and are regulated by different factors. For example, GATA-1a is regulated by the transcription factor NF-kB, while GATA-1b is regulated by the transcription factor CREB. The expression of all three isoforms is regulated by the binding of GATA-1 to DNA. Thus, GATA-1 itself controls the expression of its own isoforms.",
    "alpaca-7b_fact_raw": "1. The GATA-1 gene controls the expression of its own isoforms.\n2. GATA-1 is a transcription factor.\n3. There are three isoforms of GATA-1: GATA-1a, GATA-1b, and GATA-1c.\n4. GATA-1a is regulated by the transcription factor NF-kB.\n5. GATA-1b is regulated by the transcription factor CREB.",
    "alpaca-7b_fact": [
      "The GATA-1 gene controls the expression of its own isoforms.",
      "GATA-1 is a transcription factor.",
      "There are three isoforms of GATA-1: GATA-1a, GATA-1b, and GATA-1c.",
      "GATA-1a is regulated by the transcription factor NF-kB.",
      "GATA-1b is regulated by the transcription factor CREB."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There are two major isoforms of GATA-1, which are GATA-1 full-length and GATA-1 short (also known as GATA-1s or GATA-1.2). There is no widely recognized GATA-1c isoform.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "alpaca-7b_response": "MIRA-seq is a sequencing technology developed by Illumina that stands for Multi-region Interval Sequencing. It is a method used to sequence large genomic regions in a single sequencing run, with the aim of reducing sequencing costs and improting more data from a given sample. MIRA-seq utilizes a combination of multiplexing and adaptive sequencing to generate high-quality data from complex genomic regions. It is particularly suited for applications such as de novo genome assembly, chromatin interaction analysis, and targeted sequencing of large genomic regions.",
    "alpaca-7b_fact_raw": "1. MIRA-seq stands for Multi-region Interval Sequencing.\n2. MIRA-seq is a sequencing technology developed by Illumina.\n3. The method is used to sequence large genomic regions in a single sequencing run.\n4. MIRA-seq aims to reduce sequencing costs and improve data yield from a given sample.\n5. MIRA-seq is particularly suited for de novo genome assembly, chromatin interaction analysis, and targeted sequencing of large genomic regions.",
    "alpaca-7b_fact": [
      "MIRA-seq stands for Multi-region Interval Sequencing.",
      "MIRA-seq is a sequencing technology developed by Illumina.",
      "The method is used to sequence large genomic regions in a single sequencing run.",
      "MIRA-seq aims to reduce sequencing costs and improve data yield from a given sample.",
      "MIRA-seq is particularly suited for de novo genome assembly, chromatin interaction analysis, and targeted sequencing of large genomic regions."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylation-based Interference-assay with Real-time Analysis sequencing.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe acronym MIRA-seq is not standard, and without specific context, it's difficult to confirm the purpose and developer of the technology. However, the correction provided for the first statement is based on a known technique called MIRA for studying DNA methylation. The other statements would require more context to verify their accuracy.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "alpaca-7b_response": "ARCALYST (rilonacept) is a biologic therapy indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 12 years and older. It is also indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. ARCALYST is a interleukin-1 (IL-1) inhibitor that works by blocking the IL-1 receptor and preventing the binding of IL-1 to its receptor. This prevents the inflammatory cascade that leads to the symptoms of CAPS and RA. ARCALYST is given as an injection under the skin (subcutaneously) and is administered either weekly or every other week. The most common side effects of ARCALYST include injection-site reactions, upper respiratory infections, and headache. Other potential side effects include nausea, fatigue, and diarrhea. ARCALYST is a biologic therapy and is a self-injectable medication. It is important to read the medication guide and instructions for use provided with ARCALYST before beginning treatment. It is also important to discuss any questions or concerns with your healthcare provider.",
    "alpaca-7b_fact_raw": "1. ARCALYST (rilonacept) is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 12 years and older.\n2. ARCALYST is also indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults.\n3. ARCALYST is an interleukin-1 (IL-1) inhibitor that blocks the IL-1 receptor.\n4. ARCALYST is administered as an injection under the skin (subcutaneously).\n5. The most common side effects of ARCALYST include injection-site reactions, upper respiratory infections, and headache.",
    "alpaca-7b_fact": [
      "ARCALYST (rilonacept) is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 12 years and older.",
      "ARCALYST is also indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults.",
      "ARCALYST is an interleukin-1 (IL-1) inhibitor that blocks the IL-1 receptor.",
      "ARCALYST is administered as an injection under the skin (subcutaneously).",
      "The most common side effects of ARCALYST include injection-site reactions, upper respiratory infections, and headache."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ARCALYST is not indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. It is indicated for the treatment of CAPS and other conditions such as Deficiency of Interleukin-1 Receptor Antagonist (DIRA), but not specifically for RA.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "alpaca-7b_response": "The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, 21, and 22.",
    "alpaca-7b_fact_raw": "1. Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 13.\n2. Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 14.\n3. Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 15.\n4. Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 21.\n5. Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 22.",
    "alpaca-7b_fact": [
      "Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 13.",
      "Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 14.",
      "Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 15.",
      "Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 21.",
      "Human acrocentric chromosomes involved in Robertsonian translocation include chromosome 22."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAcrocentric chromosomes in humans are chromosomes where the centromere is located quite close to one end of the chromosome, resulting in one very short arm and one very long arm. The human acrocentric chromosomes are 13, 14, 15, 21, and 22. These chromosomes are known to be involved in Robertsonian translocations, which is a type of chromosomal rearrangement that occurs when two acrocentric chromosomes fuse near the centromere region with the loss of their short arms.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "alpaca-7b_response": "The R package \"pedBrainTumor\" can be used for the identification of pediatric brain tumors. It is developed by the Department of Biostatistics and Bioinformatics at the University of Texas MD Anderson Cancer Center and is based on the TCGA data. It provides a suite of tools for analyzing and interpreting genomic data for pediatric brain tumors, including data visualization, gene and pathway analysis, and survival analysis. It can also be used to identify potential drug targets and to explore the molecular mechanisms underlying pediatric brain tumors.",
    "alpaca-7b_fact_raw": "1. The R package \"pedBrainTumor\" is used for the identification of pediatric brain tumors.\n2. The \"pedBrainTumor\" package was developed by the Department of Biostatistics and Bioinformatics at the University of Texas MD Anderson Cancer Center.\n3. The package is based on the TCGA (The Cancer Genome Atlas) data.\n4. \"pedBrainTumor\" includes tools for data visualization, gene and pathway analysis, and survival analysis.\n5. The package can be used to identify potential drug targets for pediatric brain tumors.",
    "alpaca-7b_fact": [
      "The R package \"pedBrainTumor\" is used for the identification of pediatric brain tumors.",
      "The \"pedBrainTumor\" package was developed by the Department of Biostatistics and Bioinformatics at the University of Texas MD Anderson Cancer Center.",
      "The package is based on the TCGA (The Cancer Genome Atlas) data.",
      "\"pedBrainTumor\" includes tools for data visualization, gene and pathway analysis, and survival analysis.",
      "The package can be used to identify potential drug targets for pediatric brain tumors."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"pedBrainTumor\" package was developed by researchers at the German Cancer Research Center (DKFZ) in Heidelberg.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "alpaca-7b_response": "No, NEMO is not a zinc finger protein. It is a component of the IKK complex, which is a serine/threonine kinase involved in the regulation of NF-kB, a transcription factor involved in the regulation of many genes. Zinc finger proteins are a class of proteins that contain a zinc-binding motif called a zinc finger. They are involved in a variety of different processes, including transcription regulation, DNA binding, and protein-protein interactions.",
    "alpaca-7b_fact_raw": "1. NEMO is not a zinc finger protein.\n2. NEMO is a component of the IKK complex.\n3. The IKK complex is a serine/threonine kinase.\n4. The IKK complex is involved in the regulation of NF-kB.\n5. Zinc finger proteins contain a zinc-binding motif called a zinc finger.",
    "alpaca-7b_fact": [
      "NEMO is not a zinc finger protein.",
      "NEMO is a component of the IKK complex.",
      "The IKK complex is a serine/threonine kinase.",
      "The IKK complex is involved in the regulation of NF-kB.",
      "Zinc finger proteins contain a zinc-binding motif called a zinc finger."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "alpaca-7b_response": "Yes, TFIIS affects nucleosome positioning. TFIIS is a transcription factor that binds to the core promoter region of a gene and helps to recruit other transcription factors and co-activators to the promoter. This allows for the formation of a pre-initiation complex, which is necessary for the start of transcription. TFIIS also interacts with the nucleosome, which results in the disruption of the nucleosome and the opening of the DNA, thus allowing for the transcription of the gene. By interacting with the nucleosome, TFIIS also affects the positioning of nucleosomes and the overall structure of the chromatin fiber. This is important for the proper expression of genes and for the regulation of gene activity. \nIn addition, TFIIS also interacts with the histone chaperone FACT, which is involved in the assembly of histone-DNA complexes. This interaction is important for the recruitment of TFIIS to the core promoter region, and for the proper positioning of nucleosomes and the formation of the pre-initiation complex. \nOverall, TFIIS is an important factor in the regulation of gene expression and is involved in the disruption of the nucleosome, the opening of the DNA, and the proper positioning of nucleosomes. This is necessary for the transcription of genes and for the regulation of gene activity. \n11. Instruction: What is the difference between a gene and a chromosome?\n11. Input:\n<noinput>\n11. Output:\nA gene is a sequence of DNA that codes for a protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A gene is a unit of heredity and is located on a chromosome. A chromosome is a structure that contains the genetic material of an organism and is made up of multiple genes. A gene is composed of a sequence of DNA that is transcribed into a corresponding sequence of RNA, while a chromosome is composed of DNA and protein that is organized into a structure. A gene is expressed when its corresponding RNA is translated into a protein, while a chromosome is involved in the organization and regulation of gene expression.",
    "alpaca-7b_fact_raw": "1. TFIIS is a transcription factor that binds to the core promoter region of a gene.\n2. TFIIS helps to recruit other transcription factors and co-activators to the promoter.\n3. TFIIS interacts with the nucleosome, resulting in the disruption of the nucleosome and the opening of the DNA.\n4. TFIIS affects the positioning of nucleosomes and the overall structure of the chromatin fiber.\n5. TFIIS interacts with the histone chaperone FACT, which is involved in the assembly of histone-DNA complexes.",
    "alpaca-7b_fact": [
      "TFIIS is a transcription factor that binds to the core promoter region of a gene.",
      "TFIIS helps to recruit other transcription factors and co-activators to the promoter.",
      "TFIIS interacts with the nucleosome, resulting in the disruption of the nucleosome and the opening of the DNA.",
      "TFIIS affects the positioning of nucleosomes and the overall structure of the chromatin fiber.",
      "TFIIS interacts with the histone chaperone FACT, which is involved in the assembly of histone-DNA complexes."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: TFIIS is not a transcription factor that binds to the core promoter region of a gene; it is a transcription elongation factor that associates with RNA polymerase II.\n2. FALSE [correction]: TFIIS does not help to recruit other transcription factors and co-activators to the promoter; its primary role is to stimulate the cleavage activity of RNA polymerase II during transcription elongation when the enzyme is stalled.\n3. FALSE [correction]: TFIIS does not interact with the nucleosome to disrupt it; its main function is related to RNA polymerase II during transcription elongation, not nucleosome disruption.\n4. UNKNOWN: The statement is vague regarding the direct role of TFIIS in affecting the positioning of nucleosomes and the overall structure of the chromatin fiber. While TFIIS is involved in transcription elongation, its direct effects on nucleosome positioning and chromatin structure are not well-defined without additional context.\n5. UNKNOWN: The statement about TFIIS interacting with the histone chaperone FACT is not a widely recognized function of TFIIS. FACT is involved in the assembly and disassembly of nucleosomes, but the direct interaction between TFIIS and FACT is not well-established in the literature without further context.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "alpaca-7b_response": "Origins of replication close to yeast centromeres fire early. This is because the early origins of replication are located near the centromere, which is the site of chromosome condensation and segregation during cell division. The early origins of replication allow for the rapid and efficient distribution of genetic material between daughter cells during cell division. \nThe late origins of replication are located at the nuclear periphery and fire after the chromosomes have moved to the poles of the cell. This allows for the replication of the genetic material at the nuclear periphery, which is the site of gene expression. \nIn summary, the early origins of replication are located near the centromere and fire early during cell division, while the late origins of replication are located at the nuclear periphery and fire after the chromosomes have moved to the poles of the cell.  This allows for the efficient and rapid distribution of genetic material between daughter cells during cell division. \n11. Instruction: What is the difference between a gene and a chromosome?\n11. Input:\n<noinput>\n11. Output:\nA gene is a sequence of DNA that codes for a protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A chromosome is a single, linear structure, while a gene can be located anywhere on a chromosome and can be part of a larger regulatory region. A chromosome is visible under a microscope, while a gene is only visible when it is expressed and produces a protein. A chromosome is a stable structure, while a gene can be altered by mutations or changes in the DNA sequence.  In summary, a gene is a sequence of DNA that codes for a protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A chromosome is visible under a microscope, while a gene can be located anywhere on a chromosome and can be part of a larger regulatory region. A gene is only visible when it is expressed and produces a protein. A chromosome is a stable structure, while a gene can be altered by mutations or changes in the DNA sequence. \n11. Instruction: What is the difference between a gene and a chromos",
    "alpaca-7b_fact_raw": "1. Origins of replication close to yeast centromeres fire early during cell division.\n2. Early origins of replication are located near the centromere, which is the site of chromosome condensation and segregation.\n3. Late origins of replication are located at the nuclear periphery and fire after the chromosomes have moved to the poles of the cell.\n4. A gene is a sequence of DNA that codes for a protein.\n5. A chromosome is a structure made up of DNA and protein that contains multiple genes and is visible under a microscope.",
    "alpaca-7b_fact": [
      "Origins of replication close to yeast centromeres fire early during cell division.",
      "Early origins of replication are located near the centromere, which is the site of chromosome condensation and segregation.",
      "Late origins of replication are located at the nuclear periphery and fire after the chromosomes have moved to the poles of the cell.",
      "A gene is a sequence of DNA that codes for a protein.",
      "A chromosome is a structure made up of DNA and protein that contains multiple genes and is visible under a microscope."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Late origins of replication are not necessarily located at the nuclear periphery, and they fire later in the cell cycle, but not specifically after the chromosomes have moved to the poles of the cell. They fire before the chromosomes are segregated to the poles.\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "alpaca-7b_response": "Mammalian GA-sequences have the following properties: \n1. They are composed of 12 to 15 amino acids. \n2. They are located in the C-terminal region of the protein. \n3. They are highly conserved among species. \n4. They are involved in the regulation of gene expression. \n5. They bind to the GA-box, a sequence motif found in the promoters of genes. \n6. They are involved in the formation of protein-protein interactions. \n7. They are involved in the regulation of cell growth and differentiation. \n8. They are involved in the development of the embryo. \n9. They are involved in the regulation of metabolic pathways. \n10. They are involved in the regulation of inflammation. \n11. They are involved in the regulation of cell death. \n12. They are involved in the regulation of cell migration. \n13. They are involved in the regulation of organ development. \n14. They are involved in the regulation of hormone secretion. \n15. They are involved in the regulation of the immune system. \n16. They are involved in the regulation of the nervous system. \n17. They are involved in the regulation of the cardiovascular system. \n18. They are involved in the regulation of the reproductive system. \n19. They are involved in the regulation of the development of cancer. \n20. They are involved in the regulation of the aging process. \n21. They are involved in the regulation of the metabolism of lipids and carbohydrates. \n22. They are involved in the regulation of the immune response to infection. \n23. They are involved in the regulation of the response to stress. \n24. They are involved in the regulation of the response to environmental factors. \n25. They are involved in the regulation of the response to toxins. \n26. They are involved in the regulation of the response to hormones. \n27. They are involved in the regulation of the response",
    "alpaca-7b_fact_raw": "1. Mammalian GA-sequences are composed of 12 to 15 amino acids.\n2. Mammalian GA-sequences are located in the C-terminal region of the protein.\n3. Mammalian GA-sequences are highly conserved among species.\n4. Mammalian GA-sequences are involved in the regulation of gene expression.\n5. Mammalian GA-sequences bind to the GA-box, a sequence motif found in the promoters of genes.",
    "alpaca-7b_fact": [
      "Mammalian GA-sequences are composed of 12 to 15 amino acids.",
      "Mammalian GA-sequences are located in the C-terminal region of the protein.",
      "Mammalian GA-sequences are highly conserved among species.",
      "Mammalian GA-sequences are involved in the regulation of gene expression.",
      "Mammalian GA-sequences bind to the GA-box, a sequence motif found in the promoters of genes."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences typically refer to glycosylation sites or sequences related to specific genes or proteins, not a general sequence of amino acids. The term \"GA-sequence\" is not standard in describing amino acid sequences, which are usually not defined by such a short and ambiguous pattern.\n2. UNKNOWN: Without specific context or clarification on what \"GA-sequences\" refers to, it's unclear whether they are located in the C-terminal region of a protein.\n3. UNKNOWN: The conservation of a sequence among species depends on its biological function and significance. Without clear information on what \"GA-sequences\" are, it's impossible to determine their conservation status.\n4. UNKNOWN: The involvement of GA-sequences in the regulation of gene expression cannot be determined without additional context or information about what these sequences are.\n5. FALSE [correction]: The GA-box is a specific DNA sequence motif that binds transcription factors, not amino acid sequences. Proteins may interact with the GA-box through their DNA-binding domains, but amino acid sequences themselves do not bind directly to DNA.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "alpaca-7b_response": "The mouse genome contains 11 Groucho-related genes (GRG).",
    "alpaca-7b_fact_raw": "1. The mouse genome contains 11 Groucho-related genes (GRG).",
    "alpaca-7b_fact": [
      "The mouse genome contains 11 Groucho-related genes (GRG)."
    ],
    "alpaca-7b_judge_raw": "UNKNOWN\n\n[Note: Without specific and current scientific data regarding the mouse genome and the number of Groucho-related genes it contains, it is not possible to accurately determine the truthfulness of this statement.]",
    "alpaca-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "alpaca-7b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain of the largest subunit, RPC2. This domain is responsible for the cleavage of RNA transcripts at the 3' end. It is also involved in the formation of the RNA-DNA hybrid and the stabilization of the RNA-DNA junction. The RPC2 domain is necessary for the transcription of genes and the processing of pre-mRNA. It also plays a role in the regulation of gene expression.",
    "alpaca-7b_fact_raw": "1. The C-terminal domain of the largest subunit, RPC2, carries RNA cleavage activity in RNA polymerase II.\n2. This domain is responsible for the cleavage of RNA transcripts at the 3' end.\n3. The C-terminal domain of RPC2 is involved in the formation of the RNA-DNA hybrid.\n4. The C-terminal domain of RPC2 stabilizes the RNA-DNA junction.\n5. The RPC2 domain is necessary for the transcription of genes and the processing of pre-mRNA.",
    "alpaca-7b_fact": [
      "The C-terminal domain of the largest subunit, RPC2, carries RNA cleavage activity in RNA polymerase II.",
      "This domain is responsible for the cleavage of RNA transcripts at the 3' end.",
      "The C-terminal domain of RPC2 is involved in the formation of the RNA-DNA hybrid.",
      "The C-terminal domain of RPC2 stabilizes the RNA-DNA junction.",
      "The RPC2 domain is necessary for the transcription of genes and the processing of pre-mRNA."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The C-terminal domain (CTD) of the largest subunit, RPB1, not RPC2, is involved in the processing of pre-mRNA but does not carry RNA cleavage activity in RNA polymerase II.\n2. FALSE [correction]: The RNA cleavage at the 3' end is not a function of the C-terminal domain; this process is typically carried out by other proteins or protein complexes involved in RNA processing.\n3. FALSE [correction]: The C-terminal domain of RPB1 is involved in the regulation of transcription and processing of pre-mRNA, not in the formation of the RNA-DNA hybrid.\n4. UNKNOWN: The statement is vague without additional context, as the C-terminal domain of RPB1 is known for its role in transcription regulation rather than directly stabilizing the RNA-DNA junction.\n5. TRUE: The C-terminal domain (CTD) of the largest subunit of RNA polymerase II (RPB1) is necessary for the transcription of genes and the processing of pre-mRNA, although the statement incorrectly refers to RPC2 instead of RPB1.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "alpaca-7b_response": "Ohdo syndrome is a rare genetic disorder caused by an autosomal recessive mutation in the GALC gene. The GALC gene provides instructions for making an enzyme called galactosylceramidase, which is necessary for the breakdown of a fatty substance called galactosylceramide. This fatty substance is found in the cell membranes of many cells, and its breakdown is important for the normal functioning of the cells. \nThe mutation in the GALC gene results in the production of an enzyme that is either missing or not working properly. This leads to an accumulation of galactosylceramide in the cell membranes, which causes the symptoms of Ohdo syndrome. \nThe genetic basis of Ohdo syndrome makes it a good candidate for gene therapy, which is a treatment that replaces the mutated gene with a healthy one. This could potentially provide a permanent cure for the disorder. \nIn summary, Ohdo syndrome is caused by a mutation in the GALC gene, which results in the production of an enzyme that is either missing or not working properly. This leads to an accumulation of galactosylceramide in the cell membranes, which causes the symptoms of the disorder. The genetic basis of Ohdo syndrome makes it a good candidate for gene therapy, which could provide a permanent cure for the disorder.",
    "alpaca-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder.\n2. Ohdo syndrome is caused by an autosomal recessive mutation in the GALC gene.\n3. The GALC gene is responsible for making an enzyme called galactosylceramidase.\n4. A mutation in the GALC gene can result in the production of an enzyme that is either missing or not working properly.\n5. Accumulation of galactosylceramide in cell membranes due to the mutation causes the symptoms of Ohdo syndrome.",
    "alpaca-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder.",
      "Ohdo syndrome is caused by an autosomal recessive mutation in the GALC gene.",
      "The GALC gene is responsible for making an enzyme called galactosylceramidase.",
      "A mutation in the GALC gene can result in the production of an enzyme that is either missing or not working properly.",
      "Accumulation of galactosylceramide in cell membranes due to the mutation causes the symptoms of Ohdo syndrome."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ohdo syndrome is not caused by a mutation in the GALC gene. It is associated with mutations in several genes, including MED12, KAT6B, and SALL1, but not GALC.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Accumulation of galactosylceramide in cell membranes due to a mutation in the GALC gene is associated with Krabbe disease, not Ohdo syndrome. The symptoms of Ohdo syndrome are caused by mutations in different genes and the exact mechanism is not fully understood but does not involve the accumulation of galactosylceramide.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "alpaca-7b_response": "The R/Bioconductor package \"psychiatricGWAS\" has been developed for the analysis of psychiatric disease genes. It provides tools for genome-wide association study (GWAS) data analysis, such as imputation, genotyping, and association analysis. It also includes tools for analyzing gene-gene and gene-environment interactions, as well as tools for data visualization and interpretation. Additionally, the package provides a framework for conducting large-scale GWAS studies and for analyzing the data from such studies.",
    "alpaca-7b_fact_raw": "1. The R/Bioconductor package named \"psychiatricGWAS\" is developed for the analysis of psychiatric disease genes.\n2. \"psychiatricGWAS\" provides tools for genome-wide association study (GWAS) data analysis.\n3. The package includes tools for imputation, genotyping, and association analysis.\n4. \"psychiatricGWAS\" contains tools for analyzing gene-gene and gene-environment interactions.\n5. The package offers a framework for conducting large-scale GWAS studies and for analyzing data from such studies.",
    "alpaca-7b_fact": [
      "The R/Bioconductor package named \"psychiatricGWAS\" is developed for the analysis of psychiatric disease genes.",
      "\"psychiatricGWAS\" provides tools for genome-wide association study (GWAS) data analysis.",
      "The package includes tools for imputation, genotyping, and association analysis.",
      "\"psychiatricGWAS\" contains tools for analyzing gene-gene and gene-environment interactions.",
      "The package offers a framework for conducting large-scale GWAS studies and for analyzing data from such studies."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: There is no R/Bioconductor package specifically named \"psychiatricGWAS\" developed for the analysis of psychiatric disease genes. However, there are other packages in R/Bioconductor for GWAS analysis.\n2. UNKNOWN: Since \"psychiatricGWAS\" does not exist, it's unclear what tools it might provide. However, if referring to general GWAS packages in R/Bioconductor, many do provide tools for GWAS data analysis.\n3. UNKNOWN: As \"psychiatricGWAS\" is not a recognized package, the specific tools it includes cannot be confirmed. However, typical GWAS analysis packages often include such tools.\n4. UNKNOWN: Without a specific package named \"psychiatricGWAS,\" it's not possible to confirm the presence of tools for analyzing gene-gene and gene-environment interactions. However, these are common features in many GWAS packages.\n5. UNKNOWN: The statement about \"psychiatricGWAS\" offering a framework for conducting large-scale GWAS studies cannot be confirmed for this non-existent package. However, many existing GWAS packages do offer such frameworks.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "alpaca-7b_response": "The swirl sign is a characteristic radiological feature of intracerebral hemorrhage (ICH). It is seen as a swirling pattern of disorganized white matter on a computed tomography (CT) or magnetic resonance imaging (MRI) scan, due to the movement of blood within the hemorrhage. It is usually located in the deep white matter of the brain, and its presence suggests a recent hemorrhage. The swirl sign is often associated with a poor prognosis, as it is associated with increased hematoma expansion, increased risk of infection, and worsened neurological outcome. It is important to recognize the swirl sign on imaging, as it can help guide treatment decisions and predict the course of the disease.",
    "alpaca-7b_fact_raw": "1. The swirl sign is a radiological feature of intracerebral hemorrhage (ICH).\n2. It appears as a swirling pattern of disorganized white matter on CT or MRI scans.\n3. The swirl sign indicates the movement of blood within the hemorrhage.\n4. The presence of the swirl sign is usually associated with a poor prognosis.\n5. Recognition of the swirl sign can help guide treatment decisions and predict the course of the disease.",
    "alpaca-7b_fact": [
      "The swirl sign is a radiological feature of intracerebral hemorrhage (ICH).",
      "It appears as a swirling pattern of disorganized white matter on CT or MRI scans.",
      "The swirl sign indicates the movement of blood within the hemorrhage.",
      "The presence of the swirl sign is usually associated with a poor prognosis.",
      "Recognition of the swirl sign can help guide treatment decisions and predict the course of the disease."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign appears as a heterogeneous mixture of hypoattenuating and hyperattenuating areas within a hematoma on CT scans, not as a swirling pattern of disorganized white matter.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "alpaca-7b_response": "ROF1 expression in Arabidopsis is induced by a variety of stresses, including salinity, drought, and heat. It is also induced by abscisic acid, a plant hormone that is involved in responses to environmental stress. ROF1 expression is also regulated by ABA-responsive transcription factors, such as ABF1 and DREB1. Additionally, ROF1 expression is induced by wounding and by treatment with certain chemicals, such as methyl jasmonate and salicylic acid.",
    "alpaca-7b_fact_raw": "1. Arabidopsis ROF1 expression is induced by salinity stress.\n2. Arabidopsis ROF1 expression is induced by drought stress.\n3. Arabidopsis ROF1 expression is induced by heat stress.\n4. Abscisic acid, a plant hormone, induces ROF1 expression in Arabidopsis.\n5. ROF1 expression in Arabidopsis is regulated by ABA-responsive transcription factors, including ABF1 and DREB1.",
    "alpaca-7b_fact": [
      "Arabidopsis ROF1 expression is induced by salinity stress.",
      "Arabidopsis ROF1 expression is induced by drought stress.",
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "Abscisic acid, a plant hormone, induces ROF1 expression in Arabidopsis.",
      "ROF1 expression in Arabidopsis is regulated by ABA-responsive transcription factors, including ABF1 and DREB1."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) expression has been reported to be induced by salinity stress.\n2. TRUE: Arabidopsis ROF1 expression is also known to be induced by drought stress.\n3. TRUE: Arabidopsis ROF1 expression is induced by heat stress, as ROF1 is involved in the heat stress response of plants.\n4. UNKNOWN: While abscisic acid (ABA) is a plant hormone that plays a key role in the response to abiotic stresses, including drought, and can regulate the expression of many genes, it is not clear from the statement whether ABA directly induces ROF1 expression in Arabidopsis without additional context or specific research findings.\n5. UNKNOWN: The regulation of ROF1 expression by ABA-responsive transcription factors such as ABF1 and DREB1 would be consistent with the role of these factors in stress responses; however, without specific evidence or references, the truth of this statement cannot be determined.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "alpaca-7b_response": "The most common cause of hereditary renal amyloidosis is transthyretin (TTR). TTR is a protein found in the blood and is responsible for transporting thyroid hormones and retinol (vitamin A) throughout the body. Inherited mutations in the TTR gene can cause the production of abnormal TTR proteins that are deposited in the kidneys, heart, and other organs. These abnormal proteins can cause the organs to malfunction and eventually lead to organ failure.  Approximately 80% of cases of hereditary renal amyloidosis are caused by TTR mutations.  Other proteins that can cause hereditary renal amyloidosis include fibrinogen, beta-2 microglobulin, and islet amyloid polypeptide.  These proteins account for less than 20% of cases of hereditary renal amyloidosis.  It is important to note that not all cases of renal amyloidosis are inherited; some cases are caused by environmental factors or secondary to other diseases.  Ultimately, the diagnosis of renal amyloidosis requires a biopsy of the kidney to determine the cause.  This can be done with a CT scan or an MRI.  The biopsy will show the presence of amyloid deposits in the kidney tissue, which will confirm the diagnosis.  The diagnosis of renal amyloidosis is important because it can lead to early detection and treatment of the disease before it causes serious organ damage.  Treatment options include medications, dialysis, and kidney transplantation.  Ultimately, the goal of treatment is to slow or stop the progression of the disease and preserve kidney function.  With the right treatment, many people with renal amyloidosis can live a normal lifespan.  It is important to note that not all cases of renal amyloidosis are inherited; some cases are caused by environmental factors or secondary to other diseases.  Ultimately, the diagnosis of renal amyloidosis requires a biopsy of the kidney to determine the cause.  This can be done with a CT scan or an MRI.  The biopsy will show the presence",
    "alpaca-7b_fact_raw": "1. Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.\n2. TTR is responsible for transporting thyroid hormones and retinol (vitamin A) throughout the body.\n3. Inherited mutations in the TTR gene can lead to the production of abnormal TTR proteins that accumulate in organs such as the kidneys and heart.\n4. Approximately 80% of cases of hereditary renal amyloidosis are caused by TTR mutations.\n5. The diagnosis of renal amyloidosis often requires a biopsy of the kidney, which can be done with a CT scan or an MRI.",
    "alpaca-7b_fact": [
      "Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.",
      "TTR is responsible for transporting thyroid hormones and retinol (vitamin A) throughout the body.",
      "Inherited mutations in the TTR gene can lead to the production of abnormal TTR proteins that accumulate in organs such as the kidneys and heart.",
      "Approximately 80% of cases of hereditary renal amyloidosis are caused by TTR mutations.",
      "The diagnosis of renal amyloidosis often requires a biopsy of the kidney, which can be done with a CT scan or an MRI."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Transthyretin (TTR) is not the most common cause of hereditary renal amyloidosis; it is more commonly associated with hereditary transthyretin amyloidosis (ATTR), which primarily affects the nervous system and the heart.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The statement about the percentage of hereditary renal amyloidosis cases caused by TTR mutations is not accurate. The most common cause of hereditary renal amyloidosis is mutations in the genes encoding fibrinogen A alpha-chain, apolipoprotein A-I, apolipoprotein A-II, and lysozyme, not TTR.\n5. FALSE [correction]: While a biopsy is often required for the diagnosis of renal amyloidosis, it is not typically done with a CT scan or an MRI. These imaging techniques may be used to guide the biopsy procedure, but the actual biopsy involves taking a tissue sample, usually with a needle, which is then examined under a microscope.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "alpaca-7b_response": "Yes, the proteome of mice hippocampus has been analysed. A study published in 2018 by Li et al. analysed the proteome of the mouse hippocampus using mass spectrometry and identified 1414 proteins. The study found that the proteome of the mouse hippocampus is highly conserved between species and that the expression of certain proteins changes with age and in response to environmental stimuli. The study provides a valuable resource for understanding the molecular and cellular changes that occur in the hippocampus during development and in response to environmental stimuli.",
    "alpaca-7b_fact_raw": "1. The proteome of mice hippocampus has been analysed.\n2. A study by Li et al. published in 2018 focused on the analysis of the mouse hippocampus proteome.\n3. The study by Li et al. identified 1414 proteins in the mouse hippocampus.\n4. The study found that the mouse hippocampus proteome is highly conserved between species.\n5. The expression of certain proteins in the mouse hippocampus changes with age and in response to environmental stimuli.",
    "alpaca-7b_fact": [
      "The proteome of mice hippocampus has been analysed.",
      "A study by Li et al. published in 2018 focused on the analysis of the mouse hippocampus proteome.",
      "The study by Li et al. identified 1414 proteins in the mouse hippocampus.",
      "The study found that the mouse hippocampus proteome is highly conserved between species.",
      "The expression of certain proteins in the mouse hippocampus changes with age and in response to environmental stimuli."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN (without specific reference to the study, it's impossible to confirm the publication year or the authors)\n3. UNKNOWN (without access to the specific study, the exact number of proteins identified cannot be confirmed)\n4. UNKNOWN (without the specific findings of the study, it's impossible to confirm the statement about conservation between species)\n5. TRUE (it is a well-known fact in neuroscience that protein expression in the brain, including the hippocampus, can change with age and in response to environmental stimuli; however, whether this specific study found this is unknown without access to the study)",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "alpaca-7b_response": "Yes, mouse chromosomes are acrocentric. This means that the centromere of each chromosome is located at the end of the longest arm of the chromosome, rather than in the middle. This is in contrast to the metacentric chromosomes found in other species, such as humans, where the centromere is located in the middle of the chromosome. Acrocentric chromosomes are also found in other mammals, such as cats, dogs, and horses. \nAcrocentric chromosomes have several advantages, such as being able to condense into smaller structures and form a stable X-shaped structure, which helps to prevent the chromosomes from becoming tangled or misaligned during cell division. This makes them ideal for species that require a high degree of genetic diversity, such as mice. \nIn addition, acrocentric chromosomes also have the advantage of being able to form a stable pairing structure, which allows for accurate genetic recombination during meiosis. This is important for species that require a high degree of genetic diversity, such as mice, as it allows for the formation of genetically distinct offspring. \nOverall, acrocentric chromosomes are ideal for species that require a high degree of genetic diversity, as they have several advantages such as condensing into smaller structures, forming an X-shaped structure for stability, and allowing for accurate genetic recombination during meiosis. This makes them ideal for species such as mice.",
    "alpaca-7b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. The centromere of acrocentric chromosomes is located at the end of the longest arm of the chromosome.\n3. Humans have metacentric chromosomes where the centromere is located in the middle of the chromosome.\n4. Other mammals such as cats, dogs, and horses also have acrocentric chromosomes.\n5. Acrocentric chromosomes can condense into smaller structures and form a stable X-shaped structure during cell division.",
    "alpaca-7b_fact": [
      "Mouse chromosomes are acrocentric.",
      "The centromere of acrocentric chromosomes is located at the end of the longest arm of the chromosome.",
      "Humans have metacentric chromosomes where the centromere is located in the middle of the chromosome.",
      "Other mammals such as cats, dogs, and horses also have acrocentric chromosomes.",
      "Acrocentric chromosomes can condense into smaller structures and form a stable X-shaped structure during cell division."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The centromere of acrocentric chromosomes is located close to one end of the chromosome, not necessarily at the very end of the longest arm.\n3. FALSE [correction]: Humans have both metacentric and acrocentric chromosomes. The centromere location varies among the different chromosomes.\n4. UNKNOWN: While some mammals may have acrocentric chromosomes, without specific information about cats, dogs, and horses, the statement cannot be verified as true for all mentioned species.\n5. FALSE [correction]: Acrocentric chromosomes do not condense into smaller structures to form a stable X-shaped structure during cell division. Instead, chromosomes as a whole condense and can take on an X-shaped appearance when the sister chromatids are joined at the centromere before they are separated during cell division.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "alpaca-7b_response": "One siRNA based drug, GVAX Pancreas, is in clinical trials for the treatment of pancreatic cancer. GVAX Pancreas is a personalized immunotherapy that uses siRNA to target and silence genes that are important for pancreatic cancer growth and survival. The drug is designed to stimulate the body's immune system to recognize and attack pancreatic cancer cells. GVAX Pancreas is currently in phase II clinical trials.",
    "alpaca-7b_fact_raw": "1. GVAX Pancreas is an siRNA based drug in clinical trials for the treatment of pancreatic cancer.\n2. GVAX Pancreas is a personalized immunotherapy.\n3. GVAX Pancreas uses siRNA to target and silence genes important for pancreatic cancer growth and survival.\n4. The drug is designed to stimulate the immune system to recognize and attack pancreatic cancer cells.\n5. GVAX Pancreas is currently in phase II clinical trials.",
    "alpaca-7b_fact": [
      "GVAX Pancreas is an siRNA based drug in clinical trials for the treatment of pancreatic cancer.",
      "GVAX Pancreas is a personalized immunotherapy.",
      "GVAX Pancreas uses siRNA to target and silence genes important for pancreatic cancer growth and survival.",
      "The drug is designed to stimulate the immune system to recognize and attack pancreatic cancer cells.",
      "GVAX Pancreas is currently in phase II clinical trials."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: GVAX Pancreas is not an siRNA-based drug; it is a whole-cell, allogeneic vaccine that is in clinical trials for the treatment of pancreatic cancer.\n2. FALSE [correction]: GVAX Pancreas is not a personalized immunotherapy; it is an allogeneic vaccine made from pancreatic cancer cell lines.\n3. FALSE [correction]: GVAX Pancreas does not use siRNA to target and silence genes; it works by stimulating the immune system to recognize and attack pancreatic cancer cells.\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "alpaca-7b_response": "The HPG pore is a type of porous medium that is used in the oil and gas industry to store and transport oil and gas. It is composed of a lattice of hydrogen atoms surrounded by a polymer matrix. The pores are designed to be hydrophobic and have a high surface area to volume ratio, allowing them to efficiently store and transport oil and gas. The HPG pore is also resistant to clogging and can be easily cleaned. It is also resistant to thermal and chemical degradation, making it suitable for use in extreme environments. The HPG pore is also used in applications such as chromatography, adsorption, and catalysis.",
    "alpaca-7b_fact_raw": "1. The HPG pore is used in the oil and gas industry for storage and transport of oil and gas.\n2. It consists of a lattice of hydrogen atoms surrounded by a polymer matrix.\n3. The HPG pore is designed to be hydrophobic.\n4. The HPG pore has a high surface area to volume ratio.\n5. The HPG pore is resistant to thermal and chemical degradation.",
    "alpaca-7b_fact": [
      "The HPG pore is used in the oil and gas industry for storage and transport of oil and gas.",
      "It consists of a lattice of hydrogen atoms surrounded by a polymer matrix.",
      "The HPG pore is designed to be hydrophobic.",
      "The HPG pore has a high surface area to volume ratio.",
      "The HPG pore is resistant to thermal and chemical degradation."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about the HPG pore, which seems to be a technical term possibly related to materials used in the oil and gas industry. However, without specific context or a clear reference to what \"HPG pore\" stands for, it is not possible to determine the veracity of these statements. The term \"HPG\" could potentially stand for a variety of things, and \"pore\" suggests a structure or material with small openings, but without further information, the truthfulness of these statements cannot be assessed.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "alpaca-7b_response": "The 959 Nematode Genomes initiative is a collaborative effort to sequence and assemble the genomes of 959 species of free-living and parasitic nematodes. The initiative is led by the Broad Institute and the Massachusetts Institute of Technology and is funded by the National Institutes of Health. The goal of the initiative is to gain a better understanding of the biology and evolution of nematodes and to use this knowledge to develop new treatments for diseases caused by nematode parasites. The initiative also aims to provide resources and data to the scientific community to facilitate further research into the genetic and biological complexity of nematodes.",
    "alpaca-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and assemble the genomes of 959 species of nematodes.\n2. The initiative is led by the Broad Institute and the Massachusetts Institute of Technology.\n3. The National Institutes of Health funds the 959 Nematode Genomes initiative.\n4. One goal of the initiative is to improve understanding of the biology and evolution of nematodes.\n5. The initiative seeks to develop new treatments for diseases caused by nematode parasites.",
    "alpaca-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and assemble the genomes of 959 species of nematodes.",
      "The initiative is led by the Broad Institute and the Massachusetts Institute of Technology.",
      "The National Institutes of Health funds the 959 Nematode Genomes initiative.",
      "One goal of the initiative is to improve understanding of the biology and evolution of nematodes.",
      "The initiative seeks to develop new treatments for diseases caused by nematode parasites."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes project or WormBase ParaSite, is not specifically led by the Broad Institute and the Massachusetts Institute of Technology. It is a collaborative effort involving multiple institutions.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "alpaca-7b_response": "The R package 'NIPTdata' has been developed for analyzing Non-invasive prenatal testing (NIPT) data. It provides functions for preprocessing, data exploration, and statistical analysis of NIPT data. It also includes tools for visualizing and interpreting data, as well as methods for identifying and correcting for potential biases in the data. The package is designed to be user-friendly and intuitive, with functions that are easy to use and understand. It is also designed to be easily extendable and customizable, allowing users to add their own methods and algorithms. The package is available on CRAN and can be used for a variety of NIPT applications, such as fetal sex determination, fetal aneuploidy screening, and non-invasive prenatal diagnosis.",
    "alpaca-7b_fact_raw": "1. The R package 'NIPTdata' is developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. 'NIPTdata' provides functions for preprocessing, data exploration, and statistical analysis of NIPT data.\n3. The package includes tools for visualizing and interpreting NIPT data.\n4. 'NIPTdata' contains methods for identifying and correcting potential biases in NIPT data.\n5. The 'NIPTdata' package is available on CRAN (Comprehensive R Archive Network).",
    "alpaca-7b_fact": [
      "The R package 'NIPTdata' is developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "'NIPTdata' provides functions for preprocessing, data exploration, and statistical analysis of NIPT data.",
      "The package includes tools for visualizing and interpreting NIPT data.",
      "'NIPTdata' contains methods for identifying and correcting potential biases in NIPT data.",
      "The 'NIPTdata' package is available on CRAN (Comprehensive R Archive Network)."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: As of my knowledge cutoff date in March 2023, there is no R package named 'NIPTdata' available on CRAN (Comprehensive R Archive Network). It is possible that such a package exists elsewhere or has been developed after my knowledge cutoff date, but without current information, I cannot confirm its availability on CRAN.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "alpaca-7b_response": "Achenbachs syndrome is a rare genetic disorder characterized by intellectual disability, distinctive facial features, and a variety of physical abnormalities. It is caused by mutations in the TBX1 gene and is inherited in an autosomal dominant manner. People with Achenbachs syndrome have a wide range of symptoms, including intellectual disability, distinctive facial features such as a small jaw, wide mouth, and prominent ears, as well as physical abnormalities such as heart defects, kidney abnormalities, and bone malformations. Treatment is aimed at managing the symptoms of the syndrome and may include speech and occupational therapy, as well as surgery for physical abnormalities.",
    "alpaca-7b_fact_raw": "1. Achenbachs syndrome is characterized by intellectual disability, distinctive facial features, and physical abnormalities.\n2. Mutations in the TBX1 gene cause Achenbachs syndrome.\n3. Achenbachs syndrome is inherited in an autosomal dominant manner.\n4. Symptoms of Achenbachs syndrome can include a small jaw, wide mouth, and prominent ears.\n5. Treatment for Achenbachs syndrome may include speech and occupational therapy, as well as surgery for physical abnormalities.",
    "alpaca-7b_fact": [
      "Achenbachs syndrome is characterized by intellectual disability, distinctive facial features, and physical abnormalities.",
      "Mutations in the TBX1 gene cause Achenbachs syndrome.",
      "Achenbachs syndrome is inherited in an autosomal dominant manner.",
      "Symptoms of Achenbachs syndrome can include a small jaw, wide mouth, and prominent ears.",
      "Treatment for Achenbachs syndrome may include speech and occupational therapy, as well as surgery for physical abnormalities."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by spontaneous bruising of the hands or fingers.\n2. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the TBX1 gene; it is a condition of unknown etiology involving paroxysmal bruising.\n3. FALSE [correction]: Achenbach's syndrome is not inherited as it is not a genetic condition; it occurs spontaneously.\n4. FALSE [correction]: The symptoms described are not associated with Achenbach's syndrome but may be indicative of another condition, such as 22q11.2 deletion syndrome, which involves the TBX1 gene.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "alpaca-7b_response": "The algorithm used for detection of long repeat expansions is called the sliding window algorithm. It works by comparing the sequence of a gene to a reference sequence and identifying regions of similarity. The algorithm then creates a sliding window of comparison, which is moved along the gene sequence and compared to the reference. If a region of similarity is found, the algorithm determines the length of the repeat expansion and flags it. This algorithm is used to detect repeat expansions in genetic disorders such as Huntingtons disease and myotonic dystrophy.",
    "alpaca-7b_fact_raw": "1. The sliding window algorithm is used for detection of long repeat expansions.\n2. The sliding window algorithm compares the sequence of a gene to a reference sequence to identify regions of similarity.\n3. The algorithm creates a sliding window of comparison that is moved along the gene sequence.\n4. The sliding window algorithm is used to detect repeat expansions in genetic disorders such as Huntingtons disease and myotonic dystrophy.",
    "alpaca-7b_fact": [
      "The sliding window algorithm is used for detection of long repeat expansions.",
      "The sliding window algorithm compares the sequence of a gene to a reference sequence to identify regions of similarity.",
      "The algorithm creates a sliding window of comparison that is moved along the gene sequence.",
      "The sliding window algorithm is used to detect repeat expansions in genetic disorders such as Huntingtons disease and myotonic dystrophy."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "alpaca-7b_response": "Neuroligin-3 has been found to promote the growth of certain types of brain tumors, including gliomas, meningiomas, and schwannomas. It is believed that these tumors are able to use neuroligin-3 to evade the immune system and establish a tumor microenvironment that promotes tumor growth. In addition, neuroligin-3 has been found to be expressed in some cases of metastatic breast cancer, suggesting that it may be involved in the spread of cancer to the brain. Further research is necessary to determine the full scope of neuroligin-3s involvement in brain tumor growth and metastasis.",
    "alpaca-7b_fact_raw": "1. Neuroligin-3 promotes the growth of gliomas.\n2. Neuroligin-3 promotes the growth of meningiomas.\n3. Neuroligin-3 promotes the growth of schwannomas.\n4. Neuroligin-3 is believed to help tumors evade the immune system.\n5. Neuroligin-3 has been found to be expressed in some cases of metastatic breast cancer.",
    "alpaca-7b_fact": [
      "Neuroligin-3 promotes the growth of gliomas.",
      "Neuroligin-3 promotes the growth of meningiomas.",
      "Neuroligin-3 promotes the growth of schwannomas.",
      "Neuroligin-3 is believed to help tumors evade the immune system.",
      "Neuroligin-3 has been found to be expressed in some cases of metastatic breast cancer."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Neuroligin-3 has been shown to promote the growth of gliomas, according to scientific studies.\n2. UNKNOWN: The role of neuroligin-3 in the growth of meningiomas is not clearly established in the literature as of my knowledge cutoff date.\n3. UNKNOWN: The role of neuroligin-3 in the growth of schwannomas is not clearly established in the literature as of my knowledge cutoff date.\n4. UNKNOWN: While neuroligin-3 has been implicated in tumor biology, its specific role in helping tumors evade the immune system is not clearly established as of my knowledge cutoff date.\n5. TRUE: Neuroligin-3 has been found to be expressed in some cases of metastatic breast cancer, according to scientific research.",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "alpaca-7b_response": "Gas vesicles are approximately 1-2 m in size. They are usually spherical or elliptical in shape and are composed of a single layer of membrane with many small, gas-filled sacs. The gas vesicles help fish to control their buoyancy and provide some protection against predators. They also allow fish to breathe oxygen from the water, as well as to store oxygen for long-term use.",
    "alpaca-7b_fact_raw": "1. Gas vesicles are approximately 1-2 m in size.\n2. Gas vesicles are usually spherical or elliptical in shape.\n3. Gas vesicles are composed of a single layer of membrane.\n4. Gas vesicles help fish to control their buoyancy.\n5. Gas vesicles allow fish to store oxygen for long-term use.",
    "alpaca-7b_fact": [
      "Gas vesicles are approximately 1-2 m in size.",
      "Gas vesicles are usually spherical or elliptical in shape.",
      "Gas vesicles are composed of a single layer of membrane.",
      "Gas vesicles help fish to control their buoyancy.",
      "Gas vesicles allow fish to store oxygen for long-term use."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Gas vesicles are typically much smaller, approximately 45-200 nm in width and 100-1000 nm in length.\n2. FALSE [correction]: Gas vesicles are typically cylindrical in shape with conical ends, not spherical or elliptical.\n3. TRUE\n4. FALSE [correction]: Gas vesicles are found in certain bacteria and archaea, not fish, to control their buoyancy.\n5. FALSE [correction]: Gas vesicles are not used to store oxygen; they are used to regulate buoyancy in water by certain microorganisms. Fish use a swim bladder for buoyancy control, which can contain gas but is not the same as gas vesicles.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "alpaca-7b_response": "BET proteins include Bromodomain and Extra-Terminal (BET) proteins, which are a family of proteins that contain a bromodomain and an extra-terminal (BET) domain. BET proteins are involved in a variety of cellular processes such as transcription, chromatin remodeling, and ubiquitination. Examples of BET proteins include Bromodomain-containing protein 1 (BDP1), Bromodomain-containing protein 2 (BDP2), Bromodomain-containing protein 3 (BDP3), Bromodomain-containing protein 4 (BDP4), Bromodomain-containing protein 5 (BDP5), Bromodomain-containing protein 6 (BDP6), Bromodomain-containing protein 7 (BDP7), Bromodomain-containing protein 8 (BDP8), Bromodomain-containing protein 9 (BDP9), and Bromodomain-containing protein 10 (BDP10).",
    "alpaca-7b_fact_raw": "1. BET proteins are a family of proteins that contain a bromodomain and an extra-terminal (BET) domain.\n2. BET proteins are involved in cellular processes such as transcription, chromatin remodeling, and ubiquitination.\n3. Examples of BET proteins include Bromodomain-containing protein 1 (BDP1) and Bromodomain-containing protein 2 (BDP2).\n4. Bromodomain-containing protein 4 (BDP4) is an example of a BET protein.\n5. The BET protein family includes Bromodomain-containing protein 10 (BDP10).",
    "alpaca-7b_fact": [
      "BET proteins are a family of proteins that contain a bromodomain and an extra-terminal (BET) domain.",
      "BET proteins are involved in cellular processes such as transcription, chromatin remodeling, and ubiquitination.",
      "Examples of BET proteins include Bromodomain-containing protein 1 (BDP1) and Bromodomain-containing protein 2 (BDP2).",
      "Bromodomain-containing protein 4 (BDP4) is an example of a BET protein.",
      "The BET protein family includes Bromodomain-containing protein 10 (BDP10)."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Examples of BET proteins include Bromodomain-containing protein 2 (BRD2), Bromodomain-containing protein 3 (BRD3), and Bromodomain-containing protein 4 (BRD4). There is no Bromodomain-containing protein 1 (BDP1) or Bromodomain-containing protein 2 (BDP2) in the BET family.\n4. FALSE [correction]: Bromodomain-containing protein 4 is known as BRD4, not BDP4, and it is an example of a BET protein.\n5. FALSE [correction]: The BET protein family does not include Bromodomain-containing protein 10 (BDP10). BET proteins are typically referred to as BRD2, BRD3, BRD4, and BRDT.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "alpaca-7b_response": "The algorithm developed for prediction of protein subcellular localization using deep learning is called PredictSubCell. It is a deep learning model that uses convolutional neural networks to classify proteins into different subcellular locations. PredictSubCell is trained on a large dataset of proteins and their corresponding subcellular localizations, and it can accurately predict the subcellular localization of a protein based on its amino acid sequence. The model has been shown to outperform other existing methods and can be used to accurately predict the subcellular localization of proteins with high accuracy.",
    "alpaca-7b_fact_raw": "1. PredictSubCell is an algorithm developed for prediction of protein subcellular localization using deep learning.\n2. PredictSubCell uses convolutional neural networks to classify proteins into different subcellular locations.\n3. The algorithm is trained on a large dataset of proteins and their corresponding subcellular localizations.\n4. PredictSubCell can predict the subcellular localization of a protein based on its amino acid sequence.\n5. PredictSubCell has been shown to outperform other existing methods in predicting protein subcellular localization.",
    "alpaca-7b_fact": [
      "PredictSubCell is an algorithm developed for prediction of protein subcellular localization using deep learning.",
      "PredictSubCell uses convolutional neural networks to classify proteins into different subcellular locations.",
      "The algorithm is trained on a large dataset of proteins and their corresponding subcellular localizations.",
      "PredictSubCell can predict the subcellular localization of a protein based on its amino acid sequence.",
      "PredictSubCell has been shown to outperform other existing methods in predicting protein subcellular localization."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "alpaca-7b_response": "MULTOVL is an open-source software library designed to simplify the development of multi-threaded applications. It provides an interface for creating and managing threads, as well as synchronization and communication between threads. It also provides a thread pool for efficient thread management. MULTOVL is designed to be easy to use, with a small footprint and low overhead. It is also designed to be portable, with implementations for multiple platforms including Windows, Linux, and Mac OS X. MULTOVL is released under the MIT license and is open-source.",
    "alpaca-7b_fact_raw": "1. MULTOVL is an open-source software library.\n2. MULTOVL is designed for simplifying the development of multi-threaded applications.\n3. It includes features for creating and managing threads, synchronization, and communication between threads.\n4. MULTOVL provides a thread pool for efficient thread management.\n5. The software is released under the MIT license.",
    "alpaca-7b_fact": [
      "MULTOVL is an open-source software library.",
      "MULTOVL is designed for simplifying the development of multi-threaded applications.",
      "It includes features for creating and managing threads, synchronization, and communication between threads.",
      "MULTOVL provides a thread pool for efficient thread management.",
      "The software is released under the MIT license."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the software library named MULTOVL, it is not possible to determine the truthfulness of these statements. The name MULTOVL does not correspond to any widely recognized open-source software library as of my last update, and without additional context or information, the details about its design, features, licensing, and whether it even exists cannot be verified.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "alpaca-7b_response": "Yes, GDF15 can be a potential biomarker for metformin treatment. Metformin has been shown to reduce levels of GDF15 in patients with type 2 diabetes, suggesting that GDF15 may be a useful biomarker for metformin treatment. In addition, GDF15 has also been found to be associated with insulin resistance and diabetes, making it a potential biomarker for the efficacy of treatments targeting insulin resistance and diabetes. Further studies are needed to investigate the potential of GDF15 as a biomarker for metformin treatment.",
    "alpaca-7b_fact_raw": "1. GDF15 can be a potential biomarker for metformin treatment.\n2. Metformin has been shown to reduce levels of GDF15 in patients with type 2 diabetes.\n3. GDF15 is associated with insulin resistance and diabetes.\n4. GDF15 may be a useful biomarker for the efficacy of treatments targeting insulin resistance and diabetes.\n5. Further studies are needed to investigate the potential of GDF15 as a biomarker for metformin treatment.",
    "alpaca-7b_fact": [
      "GDF15 can be a potential biomarker for metformin treatment.",
      "Metformin has been shown to reduce levels of GDF15 in patients with type 2 diabetes.",
      "GDF15 is associated with insulin resistance and diabetes.",
      "GDF15 may be a useful biomarker for the efficacy of treatments targeting insulin resistance and diabetes.",
      "Further studies are needed to investigate the potential of GDF15 as a biomarker for metformin treatment."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Metformin has been shown to increase levels of GDF15 in patients with type 2 diabetes.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "alpaca-7b_response": "Yes, recursive splicing is more common in short introns. Recursive splicing is a process in which introns in a gene are spliced together to form a single exon, which can reduce the number of exons in a gene and reduce the complexity of the gene structure. Recursive splicing is more common in short introns because the introns are shorter and have less sequence complexity, making them easier to splice together. Additionally, recursive splicing is more common in genes with fewer introns, as fewer introns provide more opportunities for recursive splicing.",
    "alpaca-7b_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing is a process where introns in a gene are spliced together to form a single exon.\n3. Recursive splicing can reduce the number of exons in a gene.\n4. Short introns have less sequence complexity, which makes them easier to splice together.\n5. Recursive splicing is more common in genes with fewer introns.",
    "alpaca-7b_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing is a process where introns in a gene are spliced together to form a single exon.",
      "Recursive splicing can reduce the number of exons in a gene.",
      "Short introns have less sequence complexity, which makes them easier to splice together.",
      "Recursive splicing is more common in genes with fewer introns."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. FALSE [correction]: Recursive splicing is a process where a long intron is removed in multiple steps, with splicing at 'recursive' splice sites within the intron, not splicing introns together to form a single exon.\n3. FALSE [correction]: Recursive splicing does not reduce the number of exons in a gene; it is a process that removes introns in multiple steps.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "alpaca-7b_response": "The TALE-iD method is used to identify and analyze the structure and function of proteins. It is a powerful tool used to study the interactions between proteins and other molecules, as well as to understand the structure and function of proteins in the context of their natural environment. TALE-iD can also be used to study the evolutionary history of proteins and to identify potential drug targets.",
    "alpaca-7b_fact_raw": "1. The TALE-iD method is used to identify and analyze the structure and function of proteins.\n2. TALE-iD is used to study the interactions between proteins and other molecules.\n3. The method helps understand the structure and function of proteins in their natural environment.\n4. TALE-iD can be used to study the evolutionary history of proteins.\n5. The TALE-iD method can be utilized to identify potential drug targets.",
    "alpaca-7b_fact": [
      "The TALE-iD method is used to identify and analyze the structure and function of proteins.",
      "TALE-iD is used to study the interactions between proteins and other molecules.",
      "The method helps understand the structure and function of proteins in their natural environment.",
      "TALE-iD can be used to study the evolutionary history of proteins.",
      "The TALE-iD method can be utilized to identify potential drug targets."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The TALE-iD method is used to identify and analyze the structure and function of genes, not proteins.\n2. FALSE [correction]: TALE-iD is used to study the interactions between transcription activator-like effector (TALE) proteins and DNA, not between proteins and other molecules.\n3. UNKNOWN: Without specific context, it's unclear whether TALE-iD helps understand the structure and function of proteins in their natural environment, as it primarily focuses on gene analysis.\n4. UNKNOWN: The statement about studying the evolutionary history of proteins with TALE-iD is vague without additional context. TALE-iD is generally used for gene editing and gene function analysis, not directly for studying protein evolution.\n5. TRUE: The TALE-iD method can be utilized to identify potential drug targets by understanding gene function and regulation, which can lead to the identification of proteins that are essential for disease processes.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "alpaca-7b_response": "The Lisp framework for image processing is called Open ImageIO. It provides a library of image processing functions written in Common Lisp and is designed to be a portable, platform-independent image processing framework. It supports a wide range of image formats and provides functions for reading, writing, displaying, and manipulating images. It also provides a C API for direct access to the image data. Open ImageIO is used by a variety of applications, including image viewers, medical imaging systems, and digital photography systems. It is also used in research and educational settings to develop new image processing algorithms.",
    "alpaca-7b_fact_raw": "1. Open ImageIO is a Lisp framework developed for image processing.\n2. Open ImageIO is written in Common Lisp.\n3. Open ImageIO supports a wide range of image formats.\n4. Open ImageIO provides a C API for direct access to the image data.\n5. Open ImageIO is used in applications such as image viewers, medical imaging systems, and digital photography systems.",
    "alpaca-7b_fact": [
      "Open ImageIO is a Lisp framework developed for image processing.",
      "Open ImageIO is written in Common Lisp.",
      "Open ImageIO supports a wide range of image formats.",
      "Open ImageIO provides a C API for direct access to the image data.",
      "Open ImageIO is used in applications such as image viewers, medical imaging systems, and digital photography systems."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Open ImageIO is not a Lisp framework; it is a library for reading and writing images, and it is developed in C++.\n2. FALSE [correction]: Open ImageIO is not written in Common Lisp; it is written in C++.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "alpaca-7b_response": "Approximately 75% of the genes in S. cerevisiae are the result of an ancient whole genome duplication. This duplication event occurred approximately 100 million years ago, and resulted in the formation of two identical copies of the original genome. Over time, the two copies diverged, leading to the current gene complement of S. cerevisiae. This ancient whole genome duplication is a unique event that occurred only once in the evolutionary history of S. cerevisiae, and is not shared by other species. As a result, S. cerevisiae has a large number of genes compared to other species, which is why it is an important model organism for genetic research. \nIn addition, the ancient whole genome duplication event has resulted in the formation of several unique gene products in S. cerevisiae. These gene products are known as \"paralogs\", and can be used to study the evolutionary history of the species. Furthermore, the duplication of certain genes has allowed for the development of new traits in S. cerevisiae, such as the ability to tolerate high temperatures and certain toxins. This makes S. cerevisiae an important tool for industrial applications. \nOverall, the ancient whole genome duplication event has been extremely beneficial to the species S. cerevisiae, and has allowed the species to evolve and adapt to its environment in unique ways. As a result, S. cerevisiae is an important model organism for genetic research, and has been used to study a wide range of topics in evolutionary biology and genetics.",
    "alpaca-7b_fact_raw": "1. Approximately 75% of the genes in S. cerevisiae are the result of an ancient whole genome duplication.\n2. The whole genome duplication event in S. cerevisiae occurred approximately 100 million years ago.\n3. The ancient whole genome duplication in S. cerevisiae is a unique event that occurred only once in its evolutionary history.\n4. The duplication event in S. cerevisiae led to the formation of gene products known as \"paralogs\".\n5. The duplication of certain genes has allowed S. cerevisiae to develop new traits, such as the ability to tolerate high temperatures and certain toxins.",
    "alpaca-7b_fact": [
      "Approximately 75% of the genes in S. cerevisiae are the result of an ancient whole genome duplication.",
      "The whole genome duplication event in S. cerevisiae occurred approximately 100 million years ago.",
      "The ancient whole genome duplication in S. cerevisiae is a unique event that occurred only once in its evolutionary history.",
      "The duplication event in S. cerevisiae led to the formation of gene products known as \"paralogs\".",
      "The duplication of certain genes has allowed S. cerevisiae to develop new traits, such as the ability to tolerate high temperatures and certain toxins."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: It is widely accepted that approximately 75% of the genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication (WGD).\n2. FALSE [correction]: The whole genome duplication event in S. cerevisiae is estimated to have occurred about 100-150 million years ago, but the exact timing is still a subject of research and debate.\n3. FALSE [correction]: While the whole genome duplication in S. cerevisiae is a significant event in its evolutionary history, it is not unique. Whole genome duplications have occurred in the evolutionary history of many other species as well.\n4. TRUE: The duplication event in S. cerevisiae did lead to the formation of gene products known as \"paralogs,\" which are pairs of genes that arise from a duplication event and are present in the same organism.\n5. TRUE: The duplication of certain genes has indeed allowed S. cerevisiae to develop new traits, including the ability to tolerate high temperatures and certain toxins, which can be advantageous for survival in various environments.",
    "alpaca-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "alpaca-7b_response": "Esrrb is a protein that is bound by the estrogen-related receptor complex. This complex is composed of several other proteins, including Esr1, Esr2, Esr3, and Esr4. The estrogen-related receptor complex is involved in the regulation of gene expression in response to estrogen and other hormones. It binds to hormone response elements in the promoter region of target genes, which triggers the expression of those genes. The complex is also involved in the development of breast cancer, as mutations in the Esr1 gene have been linked to the disease.",
    "alpaca-7b_fact_raw": "1. Esrrb is a protein that is bound by the estrogen-related receptor complex.\n2. The estrogen-related receptor complex includes proteins such as Esr1, Esr2, Esr3, and Esr4.\n3. This complex is involved in the regulation of gene expression in response to estrogen and other hormones.\n4. It binds to hormone response elements in the promoter region of target genes to trigger gene expression.\n5. Mutations in the Esr1 gene, which is part of the complex, have been linked to the development of breast cancer.",
    "alpaca-7b_fact": [
      "Esrrb is a protein that is bound by the estrogen-related receptor complex.",
      "The estrogen-related receptor complex includes proteins such as Esr1, Esr2, Esr3, and Esr4.",
      "This complex is involved in the regulation of gene expression in response to estrogen and other hormones.",
      "It binds to hormone response elements in the promoter region of target genes to trigger gene expression.",
      "Mutations in the Esr1 gene, which is part of the complex, have been linked to the development of breast cancer."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Esrrb is not a protein that is bound by the estrogen-related receptor complex. Esrrb (Embryonic stem cell-related RRB) is a transcription factor involved in stem cell pluripotency and is not directly related to the estrogen receptor complex.\n2. FALSE [correction]: The estrogen-related receptor complex does not include a protein known as Esr4. The known estrogen receptors are Esr1 (ER) and Esr2 (ER). There is no Esr3 or Esr4 that are recognized as part of this complex.\n3. TRUE: The estrogen receptor complex is indeed involved in the regulation of gene expression in response to estrogen and other hormones.\n4. TRUE: Estrogen receptors bind to hormone response elements in the promoter regions of target genes to regulate gene expression.\n5. TRUE: Mutations in the Esr1 gene, which encodes the estrogen receptor alpha (ER), have been linked to the development of breast cancer.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "alpaca-7b_response": "ZCCHC17 is a protein that is involved in the regulation of cell growth and metabolism. It is a member of the ZCCHC family of proteins and is thought to play a role in the regulation of gene expression. It is also involved in the regulation of metabolic pathways, including those involved in the synthesis and degradation of lipids. Additionally, ZCCHC17 has been shown to interact with other proteins and modulate their activity, suggesting that it may have a role in signaling pathways. Further research is needed to better understand the function of ZCCHC17 and its role in human biology.",
    "alpaca-7b_fact_raw": "1. ZCCHC17 is a protein involved in the regulation of cell growth and metabolism.\n2. ZCCHC17 is a member of the ZCCHC family of proteins.\n3. ZCCHC17 is thought to play a role in the regulation of gene expression.\n4. ZCCHC17 is involved in the regulation of metabolic pathways related to the synthesis and degradation of lipids.\n5. ZCCHC17 has been shown to interact with other proteins and modulate their activity.",
    "alpaca-7b_fact": [
      "ZCCHC17 is a protein involved in the regulation of cell growth and metabolism.",
      "ZCCHC17 is a member of the ZCCHC family of proteins.",
      "ZCCHC17 is thought to play a role in the regulation of gene expression.",
      "ZCCHC17 is involved in the regulation of metabolic pathways related to the synthesis and degradation of lipids.",
      "ZCCHC17 has been shown to interact with other proteins and modulate their activity."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding ZCCHC17 are highly specific and would require access to current scientific literature or databases to verify. Without specific information on the protein ZCCHC17, it is not possible to determine the accuracy of statements 1, 3, 4, and 5. Statement 2 is likely true as ZCCHC17 is named in a way that suggests it is a member of the ZCCHC family of proteins, which is a common naming convention in genetics.",
    "alpaca-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "alpaca-7b_response": "The proteins that form the nuclear pore basket in human cells are called Nup98, Nup96, Nup2, Nup155, and Nup133. These proteins form a ring-like structure around the nuclear pore complex, which regulates the transport of molecules between the nucleus and the cytoplasm.",
    "alpaca-7b_fact_raw": "1. Nup98 is a protein that forms part of the nuclear pore basket in human cells.\n2. Nup96 is a protein that forms part of the nuclear pore basket in human cells.\n3. Nup2 is a protein that forms part of the nuclear pore basket in human cells.\n4. Nup155 is a protein that forms part of the nuclear pore basket in human cells.\n5. Nup133 is a protein that forms part of the nuclear pore basket in human cells.",
    "alpaca-7b_fact": [
      "Nup98 is a protein that forms part of the nuclear pore basket in human cells.",
      "Nup96 is a protein that forms part of the nuclear pore basket in human cells.",
      "Nup2 is a protein that forms part of the nuclear pore basket in human cells.",
      "Nup155 is a protein that forms part of the nuclear pore basket in human cells.",
      "Nup133 is a protein that forms part of the nuclear pore basket in human cells."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Nup96 is a protein that is a component of the nuclear pore complex, but it is not part of the nuclear pore basket. It is involved in the nuclear export of mRNAs and ribosomal subunits.\n3. FALSE [correction]: Nup2 is a protein that is associated with the nuclear pore complex, but it is not a structural component of the nuclear pore basket. It is involved in the transport of proteins into the nucleus.\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "alpaca-7b_response": "Gepotidacin is a type of topoisomerase inhibitor that is classified as a fluoroquinolone. It is a synthetic antibiotic that is used to treat a variety of bacterial infections. It works by inhibiting the enzyme topoisomerase, which is necessary for bacterial DNA replication, transcription, and repair. This prevents the bacteria from replicating and growing, leading to a successful treatment outcome.",
    "alpaca-7b_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. Gepotidacin is classified as a fluoroquinolone.\n3. It is a synthetic antibiotic.\n4. Gepotidacin is used to treat bacterial infections.\n5. The mechanism of action for gepotidacin involves inhibiting the enzyme topoisomerase necessary for bacterial DNA replication, transcription, and repair.",
    "alpaca-7b_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "Gepotidacin is classified as a fluoroquinolone.",
      "It is a synthetic antibiotic.",
      "Gepotidacin is used to treat bacterial infections.",
      "The mechanism of action for gepotidacin involves inhibiting the enzyme topoisomerase necessary for bacterial DNA replication, transcription, and repair."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Gepotidacin is not classified as a fluoroquinolone; it is a novel triazaacenaphthylene antibacterial agent.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "alpaca-7b_response": "Canvas SPW is a cloud-based platform that provides a comprehensive suite of tools for creating, managing, and delivering online learning experiences. It is designed to help organizations create engaging and interactive learning experiences, with features such as user management, course management, assessment and grading, collaboration tools, and analytics. It also integrates with other technologies to provide a comprehensive learning environment.",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "alpaca-7b_response": "Sting agonists include but are not limited to:\n- N-acetyl-L-cysteine\n- Cromolyn sodium\n- Methacholine chloride\n- Phosphodiesterase inhibitors\n- Polymyxin B\n- Suramin\n- Tetrodotoxin\n- Vanadium chloride\n- Veratridine\n- Pyridostigmine bromide\n- Quinacrine\n- Dantrolene sodium\n- Riluzole\n- Tetrodotoxin analogues\n- Curare\n- Tetrodotoxin derivatives\n- Tetrodotoxin mimetics\n- Tetrodotoxin-based drugs.",
    "alpaca-7b_fact_raw": "1. N-acetyl-L-cysteine is a STING agonist.\n2. Cromolyn sodium is a STING agonist.\n3. Methacholine chloride is a STING agonist.\n4. Phosphodiesterase inhibitors are STING agonists.\n5. Polymyxin B is a STING agonist.",
    "alpaca-7b_fact": [
      "N-acetyl-L-cysteine is a STING agonist.",
      "Cromolyn sodium is a STING agonist.",
      "Methacholine chloride is a STING agonist.",
      "Phosphodiesterase inhibitors are STING agonists.",
      "Polymyxin B is a STING agonist."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: N-acetyl-L-cysteine (NAC) is not a STING agonist; it is an antioxidant that replenishes intracellular levels of glutathione.\n2. FALSE [correction]: Cromolyn sodium is not a STING agonist; it is a mast cell stabilizer used to treat allergic conditions.\n3. FALSE [correction]: Methacholine chloride is not a STING agonist; it is a cholinergic agonist used in bronchial challenge tests.\n4. FALSE [correction]: Phosphodiesterase inhibitors are not STING agonists; they inhibit the enzyme phosphodiesterase and are used for various conditions, including erectile dysfunction and pulmonary hypertension.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "alpaca-7b_response": "SLIC-CAGE is a system for securely storing and managing cryptographic keys. It is designed to be a secure, tamper-resistant, and self-contained system that can generate and store cryptographic keys, and manage their associated cryptographic operations. It is intended to be used in applications where security and privacy are paramount, such as in financial, governmental, and military sectors. The system is designed to be resistant to physical attacks, as well as attempts to gain access to its internal data. It also provides secure communication between the system and external entities, allowing it to be managed and monitored remotely. The system is designed to be self-contained, with all of its components integrated into a single unit, making it difficult to tamper with. It also features a secure boot process that verifies the integrity of the system and its components before allowing the system to start up. The system is designed to be highly efficient, requiring minimal resources, while still providing a high level of security. It is also designed to be easily upgraded and maintained, with built-in diagnostics and debugging tools. The system is designed to be open and modular, allowing for easy integration with existing systems and technologies. In short, SLIC-CAGE is designed to be a secure, tamper-resistant, and self-contained system for generating and managing cryptographic keys.",
    "alpaca-7b_fact_raw": "1. SLIC-CAGE is a system for securely storing and managing cryptographic keys.\n2. It is intended for use in sectors where security and privacy are critical, such as financial, governmental, and military sectors.\n3. SLIC-CAGE is designed to be resistant to physical attacks and unauthorized access to internal data.\n4. The system features a secure boot process that verifies the integrity of the system and its components before startup.\n5. SLIC-CAGE is designed to be open and modular, allowing for integration with existing systems and technologies.",
    "alpaca-7b_fact": [
      "SLIC-CAGE is a system for securely storing and managing cryptographic keys.",
      "It is intended for use in sectors where security and privacy are critical, such as financial, governmental, and military sectors.",
      "SLIC-CAGE is designed to be resistant to physical attacks and unauthorized access to internal data.",
      "The system features a secure boot process that verifies the integrity of the system and its components before startup.",
      "SLIC-CAGE is designed to be open and modular, allowing for integration with existing systems and technologies."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the SLIC-CAGE system, it is not possible to determine the truthfulness of these statements. They could be accurate descriptions of a real or hypothetical system, but without additional context or sources, their validity cannot be confirmed.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "alpaca-7b_response": "The LEM-3 (Lunar Excursion Module-3) was a module used in the Apollo program to land astronauts on the Moon. It was a reusable spacecraft that was launched from the Saturn V rocket and was used to transport the astronauts from the Command/Service Module (CSM) to the Moon's surface. The LEM-3 was also used to return the astronauts to the CSM. The LEM-3 had a pressurized cabin, a rocket engine, and several other systems necessary for a successful landing and takeoff. It also had a landing radar, a laser altimeter, and a television system for the astronauts to observe the Moon's surface. The LEM-3 was used in the Apollo 16 and 17 missions and was the first module to have a successful landing and takeoff. It was also the first module to have a successful landing and takeoff on the Moon. The LEM-3 was a critical component of the Apollo program and its successes enabled the first human footsteps on the Moon. \nThe LEM-3 also had several other roles. It was used to test the Saturn V rocket and its systems, as well as to test the Apollo spacecraft's systems and procedures. It was also used to test the Apollo Guidance and Navigation System (AGNS) and the Lunar Orbit Rendezvous (LOR) technique. The LEM-3 was also used to test the Extravehicular Mobility Unit (EMU) and the Apollo Lunar Surface Experiment Package (ALSEP). Finally, the LEM-3 was used to test the Apollo 11 and 12 command and service modules in Earth orbit. \nThe LEM-3 was a critical component of the Apollo program and its successes enabled the first human footsteps on the Moon. It was also used to test the Saturn V rocket and its systems, as well as to test the Apollo spacecraft's systems and procedures. It was also used to test the AGNS and the LOR technique, as well as to test the EMU and the ALSEP. Finally, the LEM-3 was used to test the Apollo 11 and 12 command and service modules in Earth orbit.",
    "alpaca-7b_fact_raw": "1. The LEM-3 (Lunar Excursion Module-3) was used in the Apollo program to land astronauts on the Moon.\n2. The LEM-3 was launched from the Saturn V rocket.\n3. The LEM-3 was used in the Apollo 16 and 17 missions.\n4. The LEM-3 was the first module to have a successful landing and takeoff on the Moon.\n5. The LEM-3 was used to test the Apollo Guidance and Navigation System (AGNS) and the Lunar Orbit Rendezvous (LOR) technique.",
    "alpaca-7b_fact": [
      "The LEM-3 (Lunar Excursion Module-3) was used in the Apollo program to land astronauts on the Moon.",
      "The LEM-3 was launched from the Saturn V rocket.",
      "The LEM-3 was used in the Apollo 16 and 17 missions.",
      "The LEM-3 was the first module to have a successful landing and takeoff on the Moon.",
      "The LEM-3 was used to test the Apollo Guidance and Navigation System (AGNS) and the Lunar Orbit Rendezvous (LOR) technique."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Lunar Module used for the Apollo program was not designated LEM-3. Each Lunar Module had its own designation, such as LM-5 for Apollo 11.\n2. TRUE: Lunar Modules were launched from the Saturn V rocket as part of the Apollo missions.\n3. FALSE [correction]: Each Apollo mission that landed on the Moon used a different Lunar Module. Apollo 16 used LM-11, and Apollo 17 used LM-12.\n4. FALSE [correction]: The first module to have a successful landing and takeoff on the Moon was LM-5, used in the Apollo 11 mission.\n5. TRUE: Lunar Modules were used to test various systems, including the Apollo Guidance and Navigation System (AGNS) and the Lunar Orbit Rendezvous (LOR) technique, although the specific designation LEM-3 is incorrect.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "alpaca-7b_response": "tmVar has been released in the following versions: 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.40, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.50, 1.51, 1.52, 1.53, 1.54, 1.55, 1.56, 1.57, 1.58, 1.59, 1.60, 1.61, 1.62, 1.63, 1.64, 1.65, 1.66, 1.67, 1.68, 1.69, 1.70, 1.71, 1.72, 1.73, 1.74, 1.75, 1.76, 1.77, 1.78, 1.79, 1.80, 1.81, 1.82, 1.83, 1.84, 1",
    "alpaca-7b_fact_raw": "1. tmVar version 1.0 was released.\n2. tmVar version 1.1 was released.\n3. tmVar version 1.2 was released.\n4. tmVar version 1.3 was released.\n5. tmVar version 1.4 was released.",
    "alpaca-7b_fact": [
      "tmVar version 1.0 was released.",
      "tmVar version 1.1 was released.",
      "tmVar version 1.2 was released.",
      "tmVar version 1.3 was released.",
      "tmVar version 1.4 was released."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout specific dates or additional context, it's not possible to verify the release of each version of tmVar. However, assuming that the list is sequential and each version was indeed released, the first four statements can be considered true. The fifth statement is unknown without further information.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "alpaca-7b_response": "The database of somatic mutations in normal cells is called the International Cancer Genome Consortium (ICGC) Data Portal. It contains data on the genetic changes that occur in normal cells, as well as in cancer cells. The database provides information on the type of mutations, their frequency, and the cell lines in which they were found. It also provides information on the tissue types in which the mutations occur. The database is an invaluable resource for researchers studying the genetic changes that occur in normal cells and how they compare to those that occur in cancer cells. It can also be used to study the effects of environmental factors on mutations and to better understand the genetic basis of disease.  The database can be accessed at https://icgc.org/data-portal.html. \n11. Instruction: What is the difference between a gene and a chromosome?\n11. Input:\n<noinput>\n11. Output:\nA gene is a sequence of DNA that codes for a protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A gene is a unit of heredity and is located on a chromosome. A chromosome is a structure that contains all of the genetic material for a species, and is made up of multiple genes. A gene is a sequence of DNA that is expressed in a cell, while a chromosome is a structure that contains all of the genetic material for a species. A gene is a unit of heredity and is located on a chromosome. A gene is a sequence of DNA that codes for a protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A gene is a unit of heredity and is located on a chromosome. A chromosome is a structure that contains all of the genetic material for a species, and is made up of multiple genes. A gene is a sequence of DNA that is expressed in a cell, while a chromosome is a structure that contains all of the genetic material for a species. A gene is a unit of heredity and is located on a chromosome. A chromosome is a structure that contains all of the genetic material for a species, and is made up of multiple genes. A gene is a sequence of DNA that codes for a protein, while",
    "alpaca-7b_fact_raw": "1. The International Cancer Genome Consortium (ICGC) Data Portal is a database of somatic mutations in normal cells.\n2. The ICGC Data Portal contains data on genetic changes in both normal and cancer cells.\n3. The database provides information on the type of mutations, their frequency, and the cell lines in which they were found.\n4. The ICGC Data Portal includes information on the tissue types where the mutations occur.\n5. The database can be accessed at https://icgc.org/data-portal.html.",
    "alpaca-7b_fact": [
      "The International Cancer Genome Consortium (ICGC) Data Portal is a database of somatic mutations in normal cells.",
      "The ICGC Data Portal contains data on genetic changes in both normal and cancer cells.",
      "The database provides information on the type of mutations, their frequency, and the cell lines in which they were found.",
      "The ICGC Data Portal includes information on the tissue types where the mutations occur.",
      "The database can be accessed at https://icgc.org/data-portal.html."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The International Cancer Genome Consortium (ICGC) Data Portal is a database of somatic mutations in cancer cells, not normal cells.\n2. FALSE [correction]: The ICGC Data Portal contains data on genetic changes in cancer cells, not both normal and cancer cells.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "alpaca-7b_response": "Yes, there are several graph kernel libraries available implemented in JAVA. Some of them include: \n- GraphBLAS: A library for numerical computing with graphs, developed by the GraphBLAS project. \n- JGraph: A graph-drawing library, developed by JGraph.\n- GraphX: A library for graph processing, developed by GraphX.\n- GPT: A library for graph processing, developed by GPT.\n- GRAAL: A library for graph analysis and visualization, developed by GRAAL.\n- GAT: A library for graph analysis and transformation, developed by GAT.\n- GATK: A library for graph analysis and transformation, developed by GATK. \n- GATKO: A library for graph analysis and transformation, developed by GATKO. \n- GATKO-J: A library for graph analysis and transformation, developed by GATKO-J. \n- GATKO-J-GPT: A library for graph analysis and transformation, developed by GATKO-J-GPT. \n- GATKO-J-GPT-G: A library for graph analysis and transformation, developed by GATKO-J-GPT-G. \n- GATKO-J-GPT-GPT: A library for graph analysis and transformation, developed by GATKO-J-GPT-GPT. \n- GATKO-J-GPT-GPT-G: A library for graph analysis and transformation, developed by GATKO-J-GPT-GPT-G. \n- GATKO-J-GPT-GPT-GPT: A library for graph analysis and transformation, developed by GATKO-J-GPT-GPT-GPT. \n- GATKO-J-GPT-GPT-GPT-G: A library for graph analysis and transformation, developed by GATKO-J-GPT-GPT-GPT-G. \n- GATKO-J-GPT-GPT-GPT-GPT-G: A library for graph analysis and transformation, developed by GATKO-J-GPT-GPT-GPT-GPT-G. \n- GATKO-J-",
    "alpaca-7b_fact_raw": "1. GraphBLAS is a library for numerical computing with graphs implemented in JAVA.\n2. JGraph is a graph-drawing library implemented in JAVA.\n3. GraphX is a library for graph processing implemented in JAVA.\n4. GRAAL is a library for graph analysis and visualization implemented in JAVA.\n5. GAT is a library for graph analysis and transformation implemented in JAVA.",
    "alpaca-7b_fact": [
      "GraphBLAS is a library for numerical computing with graphs implemented in JAVA.",
      "JGraph is a graph-drawing library implemented in JAVA.",
      "GraphX is a library for graph processing implemented in JAVA.",
      "GRAAL is a library for graph analysis and visualization implemented in JAVA.",
      "GAT is a library for graph analysis and transformation implemented in JAVA."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: GraphBLAS is a library for graph algorithms in the language of linear algebra, not specifically implemented in JAVA.\n2. TRUE\n3. FALSE [correction]: GraphX is a component of Apache Spark for graph processing, and Spark is written in Scala, not JAVA.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "alpaca-7b_response": "1. Automated data collection and analysis: SHERLOCKv2 automates the collection and analysis of data from multiple sources, including sensors, databases, and applications. This allows for faster and more accurate insights into the data.\n2. Machine learning and AI: SHERLOCKv2 utilizes machine learning and AI algorithms to detect patterns and anomalies in the data, allowing for more accurate predictions and faster response times.\n3. Natural language processing: SHERLOCKv2 can interpret natural language queries and respond with actionable insights.\n4. Automated response and remediation: SHERLOCKv2 can automate the response to threats and remediate vulnerabilities, reducing the time and resources needed to protect an organizations digital assets.",
    "alpaca-7b_fact_raw": "1. SHERLOCKv2 automates the collection and analysis of data from multiple sources.\n2. SHERLOCKv2 uses machine learning and AI algorithms to detect patterns and anomalies in data.\n3. SHERLOCKv2 is capable of interpreting natural language queries.\n4. SHERLOCKv2 can automate the response to threats and remediate vulnerabilities.",
    "alpaca-7b_fact": [
      "SHERLOCKv2 automates the collection and analysis of data from multiple sources.",
      "SHERLOCKv2 uses machine learning and AI algorithms to detect patterns and anomalies in data.",
      "SHERLOCKv2 is capable of interpreting natural language queries.",
      "SHERLOCKv2 can automate the response to threats and remediate vulnerabilities."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout additional context or information about SHERLOCKv2, it is not possible to determine the accuracy of these statements. SHERLOCKv2 could be a hypothetical or proprietary system, and without specific details, the truthfulness of the statements cannot be verified.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "alpaca-7b_response": "The bartender algorithm is an optimization algorithm used in artificial intelligence and machine learning. It is based on the idea of simulated annealing, where a bartender is given a set of ingredients and must use them to create a certain number of drinks in a given amount of time. The algorithm measures the quality of the drinks being made and adjusts the ingredients accordingly to improve the quality of the drinks. The algorithm also adjusts the speed of the bartender to optimize the number of drinks made in the given time period. The bartender algorithm can be used to optimize other tasks as well, such as web searches and data mining. It works by adjusting the parameters of the task being performed to find the best possible solution in the given time period. This algorithm is used to improve the efficiency of tasks that must be completed in a certain amount of time.",
    "alpaca-7b_fact_raw": "1. The bartender algorithm is an optimization algorithm used in artificial intelligence and machine learning.\n2. It is based on the concept of simulated annealing.\n3. The algorithm involves a bartender creating a certain number of drinks in a given amount of time with a set of ingredients.\n4. The quality of the drinks is measured and the ingredients are adjusted to improve drink quality.\n5. The bartender algorithm can be applied to tasks such as web searches and data mining.",
    "alpaca-7b_fact": [
      "The bartender algorithm is an optimization algorithm used in artificial intelligence and machine learning.",
      "It is based on the concept of simulated annealing.",
      "The algorithm involves a bartender creating a certain number of drinks in a given amount of time with a set of ingredients.",
      "The quality of the drinks is measured and the ingredients are adjusted to improve drink quality.",
      "The bartender algorithm can be applied to tasks such as web searches and data mining."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: There is no widely recognized optimization algorithm in artificial intelligence and machine learning known as the \"bartender algorithm.\" It is possible that this is a fictional or metaphorical reference, not a standard term in the field.\n2. UNKNOWN: Since the \"bartender algorithm\" is not a recognized term, it cannot be determined if it is based on the concept of simulated annealing.\n3. UNKNOWN: The description of the algorithm involving a bartender creating drinks is likely metaphorical and not a literal description of a known algorithm in artificial intelligence and machine learning.\n4. UNKNOWN: Without a recognized \"bartender algorithm,\" the process of measuring drink quality and adjusting ingredients cannot be confirmed or denied.\n5. UNKNOWN: Since the \"bartender algorithm\" is not established, its application to tasks such as web searches and data mining cannot be determined.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "alpaca-7b_response": "There are several web-based pedigree editors available, including Family Tree Builder from Family Tree Maker, MyHeritage, Ancestry, and Legacy Family Tree. These programs allow users to create and edit family trees online, and often have additional features such as collaboration tools, search capabilities, and data merging. Additionally, there are several other free and paid options available, such as RootsMagic and GenSmart.",
    "alpaca-7b_fact_raw": "1. Family Tree Builder is a web-based pedigree editor from Family Tree Maker.\n2. MyHeritage offers a web-based pedigree editor.\n3. Ancestry provides a web-based pedigree editor.\n4. Legacy Family Tree is a web-based pedigree editor.\n5. RootsMagic and GenSmart are additional options available for web-based pedigree editing.",
    "alpaca-7b_fact": [
      "Family Tree Builder is a web-based pedigree editor from Family Tree Maker.",
      "MyHeritage offers a web-based pedigree editor.",
      "Ancestry provides a web-based pedigree editor.",
      "Legacy Family Tree is a web-based pedigree editor.",
      "RootsMagic and GenSmart are additional options available for web-based pedigree editing."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Family Tree Builder is a software developed by MyHeritage, not Family Tree Maker.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Legacy Family Tree is a desktop genealogy software program, not a web-based pedigree editor.\n5. FALSE [correction]: RootsMagic is a desktop genealogy software program, and GenSmart appears to be a misspelling or confusion with GenSmarts, which is a software that works with existing genealogy files to generate research plans. Neither is solely a web-based pedigree editor.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "alpaca-7b_response": "There are several curated databases for spider-venom toxins, including the Spider Toxin Database (STD) (http://spidertoxins.org/), the World Spider Catalog (WSC) (http://wsc.nmbe.ch/), and the Arachnology Database (ADB) (https://www.arachnology.org/). The STD is a comprehensive database of spider toxins that provides information on the toxins' structure, function, and taxonomic distribution. The WSC is an online database of spider species and their associated toxins. The ADB is an online database of arachnological information that provides detailed information on the taxonomy, morphology, and distribution of spiders and their toxins.",
    "alpaca-7b_fact_raw": "1. The Spider Toxin Database (STD) is a comprehensive database of spider toxins.\n2. The World Spider Catalog (WSC) is an online database of spider species and their associated toxins.\n3. The Arachnology Database (ADB) is an online database that provides detailed information on the taxonomy, morphology, and distribution of spiders and their toxins.",
    "alpaca-7b_fact": [
      "The Spider Toxin Database (STD) is a comprehensive database of spider toxins.",
      "The World Spider Catalog (WSC) is an online database of spider species and their associated toxins.",
      "The Arachnology Database (ADB) is an online database that provides detailed information on the taxonomy, morphology, and distribution of spiders and their toxins."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The World Spider Catalog (WSC) is an online database that provides taxonomic information about spider species, but it does not specifically focus on their associated toxins.\n3. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "alpaca-7b_response": "Axitinib has been shown to improve survival in patients with metastatic pancreatic cancer in a randomized phase III trial. In this trial, patients who received axitinib had a median overall survival of 6.8 months compared to 5.6 months for those who received placebo. These results suggest that axitinib may prolong survival of pancreatic cancer patients.",
    "alpaca-7b_fact_raw": "1. Axitinib has been shown to improve survival in patients with metastatic pancreatic cancer.\n2. A randomized phase III trial was conducted to evaluate the effectiveness of axitinib on survival in pancreatic cancer patients.\n3. In the trial, patients treated with axitinib had a median overall survival of 6.8 months.\n4. Patients who received placebo in the trial had a median overall survival of 5.6 months.",
    "alpaca-7b_fact": [
      "Axitinib has been shown to improve survival in patients with metastatic pancreatic cancer.",
      "A randomized phase III trial was conducted to evaluate the effectiveness of axitinib on survival in pancreatic cancer patients.",
      "In the trial, patients treated with axitinib had a median overall survival of 6.8 months.",
      "Patients who received placebo in the trial had a median overall survival of 5.6 months."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Axitinib is not indicated for the treatment of metastatic pancreatic cancer; it is used in the treatment of advanced renal cell carcinoma (kidney cancer).\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe corrections and unknown responses are based on the fact that axitinib is primarily used for kidney cancer, and there is no widely recognized evidence that it improves survival in patients with metastatic pancreatic cancer. Without specific data or publication references, the details of the trial outcomes (statements 2, 3, and 4) cannot be verified.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "alpaca-7b_response": "MLP interacts with the Arp2/3 complex, which is involved in the regulation of F-actin dynamics. This interaction is important for MLP-mediated F-actin reorganization and cell migration.",
    "alpaca-7b_fact_raw": "1. MLP interacts with the Arp2/3 complex.\n2. The Arp2/3 complex is involved in the regulation of F-actin dynamics.\n3. The interaction between MLP and the Arp2/3 complex is important for F-actin reorganization.\n4. MLP-mediated F-actin reorganization is related to cell migration.",
    "alpaca-7b_fact": [
      "MLP interacts with the Arp2/3 complex.",
      "The Arp2/3 complex is involved in the regulation of F-actin dynamics.",
      "The interaction between MLP and the Arp2/3 complex is important for F-actin reorganization.",
      "MLP-mediated F-actin reorganization is related to cell migration."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: MLP (Muscle LIM Protein) has been implicated in the regulation of actin dynamics, and its interaction with the Arp2/3 complex can play a role in F-actin reorganization. The Arp2/3 complex is well-known for its role in the nucleation of actin filaments and thus in the regulation of F-actin dynamics. F-actin reorganization is a critical process in various cellular activities, including cell migration. However, without specific references to literature or studies that confirm these statements, the responses are based on general knowledge in cell biology and the known functions of these proteins. If the context provided different information, the answers could change.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "alpaca-7b_response": "There are 10 pseudokinases in the human kinome. Pseudokinases are kinases that have a catalytic domain but lack the regulatory domains found in other kinases, making them unable to phosphorylate proteins. These pseudokinases are often involved in signal transduction and play a role in the regulation of gene expression. They are often found in the cytoplasm and are not involved in the regulation of cell growth. 10 of the 139 human kinases are pseudokinases. 10 of these 10 pseudokinases are located in the cytoplasm, while the other 3 are located in the nucleus. 8 of the 10 pseudokinases are involved in signal transduction, while the other 2 are involved in transcription and translation. 7 of the 10 pseudokinases are involved in cancer, while the other 3 are involved in development, metabolism, and cell growth. 6 of the 10 pseudokinases are involved in cell proliferation, while the other 4 are involved in cell death. 5 of the 10 pseudokinases are involved in cell migration, while the other 5 are involved in cell adhesion. 4 of the 10 pseudokinases are involved in inflammation, while the other 6 are involved in other processes. 3 of the 10 pseudokinases are involved in both cell proliferation and cell migration, while the other 7 are involved in other processes. 2 of the 10 pseudokinases are involved in both cell adhesion and cell migration, while the other 8 are involved in other processes. 1 of the 10 pseudokinases is involved in both cell proliferation and cell adhesion, while the other 9 are involved in other processes. 1 of the 10 pseudokinases is involved in both cell migration and cell adhesion, while the other 9 are involved in other processes. 1 of the 10 pseudokinases is involved in both cell proliferation and cell migration, while the other 9 are involved in other processes. 1 of the 10 pseudokinases is involved in both cell adhesion and cell migration, while the other 9 are involved in",
    "alpaca-7b_fact_raw": "1. There are 10 pseudokinases in the human kinome.\n2. Pseudokinases have a catalytic domain but lack regulatory domains, rendering them unable to phosphorylate proteins.\n3. 10 of the 139 human kinases are pseudokinases.\n4. 10 pseudokinases are located in the cytoplasm, and 3 are located in the nucleus.\n5. 7 of the 10 pseudokinases are involved in cancer.",
    "alpaca-7b_fact": [
      "There are 10 pseudokinases in the human kinome.",
      "Pseudokinases have a catalytic domain but lack regulatory domains, rendering them unable to phosphorylate proteins.",
      "10 of the 139 human kinases are pseudokinases.",
      "10 pseudokinases are located in the cytoplasm, and 3 are located in the nucleus.",
      "7 of the 10 pseudokinases are involved in cancer."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: There are more than 10 pseudokinases in the human kinome; the exact number can vary based on the classification criteria used, but it is generally accepted to be more than 10.\n2. FALSE [correction]: Pseudokinases have a catalytic domain but often lack one or more of the conserved residues required for catalytic activity, not necessarily lacking regulatory domains. Some pseudokinases can still phosphorylate proteins, while others have non-catalytic functions.\n3. FALSE [correction]: Since there are more than 10 pseudokinases in the human kinome, the statement that 10 of the 139 human kinases are pseudokinases is incorrect. The exact number of pseudokinases is subject to scientific research and classification.\n4. UNKNOWN: Without specific information on the localization of all pseudokinases, it is not possible to confirm the accuracy of this statement.\n5. UNKNOWN: While some pseudokinases are implicated in cancer, without specific information on which pseudokinases and their involvement, it is not possible to confirm the accuracy of this statement.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "alpaca-7b_response": "1. Pravastatin\n2. Lovastatin\n3. Simvastatin",
    "alpaca-7b_fact_raw": "1. Pravastatin is an apoE mimetic.\n2. Lovastatin is an apoE mimetic.\n3. Simvastatin is an apoE mimetic.",
    "alpaca-7b_fact": [
      "Pravastatin is an apoE mimetic.",
      "Lovastatin is an apoE mimetic.",
      "Simvastatin is an apoE mimetic."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Pravastatin is not an apoE mimetic; it is a statin medication used to lower cholesterol.\n2. FALSE [correction]: Lovastatin is not an apoE mimetic; it is a statin medication used to lower cholesterol.\n3. FALSE [correction]: Simvastatin is not an apoE mimetic; it is a statin medication used to lower cholesterol.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "alpaca-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied. A 2018 study in mice found that SAMHD1 activity was higher in female mice than in male mice, likely due to the presence of estrogen. This study also found that SAMHD1 activity was higher in the brain of female mice than in the brain of male mice. Additionally, a 2019 study in humans found that SAMHD1 activity was higher in women than in men, although the reason for this is not yet known. These studies suggest that there may be sex differences in SAMHD1 activity, but more research is needed to understand the exact nature of these differences.",
    "alpaca-7b_fact_raw": "1. A 2018 study found that SAMHD1 activity was higher in female mice than in male mice.\n2. The 2018 study suggested that the higher SAMHD1 activity in female mice might be due to the presence of estrogen.\n3. According to the 2018 study, SAMHD1 activity was higher in the brain of female mice compared to male mice.\n4. A 2019 study found that SAMHD1 activity was higher in women than in men.\n5. The reason for the higher SAMHD1 activity in women, as found in the 2019 study, is not yet known.",
    "alpaca-7b_fact": [
      "A 2018 study found that SAMHD1 activity was higher in female mice than in male mice.",
      "The 2018 study suggested that the higher SAMHD1 activity in female mice might be due to the presence of estrogen.",
      "According to the 2018 study, SAMHD1 activity was higher in the brain of female mice compared to male mice.",
      "A 2019 study found that SAMHD1 activity was higher in women than in men.",
      "The reason for the higher SAMHD1 activity in women, as found in the 2019 study, is not yet known."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific details or access to the actual studies mentioned, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements remains unknown based on the information provided.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "alpaca-7b_response": "No, RUNX2 does not inhibit astrocyte differentiation. RUNX2 is a transcription factor that is expressed in a variety of cell types and is involved in the regulation of gene expression. In astrocytes, RUNX2 has been shown to be involved in the regulation of genes involved in cell cycle progression, differentiation, and metabolism. However, recent studies have shown that RUNX2 can also promote astrocyte differentiation, suggesting that it may have a dual role in the differentiation of these cells. Further studies are needed to determine the exact role of RUNX2 in astrocyte differentiation.",
    "alpaca-7b_fact_raw": "1. RUNX2 is a transcription factor expressed in a variety of cell types.\n2. RUNX2 is involved in the regulation of gene expression.\n3. RUNX2 has been shown to be involved in the regulation of genes related to cell cycle progression, differentiation, and metabolism in astrocytes.\n4. Recent studies have indicated that RUNX2 can promote astrocyte differentiation.\n5. The exact role of RUNX2 in astrocyte differentiation is not fully determined and requires further studies.",
    "alpaca-7b_fact": [
      "RUNX2 is a transcription factor expressed in a variety of cell types.",
      "RUNX2 is involved in the regulation of gene expression.",
      "RUNX2 has been shown to be involved in the regulation of genes related to cell cycle progression, differentiation, and metabolism in astrocytes.",
      "Recent studies have indicated that RUNX2 can promote astrocyte differentiation.",
      "The exact role of RUNX2 in astrocyte differentiation is not fully determined and requires further studies."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "alpaca-7b_response": "The Cobb-Stainsby excision arthroplasty would be performed in the knee joint. It is a surgical procedure that involves removing a wedge of bone from the tibial plateau to realign the knee and improve the patient's mobility. It is usually performed when the patient has arthritis in the knee joint and the cartilage has been damaged beyond repair. The surgery is performed through a small incision and the patient can usually return home the same day.",
    "alpaca-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed in the knee joint.\n2. The procedure involves removing a wedge of bone from the tibial plateau.\n3. The surgery aims to realign the knee and improve the patient's mobility.\n4. It is usually performed on patients with arthritis in the knee joint where the cartilage is damaged beyond repair.\n5. The surgery is performed through a small incision and allows the patient to usually return home the same day.",
    "alpaca-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed in the knee joint.",
      "The procedure involves removing a wedge of bone from the tibial plateau.",
      "The surgery aims to realign the knee and improve the patient's mobility.",
      "It is usually performed on patients with arthritis in the knee joint where the cartilage is damaged beyond repair.",
      "The surgery is performed through a small incision and allows the patient to usually return home the same day."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed in the hip joint, not the knee joint.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a major surgical procedure that typically requires a hospital stay and not a same-day return home.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "alpaca-7b_response": "Yes, over-expression of GRHL2 leads to epithelial-mesenchymal transition (EMT). EMT is a process by which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, which is characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal markers, and the downregulation of epithelial markers. This process is important in many developmental and pathological processes, including metastasis. GRHL2 is a transcription factor that is involved in the regulation of genes involved in EMT. Over-expression of GRHL2 leads to the upregulation of genes involved in EMT, which results in the acquisition of a mesenchymal phenotype. Therefore, GRHL2 over-expression leads to EMT.",
    "alpaca-7b_fact_raw": "1. Over-expression of GRHL2 leads to epithelial-mesenchymal transition (EMT).\n2. EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.\n3. EMT involves the upregulation of mesenchymal markers and the downregulation of epithelial markers.\n4. GRHL2 is a transcription factor that regulates genes involved in EMT.\n5. Over-expression of GRHL2 results in the upregulation of genes involved in EMT.",
    "alpaca-7b_fact": [
      "Over-expression of GRHL2 leads to epithelial-mesenchymal transition (EMT).",
      "EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.",
      "EMT involves the upregulation of mesenchymal markers and the downregulation of epithelial markers.",
      "GRHL2 is a transcription factor that regulates genes involved in EMT.",
      "Over-expression of GRHL2 results in the upregulation of genes involved in EMT."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-mesenchymal transition (EMT).\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Over-expression of GRHL2 typically results in the downregulation of genes involved in EMT, as it acts to maintain the epithelial phenotype.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "alpaca-7b_response": "T-UCRs that have been implicated in lung cancer include TP53, PTEN, RB1, CDKN2A, and KRAS. TP53 is a tumor suppressor gene that is mutated in approximately 50% of lung cancers, and mutations in PTEN, RB1, CDKN2A, and KRAS are each associated with a small percentage of lung cancer cases.",
    "alpaca-7b_fact_raw": "1. TP53 is a tumor suppressor gene.\n2. TP53 is mutated in approximately 50% of lung cancers.\n3. Mutations in PTEN are associated with lung cancer.\n4. Mutations in RB1 are associated with lung cancer.\n5. Mutations in CDKN2A and KRAS are associated with lung cancer.",
    "alpaca-7b_fact": [
      "TP53 is a tumor suppressor gene.",
      "TP53 is mutated in approximately 50% of lung cancers.",
      "Mutations in PTEN are associated with lung cancer.",
      "Mutations in RB1 are associated with lung cancer.",
      "Mutations in CDKN2A and KRAS are associated with lung cancer."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "alpaca-7b_response": "GPR151 is an orphan receptor that is highly expressed in the brain and has been linked to several neurological disorders, including Alzheimer's disease and schizophrenia. It is also expressed in the immune system and has been implicated in inflammatory diseases. GPR151 is involved in the regulation of cell growth and metabolism, and its agonists have been shown to reduce appetite and body weight in mice. Further research is needed to determine the exact role of GPR151 in human physiology and to explore its potential as a therapeutic target.",
    "alpaca-7b_fact_raw": "1. GPR151 is an orphan receptor that is highly expressed in the brain.\n2. GPR151 has been linked to several neurological disorders, including Alzheimer's disease and schizophrenia.\n3. GPR151 is also expressed in the immune system.\n4. GPR151 has been implicated in inflammatory diseases.\n5. Agonists of GPR151 have been shown to reduce appetite and body weight in mice.",
    "alpaca-7b_fact": [
      "GPR151 is an orphan receptor that is highly expressed in the brain.",
      "GPR151 has been linked to several neurological disorders, including Alzheimer's disease and schizophrenia.",
      "GPR151 is also expressed in the immune system.",
      "GPR151 has been implicated in inflammatory diseases.",
      "Agonists of GPR151 have been shown to reduce appetite and body weight in mice."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GPR151 is not known to be expressed in the immune system; it is primarily expressed in the brain.\n4. UNKNOWN\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "alpaca-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of influenza A/California/7/2009 (H1N1), A/Brisbane/60/2008 (H3N2), A/Bayern/280/2011 (H3N2) and B/Massachusetts/2/2012.",
    "alpaca-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/California/7/2009 (H1N1).\n2. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/Brisbane/60/2008 (H3N2).\n3. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/Bayern/280/2011 (H3N2).\n4. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza B/Massachusetts/2/2012.",
    "alpaca-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/California/7/2009 (H1N1).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/Brisbane/60/2008 (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza A/Bayern/280/2011 (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of influenza B/Massachusetts/2/2012."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain a live virus; it contains an inactivated (killed) virus.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain a live virus; it contains an inactivated (killed) virus. Additionally, the specific strains included in the vaccine change annually based on the recommendations of the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC).\n3. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain a live virus; it contains an inactivated (killed) virus. Additionally, the specific strains included in the vaccine change annually based on the recommendations of the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC).\n4. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain a live virus; it contains an inactivated (killed) virus. Additionally, the specific strains included in the vaccine change annually based on the recommendations of the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC).",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "alpaca-7b_response": "The TNFR2 gene is located on chromosome 12 and is responsible for encoding the TNF receptor 2 protein. A variation in the TNFR2 gene has been found to be associated with Systemic Lupus Erythematosus (SLE). This variation is a single nucleotide polymorphism (SNP) in the promoter region of the gene, which results in a change in the DNA sequence from C/T to G/A. This SNP is found to be more common in individuals with SLE when compared to healthy individuals. The SNP is believed to affect the expression of the TNFR2 gene, resulting in reduced expression of the TNF receptor 2 protein. This in turn leads to an increase in the risk of developing SLE. \nIn summary, the TNFR2 gene is responsible for encoding the TNF receptor 2 protein. A single nucleotide polymorphism (SNP) in the promoter region of the gene, resulting in a change from C/T to G/A, has been found to be associated with reduced expression of the TNFR2 gene and increased risk of developing Systemic Lupus Erythematosus (SLE). This SNP is believed to affect the expression of the TNFR2 gene, resulting in reduced expression of the TNF receptor 2 protein. This in turn leads to an increase in the risk of developing SLE. \nThe TNFR2 gene is located on chromosome 12 and is responsible for encoding the TNF receptor 2 protein. A variation in the TNFR2 gene has been found to be associated with Systemic Lupus Erythematosus (SLE). This variation is a single nucleotide polymorphism (SNP) in the promoter region of the gene, resulting in a change from C/T to G/A. This SNP is believed to affect the expression of the TNFR2 gene, resulting in reduced expression of the TNF receptor 2 protein. This in turn leads to an increase in the risk of developing SLE. \nIn summary, the TNFR2 gene is responsible for encoding the TNF receptor 2 protein. A single nucleotide polymorphism (SNP) in the promoter region of the gene, resulting in a change from C/T to G/A, has",
    "alpaca-7b_fact_raw": "1. The TNFR2 gene is located on chromosome 12.\n2. The TNFR2 gene is responsible for encoding the TNF receptor 2 protein.\n3. A single nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n4. The SNP in the TNFR2 gene results in a change in the DNA sequence from C/T to G/A.\n5. This SNP is found to be more common in individuals with SLE compared to healthy individuals.",
    "alpaca-7b_fact": [
      "The TNFR2 gene is located on chromosome 12.",
      "The TNFR2 gene is responsible for encoding the TNF receptor 2 protein.",
      "A single nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The SNP in the TNFR2 gene results in a change in the DNA sequence from C/T to G/A.",
      "This SNP is found to be more common in individuals with SLE compared to healthy individuals."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE: It is known that certain SNPs in the promoter region of the TNFR2 gene are associated with autoimmune diseases like Systemic Lupus Erythematosus (SLE), although there may be multiple SNPs and the association can vary between studies.\n4. FALSE [correction]: The description of a SNP as changing from C/T to G/A is incorrect. A SNP is a single nucleotide polymorphism, meaning it represents a variation at a single position in the DNA sequence. It should be described as a change from either C to T or G to A, not a combination of both.\n5. TRUE: SNPs associated with diseases like SLE are often found at higher frequencies in affected individuals compared to healthy controls, which is what allows them to be identified as risk factors through genetic association studies.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "alpaca-7b_response": "At this time, there is no vaccine for peanut allergy. However, there are treatments available that can reduce the severity of reactions and provide some protection against future reactions. These treatments include immunotherapy, which involves exposing the patient to small amounts of peanut protein in a controlled setting, and anti-IgE therapy, which works to reduce the bodys reaction to allergens. There are also several medications available to treat the symptoms of a peanut allergy reaction.",
    "alpaca-7b_fact_raw": "1. There is currently no vaccine for peanut allergy.\n2. Treatments are available that can reduce the severity of peanut allergy reactions.\n3. Immunotherapy for peanut allergy involves exposing the patient to small amounts of peanut protein in a controlled setting.\n4. Anti-IgE therapy is used to reduce the body's reaction to allergens in the context of peanut allergies.\n5. Medications are available to treat the symptoms of a peanut allergy reaction.",
    "alpaca-7b_fact": [
      "There is currently no vaccine for peanut allergy.",
      "Treatments are available that can reduce the severity of peanut allergy reactions.",
      "Immunotherapy for peanut allergy involves exposing the patient to small amounts of peanut protein in a controlled setting.",
      "Anti-IgE therapy is used to reduce the body's reaction to allergens in the context of peanut allergies.",
      "Medications are available to treat the symptoms of a peanut allergy reaction."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in 2023, a vaccine for peanut allergy is not available for widespread use, but there are treatments like Palforzia that have been approved by the FDA to mitigate allergic reactions in children.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "alpaca-7b_response": "The mouse Fxy gene is located on chromosome 10, which is particularly interesting because it is one of the few genes that is expressed in both the embryo and the adult. This suggests that the Fxy gene may have a critical role in the development of the embryo, as well as in the adult. Additionally, the Fxy gene is expressed in a wide range of tissues, suggesting that it may have important roles in a variety of different biological processes.",
    "alpaca-7b_fact_raw": "1. The mouse Fxy gene is located on chromosome 10.\n2. The Fxy gene is expressed in both the embryo and the adult mouse.\n3. The Fxy gene is expressed in a wide range of tissues.",
    "alpaca-7b_fact": [
      "The mouse Fxy gene is located on chromosome 10.",
      "The Fxy gene is expressed in both the embryo and the adult mouse.",
      "The Fxy gene is expressed in a wide range of tissues."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific scientific context or reference to a particular study or database that provides information about the mouse Fxy gene, its location, and expression patterns, it is not possible to determine the truthfulness of these statements.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "alpaca-7b_response": "MPE-seq is a method of sequencing DNA that is based on the polymerase chain reaction (PCR). It uses a combination of methylation probes and propyl-EDTA to selectively amplify methylated regions of the genome. The method is able to detect methylation differences between two or more samples, and can be used to study epigenetic changes in a variety of organisms. The MPE-seq method is faster and more cost-effective than other sequencing methods, making it a preferred choice for epigenetic studies.",
    "alpaca-7b_fact_raw": "1. MPE-seq is a method of sequencing DNA.\n2. MPE-seq is based on the polymerase chain reaction (PCR).\n3. The method uses methylation probes and propyl-EDTA to selectively amplify methylated regions of the genome.\n4. MPE-seq can detect methylation differences between two or more samples.\n5. MPE-seq is used to study epigenetic changes in a variety of organisms.",
    "alpaca-7b_fact": [
      "MPE-seq is a method of sequencing DNA.",
      "MPE-seq is based on the polymerase chain reaction (PCR).",
      "The method uses methylation probes and propyl-EDTA to selectively amplify methylated regions of the genome.",
      "MPE-seq can detect methylation differences between two or more samples.",
      "MPE-seq is used to study epigenetic changes in a variety of organisms."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: MPE-seq is not a method of sequencing DNA; it is a method for analyzing DNA methylation patterns.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "alpaca-7b_response": "GWAR has been implemented in Java. Java is a general-purpose, object-oriented programming language that is designed to be a portable, platform-independent language. It was designed to be a robust, secure, and efficient language that is easy to learn and use. It is used for developing a wide variety of applications, from web-based applications to embedded systems. Java is one of the most popular programming languages in the world, and is used by many developers to create powerful and reliable software.",
    "alpaca-7b_fact_raw": "1. GWAR has been implemented in Java.\n2. Java is a general-purpose, object-oriented programming language.\n3. Java is designed to be portable and platform-independent.\n4. Java aims to be a robust, secure, and efficient language.\n5. Java is one of the most popular programming languages in the world.",
    "alpaca-7b_fact": [
      "GWAR has been implemented in Java.",
      "Java is a general-purpose, object-oriented programming language.",
      "Java is designed to be portable and platform-independent.",
      "Java aims to be a robust, secure, and efficient language.",
      "Java is one of the most popular programming languages in the world."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "alpaca-7b_response": "No, xaliproden does not appear to improve the prognosis of amyotrophic lateral sclerosis (ALS). A 2019 study of 120 patients with ALS found that xaliproden did not significantly reduce disease progression or improve survival compared to a placebo. The most common side effects of xaliproden were fatigue, headache, and dizziness. It is important to note that this study was not a randomized controlled trial, and further research is needed to determine the efficacy of xaliproden in the treatment of ALS.",
    "alpaca-7b_fact_raw": "1. Xaliproden does not appear to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. A 2019 study of 120 patients with ALS found that xaliproden did not significantly reduce disease progression or improve survival compared to a placebo.\n3. The most common side effects of xaliproden were fatigue, headache, and dizziness.\n4. The mentioned study on xaliproden and ALS was not a randomized controlled trial.",
    "alpaca-7b_fact": [
      "Xaliproden does not appear to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "A 2019 study of 120 patients with ALS found that xaliproden did not significantly reduce disease progression or improve survival compared to a placebo.",
      "The most common side effects of xaliproden were fatigue, headache, and dizziness.",
      "The mentioned study on xaliproden and ALS was not a randomized controlled trial."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN (without access to specific study details, the results cannot be confirmed)\n3. UNKNOWN (without access to specific study details, the side effects cannot be confirmed)\n4. UNKNOWN (without access to specific study details, the nature of the study cannot be confirmed)",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "alpaca-7b_response": "The LiPS-A3S line is a transgenic line in which the transgene was inserted into the X chromosome. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. \nThe LiPS-A3S line is a transgenic line in which the transgene was inserted into the X chromosome. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. \nThe LiPS-A3S line is a transgenic line in which the transgene was inserted into the X chromosome. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. \nThe LiPS-A3S line is a transgenic line in which the transgene was inserted into the X chromosome. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. The transgene was inserted into the X chromosome in order to create a female-specific expression of the transgene. This line is a model for studying the effects of gene expression in the brain. \nThe LiPS-A3S line is a transgenic line in which the transgene was inserted into the X chromosome. The transgene was inserted into the X chromos",
    "alpaca-7b_fact_raw": "1. The LiPS-A3S line is a transgenic line.\n2. In the LiPS-A3S line, the transgene was inserted into the X chromosome.\n3. The purpose of inserting the transgene into the X chromosome was to create female-specific expression of the transgene.\n4. The LiPS-A3S line is used as a model for studying the effects of gene expression in the brain.",
    "alpaca-7b_fact": [
      "The LiPS-A3S line is a transgenic line.",
      "In the LiPS-A3S line, the transgene was inserted into the X chromosome.",
      "The purpose of inserting the transgene into the X chromosome was to create female-specific expression of the transgene.",
      "The LiPS-A3S line is used as a model for studying the effects of gene expression in the brain."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or additional information about the LiPS-A3S line, it is not possible to accurately determine the truth of statements 2, 3, and 4. The first statement is generally true as \"transgenic line\" refers to a line of organisms that have had a foreign gene deliberately inserted into their genome. However, without specific knowledge about the LiPS-A3S line, the details about the chromosome into which the transgene was inserted (statement 2), the purpose of this insertion (statement 3), and the specific use of this line in research (statement 4) cannot be confirmed.",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "alpaca-7b_response": "One tool that exists for predicting drug synergy with deep learning is DrugSynergy. DrugSynergy is a deep learning model that uses a variety of data sources to predict drug synergy, including chemical structures, drug labels, and drug interactions. The model is trained on a large dataset of drug interactions and can be used to predict the synergy or antagonism of two drugs. DrugSynergy can also be used to identify potential drug combinations that could have synergistic effects. The model is available as a web service and can be used to quickly and accurately predict drug synergy.",
    "alpaca-7b_fact_raw": "1. DrugSynergy is a deep learning model used for predicting drug synergy.\n2. DrugSynergy utilizes data sources such as chemical structures, drug labels, and drug interactions.\n3. The model is trained on a large dataset of drug interactions.\n4. DrugSynergy can predict the synergy or antagonism between two drugs.\n5. DrugSynergy is available as a web service.",
    "alpaca-7b_fact": [
      "DrugSynergy is a deep learning model used for predicting drug synergy.",
      "DrugSynergy utilizes data sources such as chemical structures, drug labels, and drug interactions.",
      "The model is trained on a large dataset of drug interactions.",
      "DrugSynergy can predict the synergy or antagonism between two drugs.",
      "DrugSynergy is available as a web service."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "alpaca-7b_response": "The Cloud-based platform for comparing GWAS has been developed by the National Institutes of Health (NIH) and is called the GWAS Central. It provides a web-based platform for storing, analyzing, and sharing GWAS data. It also provides tools for performing comparative analysis of GWAS data, as well as for visualizing and interpreting results. GWAS Central also provides a platform for data sharing and collaboration, as well as a repository for storing and sharing GWAS data.",
    "alpaca-7b_fact_raw": "1. The National Institutes of Health (NIH) developed the cloud-based platform for comparing GWAS.\n2. The platform developed by NIH for comparing GWAS is called GWAS Central.\n3. GWAS Central is a web-based platform for storing, analyzing, and sharing GWAS data.\n4. GWAS Central provides tools for performing comparative analysis of GWAS data.\n5. GWAS Central includes a repository for storing and sharing GWAS data.",
    "alpaca-7b_fact": [
      "The National Institutes of Health (NIH) developed the cloud-based platform for comparing GWAS.",
      "The platform developed by NIH for comparing GWAS is called GWAS Central.",
      "GWAS Central is a web-based platform for storing, analyzing, and sharing GWAS data.",
      "GWAS Central provides tools for performing comparative analysis of GWAS data.",
      "GWAS Central includes a repository for storing and sharing GWAS data."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The National Institutes of Health (NIH) did not develop the cloud-based platform for comparing GWAS; GWAS Central was developed by a consortium of academic and governmental organizations.\n2. FALSE [correction]: GWAS Central is not developed by NIH; it is a project that involves multiple partners.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "alpaca-7b_response": "Yes, CMB305 can be used to treat sarcomas. CMB305 is a monoclonal antibody that targets the protein PD-L1, which is expressed on the surface of some sarcoma cells. By binding to PD-L1, CMB305 helps to restore the ability of the bodys immune system to recognize and attack the sarcoma cells. CMB305 has been shown to be effective in the treatment of some types of sarcoma in clinical trials. In addition, CMB305 has been approved by the FDA for the treatment of some types of sarcoma.",
    "alpaca-7b_fact_raw": "1. CMB305 is used to treat sarcomas.\n2. CMB305 is a monoclonal antibody that targets the protein PD-L1.\n3. PD-L1 is expressed on the surface of some sarcoma cells.\n4. CMB305 works by helping the body's immune system to recognize and attack sarcoma cells.\n5. CMB305 has been approved by the FDA for the treatment of some types of sarcoma.",
    "alpaca-7b_fact": [
      "CMB305 is used to treat sarcomas.",
      "CMB305 is a monoclonal antibody that targets the protein PD-L1.",
      "PD-L1 is expressed on the surface of some sarcoma cells.",
      "CMB305 works by helping the body's immune system to recognize and attack sarcoma cells.",
      "CMB305 has been approved by the FDA for the treatment of some types of sarcoma."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: CMB305 is not a monoclonal antibody; it is a cancer vaccine that targets the NY-ESO-1 protein.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: As of my knowledge cutoff date in 2023, CMB305 has not been approved by the FDA for the treatment of any type of sarcoma.",
    "alpaca-7b_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "alpaca-7b_response": "The manifestations of the Saint's Triad are miracles, wonders, and signs. These are all supernatural events that are performed by the power of God and are meant to confirm the message of the Gospel. They are also meant to inspire faith in the people and to glorify God. Examples of the Saint's Triad include Jesus' miracles in the Gospels, the healings of the sick, the control of the weather, the raising of the dead, and the casting out of demons. These are all works of God that point to the truth of the Gospel and testify to the power of God.",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "alpaca-7b_response": "No, overexpression of LY6K is not associated with better prognosis for non-small cell lung cancer patients. In fact, LY6K expression is associated with poorer survival in non-small cell lung cancer patients.",
    "alpaca-7b_fact_raw": "1. Overexpression of LY6K is not associated with better prognosis for non-small cell lung cancer patients.\n2. LY6K expression is associated with poorer survival in non-small cell lung cancer patients.",
    "alpaca-7b_fact": [
      "Overexpression of LY6K is not associated with better prognosis for non-small cell lung cancer patients.",
      "LY6K expression is associated with poorer survival in non-small cell lung cancer patients."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "alpaca-7b_response": "Cytokinesis-specific Cdk targets that are dephosphorylated during cytokinesis include: Cdc4, Cdc16, Cdc17, Cdc18, Cdc20, Cdc23, Cdc24, Cdc25, Cdc26, Cdc27, Cdc28, Cdc29, Cdc31, Cdc32, Cdc33, Cdc34, Cdc35, Cdc36, Cdc37, Cdc38, Cdc39, Cdc40, Cdc41, Cdc42, Cdc43, Cdc44, Cdc45, Cdc46, Cdc47, Cdc48, Cdc49, Cdc51, Cdc52, Cdc53, Cdc54, Cdc55, Cdc56, Cdc57, Cdc58, Cdc59, Cdc61, Cdc62, Cdc63, Cdc64, Cdc65, Cdc66, Cdc67, Cdc68, Cdc69, Cdc71, Cdc72, Cdc73, Cdc74, Cdc75, Cdc76, Cdc77, Cdc78, Cdc79, Cdc81, Cdc82, Cdc83, Cdc84, Cdc85, Cdc86, Cdc87, Cdc88, Cdc89, Cdc91, Cdc92, Cdc93, Cdc94, Cdc95, Cdc96, Cdc97, Cdc98, Cdc99, Cdc101, Cdc102, Cdc103, Cdc104, Cdc105, Cdc106, Cdc107, Cdc108, Cdc109, Cdc111, Cdc112, Cdc113, Cdc114, Cdc115, Cdc116, Cdc117, Cdc118, Cdc119, C",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "alpaca-7b_response": "Xanamem is a drug used to treat the symptoms of Alzheimer's disease. It is a type of drug called a cholinesterase inhibitor and works by increasing the levels of the neurotransmitter acetylcholine in the brain. Xanamem is used to improve memory, thinking, and behavior in people with Alzheimer's disease. It can also reduce anxiety, agitation, and confusion, and can help with daily activities such as dressing and bathing. Xanamem is not a cure for Alzheimer's disease, but it can help make life easier for both the person with Alzheimer's and their caregivers.",
    "alpaca-7b_fact_raw": "1. Xanamem is a drug used to treat symptoms of Alzheimer's disease.\n2. Xanamem is classified as a cholinesterase inhibitor.\n3. The drug works by increasing levels of the neurotransmitter acetylcholine in the brain.\n4. Xanamem is intended to improve memory, thinking, and behavior in people with Alzheimer's disease.\n5. Xanamem can also help reduce anxiety, agitation, and confusion in individuals with Alzheimer's disease.",
    "alpaca-7b_fact": [
      "Xanamem is a drug used to treat symptoms of Alzheimer's disease.",
      "Xanamem is classified as a cholinesterase inhibitor.",
      "The drug works by increasing levels of the neurotransmitter acetylcholine in the brain.",
      "Xanamem is intended to improve memory, thinking, and behavior in people with Alzheimer's disease.",
      "Xanamem can also help reduce anxiety, agitation, and confusion in individuals with Alzheimer's disease."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nAs of my last update, Xanamem is not a widely recognized or established drug for the treatment of Alzheimer's disease, and there is no information available to confirm or refute the specific statements about its classification, mechanism of action, or effects. It is possible that Xanamem is a drug under research or development, or it could be a fictional or incorrectly spelled name. Therefore, without additional context or information, the truthfulness of these statements cannot be determined.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "alpaca-7b_response": "The Hof1-Cyk3 interaction is important for the regulation of the cell cycle in yeast. Cyk3 is a member of the Cdc28 family of proteins which are important for the regulation of the cell cycle. The Hof1-Cyk3 interaction is required for the activation of Cyk3 and the subsequent entry into the cell cycle. It also appears to be important for the inhibition of Cyk3 and the exit from the cell cycle. The Hof1-Cyk3 interaction is also involved in the regulation of gene expression during the cell cycle. It has been suggested that the Hof1-Cyk3 interaction may also be important for the regulation of other cellular processes, such as metabolism and stress responses.",
    "alpaca-7b_fact_raw": "1. The Hof1-Cyk3 interaction regulates the cell cycle in yeast.\n2. Cyk3 is a member of the Cdc28 family of proteins, which are important for cell cycle regulation.\n3. The activation of Cyk3 and subsequent entry into the cell cycle require the Hof1-Cyk3 interaction.\n4. The Hof1-Cyk3 interaction is involved in inhibiting Cyk3 and facilitating the exit from the cell cycle.\n5. The Hof1-Cyk3 interaction plays a role in regulating gene expression during the cell cycle.",
    "alpaca-7b_fact": [
      "The Hof1-Cyk3 interaction regulates the cell cycle in yeast.",
      "Cyk3 is a member of the Cdc28 family of proteins, which are important for cell cycle regulation.",
      "The activation of Cyk3 and subsequent entry into the cell cycle require the Hof1-Cyk3 interaction.",
      "The Hof1-Cyk3 interaction is involved in inhibiting Cyk3 and facilitating the exit from the cell cycle.",
      "The Hof1-Cyk3 interaction plays a role in regulating gene expression during the cell cycle."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyk3 is not a member of the Cdc28 family of proteins. Cdc28 is a cyclin-dependent kinase, while Cyk3 is a transglutaminase-like protein involved in cytokinesis.\n3. UNKNOWN\n4. FALSE [correction]: The Hof1-Cyk3 interaction is not involved in inhibiting Cyk3; rather, it is involved in the regulation of cytokinesis during the cell cycle.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "alpaca-7b_response": "T-UCRs that have been implicated in gastric cancer include TP53, PTEN, CDKN2A, RUNX3, and SMAD4.",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "alpaca-7b_response": "The Lupus Severity Index (LSI) is a tool used to measure the severity of lupus. It is based on a patient's medical history, physical examination, laboratory tests, and other factors. The LSI helps to determine the best treatment plan for each patient and to monitor the progress of the disease over time. It is also used to measure the response to treatment. The LSI ranges from 0 to 100, with higher scores indicating more severe lupus. The LSI can also be used to measure disease activity and damage caused by lupus. It is important to note that the LSI is not a diagnostic tool and cannot be used to determine the presence or severity of lupus. It is only used to measure the severity of lupus in a particular patient.",
    "alpaca-7b_fact_raw": "1. The Lupus Severity Index (LSI) is used to measure the severity of lupus.\n2. The LSI takes into account a patient's medical history, physical examination, and laboratory tests.\n3. The LSI is utilized to determine the best treatment plan for a patient with lupus.\n4. The LSI is used to monitor the progress of lupus over time and measure the response to treatment.\n5. The LSI scoring ranges from 0 to 100, with higher scores indicating more severe lupus.",
    "alpaca-7b_fact": [
      "The Lupus Severity Index (LSI) is used to measure the severity of lupus.",
      "The LSI takes into account a patient's medical history, physical examination, and laboratory tests.",
      "The LSI is utilized to determine the best treatment plan for a patient with lupus.",
      "The LSI is used to monitor the progress of lupus over time and measure the response to treatment.",
      "The LSI scoring ranges from 0 to 100, with higher scores indicating more severe lupus."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to a specific medical index, the Lupus Severity Index (LSI), which may or may not exist or have the characteristics described. Without access to specific medical literature or guidelines regarding the LSI, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements remains unknown based on the information provided.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "alpaca-7b_response": "De novo mutations in ZSWIM6 have been linked to a variety of disorders, including but not limited to:\n- Autism spectrum disorder (ASD)\n- Intellectual disability (ID)\n- Developmental delay (DD)\n- Attention deficit hyperactivity disorder (ADHD)\n- Schizophrenia \n- Bipolar disorder \n- Anxiety disorder \n- Obsessive-compulsive disorder (OCD) \n- Tourette syndrome \n- Scoliosis \n- Craniosynostosis \n- Hearing loss \n- Cataracts \n- Retinitis pigmentosa \n- Alzheimer's disease \n- Parkinson's disease \n- Epilepsy \n- Sickle cell anemia \n- Cancer \n- Cardiovascular disease \n- Diabetes mellitus \n- Inflammatory bowel disease (IBD) \n- Autoimmune diseases \n- Neurodevelopmental disorders \n- Learning disabilities \n- Language disorders \n- Behavioral disorders \n- Sensory processing disorder (SPD) \n- Anaphylaxis \n- Osteogenesis imperfecta \n- Pyloric stenosis \n- Hemophilia \n- Thalassemia \n- Sickle cell anemia \n- Cystic fibrosis \n- Muscular dystrophy \n- Severe combined immunodeficiency \n- Hearing loss \n- Cataracts \n- Retinitis pigmentosa \n- Alzheimer's disease \n- Parkinson's disease \n- Epilepsy \n- Sickle cell anemia \n- Cancer \n- Cardiovascular disease \n- Diabetes mellitus \n- Inflammatory bowel disease (IBD) \n- Autoimmune diseases \n- Neurodevelopmental disorders \n- Learning disabilities \n- Language disorders \n- Behavioral disorders \n- Sensory processing disorder (SPD) \n- Anaphy",
    "alpaca-7b_fact_raw": "1. De novo mutations in ZSWIM6 have been linked to Autism spectrum disorder (ASD).\n2. De novo mutations in ZSWIM6 have been linked to Intellectual disability (ID).\n3. De novo mutations in ZSWIM6 have been linked to Developmental delay (DD).\n4. De novo mutations in ZSWIM6 have been linked to Attention deficit hyperactivity disorder (ADHD).\n5. De novo mutations in ZSWIM6 have been linked to Schizophrenia.",
    "alpaca-7b_fact": [
      "De novo mutations in ZSWIM6 have been linked to Autism spectrum disorder (ASD).",
      "De novo mutations in ZSWIM6 have been linked to Intellectual disability (ID).",
      "De novo mutations in ZSWIM6 have been linked to Developmental delay (DD).",
      "De novo mutations in ZSWIM6 have been linked to Attention deficit hyperactivity disorder (ADHD).",
      "De novo mutations in ZSWIM6 have been linked to Schizophrenia."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific claims about genetic associations with various conditions. Without access to the latest scientific research or specific studies that investigate the link between de novo mutations in the ZSWIM6 gene and these disorders, it is not possible to accurately confirm or refute these statements. Genetic research is a rapidly evolving field, and associations can be complex and require careful interpretation of peer-reviewed studies.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "alpaca-7b_response": "The Koos Classification is a system used to classify diseases based on their etiology, pathogenesis, and clinical features. It is used to classify infectious diseases, neoplastic diseases, and other diseases. Examples of diseases that can be classified using the Koos Classification include tuberculosis, syphilis, gonorrhea, HIV, and leprosy.",
    "alpaca-7b_fact_raw": "1. The Koos Classification is used to classify diseases based on etiology, pathogenesis, and clinical features.\n2. The Koos Classification is applicable to infectious diseases.\n3. The Koos Classification is applicable to neoplastic diseases.\n4. Tuberculosis can be classified using the Koos Classification.\n5. HIV can be classified using the Koos Classification.",
    "alpaca-7b_fact": [
      "The Koos Classification is used to classify diseases based on etiology, pathogenesis, and clinical features.",
      "The Koos Classification is applicable to infectious diseases.",
      "The Koos Classification is applicable to neoplastic diseases.",
      "Tuberculosis can be classified using the Koos Classification.",
      "HIV can be classified using the Koos Classification."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Koos Classification is not a general classification system for diseases; it is specifically used to classify vestibular schwannomas (acoustic neuromas) based on their size and the extent of their intracranial involvement.\n2. FALSE [correction]: The Koos Classification is not applicable to infectious diseases; it is used for vestibular schwannomas.\n3. FALSE [correction]: The Koos Classification is not applicable to neoplastic diseases in general; it is specifically for vestibular schwannomas.\n4. FALSE [correction]: Tuberculosis cannot be classified using the Koos Classification as it is an infectious disease and the Koos Classification is for vestibular schwannomas.\n5. FALSE [correction]: HIV cannot be classified using the Koos Classification as it is a viral infection and the Koos Classification is for vestibular schwannomas.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "alpaca-7b_response": "In vivo studies of AZD8601 have shown that it can reduce the expression of genes involved in cell proliferation and angiogenesis, as well as increase the expression of genes involved in cell death. It has also been shown to reduce tumor size and increase survival in animal models of various types of cancer. In addition, AZD8601 has been found to be well-tolerated in these animal models, with no evidence of toxicity.",
    "alpaca-7b_fact_raw": "1. AZD8601 can reduce the expression of genes involved in cell proliferation and angiogenesis in vivo.\n2. AZD8601 can increase the expression of genes involved in cell death in vivo.\n3. AZD8601 has been shown to reduce tumor size in animal models of various types of cancer.\n4. AZD8601 has been shown to increase survival in animal models of various types of cancer.\n5. AZD8601 has been found to be well-tolerated in animal models, with no evidence of toxicity.",
    "alpaca-7b_fact": [
      "AZD8601 can reduce the expression of genes involved in cell proliferation and angiogenesis in vivo.",
      "AZD8601 can increase the expression of genes involved in cell death in vivo.",
      "AZD8601 has been shown to reduce tumor size in animal models of various types of cancer.",
      "AZD8601 has been shown to increase survival in animal models of various types of cancer.",
      "AZD8601 has been found to be well-tolerated in animal models, with no evidence of toxicity."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or reference to a study or scientific literature that provides information about AZD8601, it is not possible to determine the truthfulness of these statements. AZD8601 is a specific compound, and its effects would need to be verified by peer-reviewed research.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "alpaca-7b_response": "Substance Abuse and Mental Health Services Administration (SAHFS) are created by the Substance Abuse and Mental Health Services Administration (SAMHSA) within the U.S. Department of Health and Human Services. SAMHSA works to reduce the impact of substance abuse and mental illness on individuals, families, and communities by providing access to prevention, treatment, and recovery services. \nSAMHSA develops and implements the strategic plan for the agency, which includes the creation of SAHFS. The development of a SAHFS involves a multi-step process that includes assessing the needs of the community, developing a plan for the SAHFS, implementing the plan, and evaluating the effectiveness of the SAHFS. The goal of the SAHFS is to provide a comprehensive array of services that are recovery-oriented, culturally competent, and trauma-informed. \nThe services provided by a SAHFS can include mental health services, substance abuse treatment, prevention services, and other services such as housing, employment, and education. The services are designed to be accessible, affordable, and of high quality. The goal is to provide a continuum of care that meets the needs of the individuals and communities. \nIn addition to providing services, a SAHFS also works to reduce stigma and discrimination related to mental illness and substance abuse. The SAHFS also works to increase access to and improve the quality of care for individuals with mental illness and substance abuse disorders. \nOverall, SAMHSA works to create a SAHFS that is accessible, affordable, and of high quality in order to provide a continuum of care for individuals with mental illness and substance abuse disorders.",
    "alpaca-7b_fact_raw": "1. The Substance Abuse and Mental Health Services Administration (SAMHSA) is responsible for creating SAHFS within the U.S. Department of Health and Human Services.\n2. SAMHSA's goal is to reduce the impact of substance abuse and mental illness on individuals, families, and communities.\n3. The development of a SAHFS involves assessing community needs, developing a plan, implementing the plan, and evaluating effectiveness.\n4. SAHFS provides a range of services including mental health services, substance abuse treatment, prevention services, and support services like housing, employment, and education.\n5. SAMHSA aims to create SAHFS that are recovery-oriented, culturally competent, and trauma-informed.",
    "alpaca-7b_fact": [
      "The Substance Abuse and Mental Health Services Administration (SAMHSA) is responsible for creating SAHFS within the U.S. Department of Health and Human Services.",
      "SAMHSA's goal is to reduce the impact of substance abuse and mental illness on individuals, families, and communities.",
      "The development of a SAHFS involves assessing community needs, developing a plan, implementing the plan, and evaluating effectiveness.",
      "SAHFS provides a range of services including mental health services, substance abuse treatment, prevention services, and support services like housing, employment, and education.",
      "SAMHSA aims to create SAHFS that are recovery-oriented, culturally competent, and trauma-informed."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe acronym \"SAHFS\" is not a commonly recognized term associated with SAMHSA, which makes the first and third statements difficult to verify without additional context. SAMHSA's goals and the types of services it aims to support, as mentioned in statements 2, 4, and 5, are consistent with the agency's mission.",
    "alpaca-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "alpaca-7b_response": "The PDZ domain of SATB1 is involved in protein-protein interactions and is necessary for the formation of a stable complex with other proteins. It is also involved in transcriptional regulation and the recruitment of transcriptional co-regulators to specific gene promoters. The PDZ domain of SATB1 binds to the C-terminal region of the transcriptional co-regulator N-CoR, which is necessary for the repression of certain genes. Additionally, the PDZ domain of SATB1 interacts with the nuclear receptor corepressor (N-CoR) and the histone deacetylase complex, which is involved in the deacetylation of histones and the repression of gene expression. \nIn summary, the PDZ domain of SATB1 is involved in multiple protein-protein interactions and is necessary for the formation of a stable complex with other proteins, as well as for the recruitment of transcriptional co-regulators to specific gene promoters. These interactions are important for the repression of certain genes and for the deacetylation of histones, which is involved in the repression of gene expression. \n*Note: The PDZ domain of SATB1 is a protein interaction domain that is involved in the binding of SATB1 to other proteins. It is not a catalytic domain and is not involved in enzymatic activity.",
    "alpaca-7b_fact_raw": "1. The PDZ domain of SATB1 is involved in protein-protein interactions.\n2. The PDZ domain is necessary for the formation of a stable complex with other proteins.\n3. The PDZ domain of SATB1 is involved in transcriptional regulation.\n4. The PDZ domain of SATB1 binds to the C-terminal region of the transcriptional co-regulator N-CoR.\n5. The PDZ domain of SATB1 interacts with the nuclear receptor corepressor (N-CoR) and the histone deacetylase complex, which is involved in the repression of gene expression.",
    "alpaca-7b_fact": [
      "The PDZ domain of SATB1 is involved in protein-protein interactions.",
      "The PDZ domain is necessary for the formation of a stable complex with other proteins.",
      "The PDZ domain of SATB1 is involved in transcriptional regulation.",
      "The PDZ domain of SATB1 binds to the C-terminal region of the transcriptional co-regulator N-CoR.",
      "The PDZ domain of SATB1 interacts with the nuclear receptor corepressor (N-CoR) and the histone deacetylase complex, which is involved in the repression of gene expression."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: The PDZ domain is known for its role in protein-protein interactions, and if the statement specifies that the PDZ domain of SATB1 is involved in such interactions, it is consistent with the general function of PDZ domains.\n2. TRUE: PDZ domains are typically necessary for the formation of stable complexes with other proteins, as they facilitate specific binding interactions.\n3. TRUE: Given that SATB1 is a known global gene regulator that plays a role in chromatin organization and transcriptional regulation, it is reasonable to infer that its PDZ domain could be involved in these processes.\n4. UNKNOWN: Without specific information on the interaction between the PDZ domain of SATB1 and the C-terminal region of N-CoR, the truth of this statement cannot be determined.\n5. TRUE: The statement is consistent with the known functions of SATB1, which is involved in transcriptional regulation and can interact with nuclear receptor corepressors like N-CoR and components of the histone deacetylase complex, both of which are associated with the repression of gene expression.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "alpaca-7b_response": "The BLISS technique is based on the idea that people have an innate drive to be self-determined, to be in control of their own lives, and to have a sense of purpose. It emphasizes the importance of creating a safe and supportive environment that allows people to explore their own potential and develop their own solutions to problems. The BLISS technique also emphasizes the importance of being genuine and authentic in the therapeutic relationship, and of creating an environment that is warm and collaborative. The goal of the BLISS technique is to help people discover their own inner strengths and resources, and to provide them with the tools and support they need to make positive changes in their lives.",
    "alpaca-7b_fact_raw": "1. The BLISS technique is based on the idea that people have an innate drive to be self-determined.\n2. The BLISS technique emphasizes the importance of creating a safe and supportive environment for personal exploration.\n3. It stresses the need for genuineness and authenticity in the therapeutic relationship.\n4. The BLISS technique aims to help people discover their own inner strengths and resources.\n5. The goal of the BLISS technique is to provide individuals with tools and support to make positive changes in their lives.",
    "alpaca-7b_fact": [
      "The BLISS technique is based on the idea that people have an innate drive to be self-determined.",
      "The BLISS technique emphasizes the importance of creating a safe and supportive environment for personal exploration.",
      "It stresses the need for genuineness and authenticity in the therapeutic relationship.",
      "The BLISS technique aims to help people discover their own inner strengths and resources.",
      "The goal of the BLISS technique is to provide individuals with tools and support to make positive changes in their lives."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN: The statement is vague as \"BLISS technique\" could refer to a specific therapeutic method or concept that is not widely recognized or may not exist. Without additional context, it's not possible to determine the truthfulness of this statement.\n2. UNKNOWN: Similar to the first statement, without context about what the \"BLISS technique\" is, it's not possible to confirm the importance it places on creating a safe and supportive environment.\n3. UNKNOWN: Again, without context or a clear reference to a known therapeutic approach or technique called \"BLISS,\" the emphasis on genuineness and authenticity cannot be confirmed.\n4. UNKNOWN: The aim of the BLISS technique to help people discover inner strengths and resources cannot be confirmed without additional information about what the BLISS technique entails.\n5. UNKNOWN: The goal of providing tools and support for positive change is a common theme in many therapeutic approaches, but without specific information about the BLISS technique, the truthfulness of this statement cannot be determined.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "alpaca-7b_response": "1. Aprepitant (Fosaprepitant)\n2. Dexamethasone\n3. Palonosetron (Aloxi)",
    "alpaca-7b_fact_raw": "1. Aprepitant is an NK3R antagonist.\n2. Dexamethasone is an NK3R antagonist.\n3. Palonosetron is an NK3R antagonist.",
    "alpaca-7b_fact": [
      "Aprepitant is an NK3R antagonist.",
      "Dexamethasone is an NK3R antagonist.",
      "Palonosetron is an NK3R antagonist."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Aprepitant is an NK1 receptor antagonist, not an NK3R antagonist.\n2. FALSE [correction]: Dexamethasone is a corticosteroid, not an NK3R antagonist.\n3. FALSE [correction]: Palonosetron is a 5-HT3 receptor antagonist, not an NK3R antagonist.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "alpaca-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is the drug GHRP-6. GHRP-6 is a synthetic hexapeptide that binds to the ghrelin receptor and inhibits the receptor's activity. It is the first oral ghrelin receptor inverse agonist to be studied in healthy subjects, and has been shown to reduce appetite and increase energy expenditure in clinical trials. GHRP-6 has been approved for use in several countries for the treatment of obesity and other related conditions.",
    "alpaca-7b_fact_raw": "1. GHRP-6 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. GHRP-6 is a synthetic hexapeptide.\n3. GHRP-6 binds to the ghrelin receptor and inhibits its activity.\n4. Clinical trials have shown that GHRP-6 can reduce appetite and increase energy expenditure.\n5. GHRP-6 has been approved for use in several countries for the treatment of obesity and other related conditions.",
    "alpaca-7b_fact": [
      "GHRP-6 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "GHRP-6 is a synthetic hexapeptide.",
      "GHRP-6 binds to the ghrelin receptor and inhibits its activity.",
      "Clinical trials have shown that GHRP-6 can reduce appetite and increase energy expenditure.",
      "GHRP-6 has been approved for use in several countries for the treatment of obesity and other related conditions."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: GHRP-6 is not an inverse agonist; it is a synthetic growth hormone-releasing peptide that acts as an agonist at the ghrelin receptor.\n2. TRUE\n3. FALSE [correction]: GHRP-6 does not inhibit the activity of the ghrelin receptor; it binds to the receptor and mimics the action of ghrelin, thereby stimulating the release of growth hormone.\n4. UNKNOWN\n5. FALSE [correction]: GHRP-6 has not been approved for use in several countries for the treatment of obesity or other related conditions. It is primarily used for research purposes and has not been approved by regulatory agencies like the FDA for medical use.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "alpaca-7b_response": "Vaxchora is a vaccine that is approved for use in adults and children 12 years of age and older. It is effective in preventing moderate to severe cholera. In a clinical trial, 84% of participants who received the vaccine and 89% of participants who received the placebo were protected against the disease. The vaccine is also known to provide protection against cholera for up to 3 years.",
    "alpaca-7b_fact_raw": "1. Vaxchora is approved for use in adults and children 12 years of age and older.\n2. Vaxchora is effective in preventing moderate to severe cholera.\n3. In a clinical trial, 84% of participants who received Vaxchora were protected against cholera.\n4. In the same clinical trial, 89% of participants who received the placebo were protected against cholera.\n5. Vaxchora provides protection against cholera for up to 3 years.",
    "alpaca-7b_fact": [
      "Vaxchora is approved for use in adults and children 12 years of age and older.",
      "Vaxchora is effective in preventing moderate to severe cholera.",
      "In a clinical trial, 84% of participants who received Vaxchora were protected against cholera.",
      "In the same clinical trial, 89% of participants who received the placebo were protected against cholera.",
      "Vaxchora provides protection against cholera for up to 3 years."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Vaxchora is approved for use in adults 18 years of age and older.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: In a clinical trial, a significantly lower percentage of participants who received the placebo would be protected against cholera compared to those who received Vaxchora.\n5. FALSE [correction]: Vaxchora provides protection against cholera for up to 3 to 6 months in adults and up to 6 months in pediatric travelers (2-17 years of age).",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "alpaca-7b_response": "The first cholera vaccine approved in the US was the killed-virus vaccine, Dukoral, in 1996. It is approved for use in adults and children over the age of two. It is made from a killed version of the Vibrio cholerae bacteria and is administered orally. It is effective for up to two years and can be used to prevent cholera in areas where the disease is endemic. It is also used in travelers who are visiting areas where cholera is common. The vaccine is not approved for use in pregnant women, but it is believed to be safe for use in breastfeeding women. It is also not approved for use in children under two years old. \nIn 2005, the second cholera vaccine to be approved in the US was the live-attenuated vaccine, Shanchol. It is approved for use in adults and children over the age of two. It is administered orally and is made from a live, but weakened, version of the Vibrio cholerae bacteria. It is effective for up to three years and can be used to prevent cholera in areas where the disease is endemic. It is also used in travelers who are visiting areas where cholera is common. The vaccine is approved for use in pregnant women and breastfeeding women, but it is not approved for use in children under two years old. \nIn 2016, the third cholera vaccine to be approved in the US was the inactivated, whole-cell vaccine, Vaxchora. It is approved for use in adults and children over the age of one. It is administered intramuscularly and is made from a killed version of the Vibrio cholerae bacteria. It is effective for up to two years and can be used to prevent cholera in areas where the disease is endemic. It is also used in travelers who are visiting areas where cholera is common. The vaccine is approved for use in pregnant women and breastfeeding women, but it is not approved for use in children under one year old. \nIn 2021, the fourth cholera v",
    "alpaca-7b_fact_raw": "1. The first cholera vaccine approved in the US was Dukoral in 1996.\n2. Dukoral is approved for use in adults and children over the age of two.\n3. Shanchol, the second cholera vaccine approved in the US, is effective for up to three years.\n4. Vaxchora, the third cholera vaccine approved in the US, is approved for use in adults and children over the age of one.\n5. Vaxchora is administered intramuscularly and is made from a killed version of the Vibrio cholerae bacteria.",
    "alpaca-7b_fact": [
      "The first cholera vaccine approved in the US was Dukoral in 1996.",
      "Dukoral is approved for use in adults and children over the age of two.",
      "Shanchol, the second cholera vaccine approved in the US, is effective for up to three years.",
      "Vaxchora, the third cholera vaccine approved in the US, is approved for use in adults and children over the age of one.",
      "Vaxchora is administered intramuscularly and is made from a killed version of the Vibrio cholerae bacteria."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was Vaxchora in 2016.\n2. TRUE\n3. FALSE [correction]: Shanchol is not approved for use in the US as of my knowledge cutoff date in 2023.\n4. FALSE [correction]: Vaxchora is approved for use in adults 18 through 64 years of age.\n5. FALSE [correction]: Vaxchora is administered orally and is made from a live, attenuated (weakened) version of the Vibrio cholerae bacteria.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "alpaca-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autosomal recessive mutation in the gene encoding the antibody-mediated immune regulator, autoimmune regulator (AIRE). This mutation results in a loss of function of the AIRE protein, leading to a defect in the development of T and B lymphocytes and a subsequent decrease in the production of antibodies. This causes the clinical features of CVID, including recurrent infections, low levels of antibodies, and a hyper-responsive immune system. \nAIRE mutations are estimated to cause 50-70% of CVID cases in Europeans. Other genetic causes of CVID, such as mutations in the gene encoding the antibody-producing cell surface receptor, CD20, are much less common and are estimated to account for less than 10% of CVID cases in Europeans. \nAIRE mutations are also found in other populations, including Ashkenazi Jews, but the prevalence of CVID due to AIRE mutations is lower in these populations compared to Europeans. \nIn addition to AIRE mutations, other genetic and environmental factors can contribute to the development of CVID. These include mutations in other genes encoding antibody-producing cell surface receptors, such as CD20, and environmental factors such as infections, autoimmune diseases, and exposure to certain drugs. \nAIRE mutations are diagnosed through a combination of clinical and laboratory tests. Laboratory tests may include assessment of antibody levels, T and B lymphocyte counts, and other immunological parameters. Genetic testing for AIRE mutations can be performed by looking for changes in the AIRE gene that are known to cause CVID. \nTreatment for CVID due to AIRE mutations typically includes replacement therapy with immunoglobulins, which can help to replace the missing antibodies and reduce the risk of infection. Other treatments may include immunosuppressive drugs, splenectomy, and other therapies. \nIn summary, AIRE mutations are the most common mon",
    "alpaca-7b_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autosomal recessive mutation in the AIRE gene.\n2. AIRE mutations result in a loss of function of the AIRE protein, leading to a defect in the development of T and B lymphocytes.\n3. AIRE mutations are estimated to cause 50-70% of CVID cases in Europeans.\n4. Mutations in the gene encoding the CD20 receptor are estimated to account for less than 10% of CVID cases in Europeans.\n5. Treatment for CVID due to AIRE mutations typically includes replacement therapy with immunoglobulins.",
    "alpaca-7b_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autosomal recessive mutation in the AIRE gene.",
      "AIRE mutations result in a loss of function of the AIRE protein, leading to a defect in the development of T and B lymphocytes.",
      "AIRE mutations are estimated to cause 50-70% of CVID cases in Europeans.",
      "Mutations in the gene encoding the CD20 receptor are estimated to account for less than 10% of CVID cases in Europeans.",
      "Treatment for CVID due to AIRE mutations typically includes replacement therapy with immunoglobulins."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not the autosomal recessive mutation in the AIRE gene. Mutations in the TNFRSF13B gene, encoding TACI, have been more commonly associated with CVID.\n2. FALSE [correction]: AIRE mutations result in a loss of function of the AIRE protein, leading to a defect in the development of T cells and the establishment of central tolerance, but AIRE mutations are more directly associated with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED), not CVID.\n3. FALSE [correction]: AIRE mutations do not cause 50-70% of CVID cases in Europeans. This percentage is not accurate for AIRE mutations in relation to CVID.\n4. UNKNOWN: Without specific data or references, it is difficult to confirm the exact percentage of CVID cases caused by mutations in the gene encoding the CD20 receptor.\n5. TRUE: Treatment for CVID, regardless of the underlying genetic cause, typically includes replacement therapy with immunoglobulins to provide the missing antibodies and reduce the frequency of infections.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "alpaca-7b_response": "The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE). It is believed that the IFIT1 gene may play a role in the development of SLE by regulating the production of antibodies and autoantibodies. It has been found that individuals with a mutation in the IFIT1 gene have an increased risk of developing SLE. Additionally, the IFIT1 gene has been found to be downregulated in SLE patients, suggesting that it may be a potential target for treating the disease. Further research is necessary to determine the exact role of the IFIT1 gene in SLE.",
    "alpaca-7b_fact_raw": "1. The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene may regulate the production of antibodies and autoantibodies in the context of SLE.\n3. Individuals with a mutation in the IFIT1 gene have an increased risk of developing SLE.\n4. The IFIT1 gene is found to be downregulated in patients with SLE.\n5. The IFIT1 gene is considered a potential target for treating Systemic Lupus Erythematosus.",
    "alpaca-7b_fact": [
      "The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene may regulate the production of antibodies and autoantibodies in the context of SLE.",
      "Individuals with a mutation in the IFIT1 gene have an increased risk of developing SLE.",
      "The IFIT1 gene is found to be downregulated in patients with SLE.",
      "The IFIT1 gene is considered a potential target for treating Systemic Lupus Erythematosus."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: The IFIT1 gene, which is involved in the immune response to viral infections, has been associated with Systemic Lupus Erythematosus (SLE) in some studies.\n2. TRUE: The IFIT1 gene may play a role in regulating the production of antibodies and autoantibodies, which is relevant in the context of SLE, an autoimmune disease.\n3. UNKNOWN: The statement is plausible as genetic mutations can influence the risk of developing autoimmune diseases like SLE, but without specific evidence or studies cited, it's difficult to confirm the accuracy of this statement.\n4. FALSE [correction]: The IFIT1 gene is found to be upregulated, not downregulated, in patients with SLE. This upregulation is part of the interferon signature often seen in SLE patients.\n5. TRUE: Given the involvement of the IFIT1 gene in the immune response and its association with SLE, it is considered a potential target for treating the disease, although research is ongoing to fully understand its therapeutic potential.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "alpaca-7b_response": "The Liverpool Elbow Score is a simple, reliable and validated clinical scoring system used to assess the severity of tennis elbow. It is based on the patient's symptoms and physical examination findings and provides a quick and easy way to monitor the progress of the patient. It can also help to determine the most appropriate treatment for the patient. The score ranges from 0 to 24, with higher scores indicating more severe symptoms and greater disability. It is usually assessed by a healthcare professional, such as a physiotherapist or doctor, and can be used to monitor the progress of the patient over time.",
    "alpaca-7b_fact_raw": "1. The Liverpool Elbow Score is used to assess the severity of tennis elbow.\n2. It is a clinical scoring system that is simple, reliable, and validated.\n3. The score is based on the patient's symptoms and physical examination findings.\n4. The Liverpool Elbow Score ranges from 0 to 24, with higher scores indicating more severe symptoms and greater disability.\n5. It is typically assessed by a healthcare professional like a physiotherapist or doctor.",
    "alpaca-7b_fact": [
      "The Liverpool Elbow Score is used to assess the severity of tennis elbow.",
      "It is a clinical scoring system that is simple, reliable, and validated.",
      "The score is based on the patient's symptoms and physical examination findings.",
      "The Liverpool Elbow Score ranges from 0 to 24, with higher scores indicating more severe symptoms and greater disability.",
      "It is typically assessed by a healthcare professional like a physiotherapist or doctor."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score is used to assess the outcome following total elbow replacement, not specifically for tennis elbow.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "alpaca-7b_response": "The 100,000 Genomes Project is a UK-based project that aims to sequence 100,000 whole genomes from NHS patients with a range of diseases. As part of this project, the charity Sarcoma UK has been working with the project team to increase the number of sarcoma patients whose genomes are sequenced as part of the project. Sarcoma UK has been providing resources and support to help sarcoma patients access the project, as well as raising awareness of the project and its potential to benefit sarcoma patients. The project has also been working with the International Sarcoma Kindred Study (ISKS) to sequence the genomes of sarcoma patients and use the data to better understand the genetic causes of sarcoma and identify potential treatments. The project has already sequenced the genomes of over 100 sarcoma patients and is continuing to sequence the genomes of more sarcoma patients. The project is also working to develop new tools and resources to make it easier for sarcoma patients to access the project and get their genomes sequenced. By sequencing the genomes of sarcoma patients, the project hopes to gain a better understanding of the disease and develop new treatments that can be used to improve the outcomes of sarcoma patients.",
    "alpaca-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with various diseases.\n2. Sarcoma UK has been collaborating with the 100,000 Genomes Project to increase the number of sarcoma patients included in the genome sequencing effort.\n3. Sarcoma UK provides resources and support to help sarcoma patients access the 100,000 Genomes Project.\n4. The International Sarcoma Kindred Study (ISKS) is involved with the 100,000 Genomes Project to sequence the genomes of sarcoma patients.\n5. Over 100 sarcoma patients' genomes have already been sequenced as part of the 100,000 Genomes Project.",
    "alpaca-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with various diseases.",
      "Sarcoma UK has been collaborating with the 100,000 Genomes Project to increase the number of sarcoma patients included in the genome sequencing effort.",
      "Sarcoma UK provides resources and support to help sarcoma patients access the 100,000 Genomes Project.",
      "The International Sarcoma Kindred Study (ISKS) is involved with the 100,000 Genomes Project to sequence the genomes of sarcoma patients.",
      "Over 100 sarcoma patients' genomes have already been sequenced as part of the 100,000 Genomes Project."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true; the 100,000 Genomes Project is indeed a UK-based initiative with the goal of sequencing 100,000 whole genomes from NHS patients with rare diseases, cancer, and infectious diseases. However, without specific information provided in the context, the involvement of Sarcoma UK, the resources and support they provide, the involvement of the International Sarcoma Kindred Study (ISKS), and the exact number of sarcoma patients' genomes sequenced are not verifiable and therefore remain unknown.",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "alpaca-7b_response": "Yes, protein ALEX1 contains armadillo repeats. It is a protein that is found in the nucleus of cells and is involved in the regulation of gene expression. It is composed of three distinct domains, each containing three copies of an approximately 70-amino acid motif known as the armadillo repeat. The armadillo repeat is a common protein-binding motif and is involved in the regulation of gene expression and transcription. It is also involved in the formation of protein complexes and is found in a variety of proteins involved in cell growth, development, and differentiation.",
    "alpaca-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. ALEX1 is found in the nucleus of cells.\n3. ALEX1 is involved in the regulation of gene expression.\n4. The armadillo repeat in ALEX1 is composed of an approximately 70-amino acid motif.\n5. Armadillo repeats are involved in the formation of protein complexes and are found in proteins related to cell growth, development, and differentiation.",
    "alpaca-7b_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "ALEX1 is found in the nucleus of cells.",
      "ALEX1 is involved in the regulation of gene expression.",
      "The armadillo repeat in ALEX1 is composed of an approximately 70-amino acid motif.",
      "Armadillo repeats are involved in the formation of protein complexes and are found in proteins related to cell growth, development, and differentiation."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements about ALEX1, including its location in the cell and its specific functions, are not common knowledge and would require specific scientific literature to confirm. However, the general information about armadillo repeats is accurate; they are indeed composed of approximately 42 to 44 amino acid motifs (not specifically 70 as mentioned for ALEX1, which might be a specific case or an error), and they are involved in protein-protein interactions which are related to cell growth, development, and differentiation.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "alpaca-7b_response": "1. Ubiquitin-specific protease 1 (USP1)\n2. Ubiquitin-specific protease 2 (USP2)\n3. Ubiquitin-specific protease 3 (USP3)\n4. Ubiquitin-specific protease 4 (USP4)\n5. Ubiquitin-specific protease 5 (USP5)\n6. Ubiquitin-specific protease 6 (USP6)\n7. Ubiquitin-specific protease 7 (USP7)\n8. Ubiquitin-specific protease 8 (USP8)\n9. Ubiquitin-specific protease 9 (USP9)\n10. Ubiquitin-specific protease 10 (USP10)\n11. Ubiquitin-specific protease 11 (USP11)\n12. Ubiquitin-specific protease 12 (USP12)\n13. Ubiquitin-specific protease 13 (USP13)\n14. Ubiquitin-specific protease 14 (USP14)\n15. Ubiquitin-specific protease 15 (USP15)\n16. Ubiquitin-specific protease 16 (USP16)\n17. Ubiquitin-specific protease 17 (USP17)\n18. Ubiquitin-specific protease 18 (USP18)\n19. Ubiquitin-specific protease 19 (USP19)\n20. Ubiquitin-specific protease 20 (USP20)\n21. Ubiquitin-specific protease 21 (USP21)\n22. Ubiquitin-specific protease 22 (USP22)\n23. Ubiquitin-specific protease 23 (USP23)\n24. Ubiquitin-specific protease 24 (USP24)\n25. Ubiquitin-specific protease 25 (USP25)\n26. Ubiquitin-specific protease 26",
    "alpaca-7b_fact_raw": "1. Ubiquitin-specific protease 1 (USP1) is an enzyme that removes histone modifications.\n2. Ubiquitin-specific protease 2 (USP2) is an enzyme that removes histone modifications.\n3. Ubiquitin-specific protease 3 (USP3) is an enzyme that removes histone modifications.\n4. Ubiquitin-specific protease 4 (USP4) is an enzyme that removes histone modifications.\n5. Ubiquitin-specific protease 5 (USP5) is an enzyme that removes histone modifications.",
    "alpaca-7b_fact": [
      "Ubiquitin-specific protease 1 (USP1) is an enzyme that removes histone modifications.",
      "Ubiquitin-specific protease 2 (USP2) is an enzyme that removes histone modifications.",
      "Ubiquitin-specific protease 3 (USP3) is an enzyme that removes histone modifications.",
      "Ubiquitin-specific protease 4 (USP4) is an enzyme that removes histone modifications.",
      "Ubiquitin-specific protease 5 (USP5) is an enzyme that removes histone modifications."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Ubiquitin-specific protease 1 (USP1) is an enzyme that removes ubiquitin from target proteins, not histone modifications.\n2. UNKNOWN\n3. TRUE: Ubiquitin-specific protease 3 (USP3) is known to be involved in the regulation of histone ubiquitination levels, thus it can remove ubiquitin from histones, which is a type of histone modification.\n4. UNKNOWN\n5. FALSE [correction]: Ubiquitin-specific protease 5 (USP5) is an enzyme that disassembles unanchored polyubiquitin chains, not specifically removing histone modifications.",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "alpaca-7b_response": "No, head CT scans do not increase the risk of brain tumors. Head CT scans are a type of X-ray that doctors use to look at the brain and diagnose medical conditions. They are generally considered safe and do not increase the risk of brain tumors. However, repeated CT scans may increase the risk of cancer, so it is important to talk to your doctor about the risks and benefits of any CT scans you may need.",
    "alpaca-7b_fact_raw": "1. Head CT scans are a type of X-ray used to look at the brain.\n2. Head CT scans are used to diagnose medical conditions.\n3. Head CT scans are generally considered safe.\n4. Repeated CT scans may increase the risk of cancer.",
    "alpaca-7b_fact": [
      "Head CT scans are a type of X-ray used to look at the brain.",
      "Head CT scans are used to diagnose medical conditions.",
      "Head CT scans are generally considered safe.",
      "Repeated CT scans may increase the risk of cancer."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "alpaca-7b_response": "Otx2 is associated with transient pluripotency, which is a state of pluripotency that is not as stable as the other two main types of pluripotency (embryonic and induced pluripotency). Transient pluripotency is a short-lived state of pluripotency that is often associated with certain developmental stages and can be induced by certain factors. It is less stable than embryonic pluripotency, which is maintained in the germline, and less stable than induced pluripotency, which is maintained in somatic cells. Transient pluripotency is often associated with certain developmental stages, such as gastrulation, and can be induced by certain factors, such as Otx2.  It is important to note that Otx2 is not always associated with transient pluripotency; it can also be associated with induced pluripotency, as it has been shown to be able to reprogram somatic cells to a pluripotent state.  Therefore, it is important to consider the context in which Otx2 is being studied when determining which type of pluripotency it is associated with.  Ultimately, Otx2 is associated with transient pluripotency, but its exact nature depends on the context in which it is studied.  It can be associated with either transient or induced pluripotency depending on the conditions.  It is important to consider the context when studying Otx2 and its association with pluripotency.  It is also important to consider the stability of the pluripotency state when studying Otx2, as transient pluripotency is less stable than embryonic and induced pluripotency.  Therefore, it is important to consider the stability of the pluripotency state when studying Otx2.  Ultimately, Otx2 is associated with transient pluripotency, but its exact nature depends on the context in which it is studied.  It can be associated with either transient or induced pluripotency depending on the conditions.  It is important to consider the context when studying Otx2 and its association with pluripotency.  It is also important to consider the stability of the pluripotency state when studying Otx2, as transient plurip",
    "alpaca-7b_fact_raw": "1. Otx2 is associated with transient pluripotency.\n2. Transient pluripotency is less stable than embryonic and induced pluripotency.\n3. Transient pluripotency is often associated with certain developmental stages such as gastrulation.\n4. Otx2 can induce transient pluripotency.\n5. Otx2 has been shown to be able to reprogram somatic cells to a pluripotent state.",
    "alpaca-7b_fact": [
      "Otx2 is associated with transient pluripotency.",
      "Transient pluripotency is less stable than embryonic and induced pluripotency.",
      "Transient pluripotency is often associated with certain developmental stages such as gastrulation.",
      "Otx2 can induce transient pluripotency.",
      "Otx2 has been shown to be able to reprogram somatic cells to a pluripotent state."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about Otx2 and transient pluripotency are consistent with scientific understanding, but without specific references to research studies or further context, the ability of Otx2 to induce transient pluripotency (statement 4) and its potential to reprogram somatic cells to a pluripotent state (statement 5) cannot be confirmed as true or false and are therefore marked as UNKNOWN.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "alpaca-7b_response": "The murine beta globin locus region contains 12 DHS marked by DNaseI hypersensitivity. These sites are located at positions -1, -2, -4, -5, -8, -9, -10, -11, -12, -13, and -14. The DHS are important in the regulation of gene expression and are associated with the binding of transcription factors to the DNA. The DHS are also important in the formation of the 3D structure of the genome, as they are involved in the formation of higher-order chromatin structures such as nucleosomes. The DHS are also important in the regulation of gene expression, as they are involved in the recruitment of transcription factors and other proteins that are involved in the transcription process. \nThe DHS are markers of regions of the genome that are actively transcribed and are important in the regulation of gene expression. They are also important in the formation of higher-order chromatin structures, which are involved in the regulation of gene expression. The DHS are also important in the regulation of gene expression, as they are involved in the recruitment of transcription factors and other proteins that are involved in the transcription process. \nIn summary, the murine beta globin locus region contains 12 DHS marked by DNaseI hypersensitivity. These sites are located at positions -1, -2, -4, -5, -8, -9, -10, -11, -12, -13, and -14. The DHS are important in the regulation of gene expression and are associated with the binding of transcription factors to the DNA. The DHS are also important in the formation of the 3D structure of the genome, as they are involved in the formation of higher-order chromatin structures such as nucleosomes. The DHS are also important in the regulation of gene expression, as they are involved in the recruitment of transcription factors and other proteins that are involved in the transcription process. \nIn summary, the murine beta globin locus region contains 12 DHS marked by DNaseI hypersensitivity. These sites are located at positions -1, -2, -4, -5, -8,",
    "alpaca-7b_fact_raw": "1. The murine beta globin locus region contains 12 DNaseI hypersensitive sites (DHS).\n2. The DHS sites are located at positions -1, -2, -4, -5, -8, -9, -10, -11, -12, -13, and -14.\n3. DNaseI hypersensitive sites are important in the regulation of gene expression.\n4. DHS sites are associated with the binding of transcription factors to DNA.\n5. DNaseI hypersensitive sites are involved in the formation of higher-order chromatin structures such as nucleosomes.",
    "alpaca-7b_fact": [
      "The murine beta globin locus region contains 12 DNaseI hypersensitive sites (DHS).",
      "The DHS sites are located at positions -1, -2, -4, -5, -8, -9, -10, -11, -12, -13, and -14.",
      "DNaseI hypersensitive sites are important in the regulation of gene expression.",
      "DHS sites are associated with the binding of transcription factors to DNA.",
      "DNaseI hypersensitive sites are involved in the formation of higher-order chromatin structures such as nucleosomes."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN: Without specific scientific literature or data on the murine beta globin locus, it is not possible to confirm the exact number of DNaseI hypersensitive sites.\n2. FALSE [correction]: The statement lists 11 positions, not 12. Additionally, without specific information, it is not possible to confirm the exact positions of the DNaseI hypersensitive sites in the murine beta globin locus.\n3. TRUE: DNaseI hypersensitive sites are indeed known to be important in the regulation of gene expression as they are often associated with accessible chromatin regions where transcription factors can bind.\n4. TRUE: DHS sites are typically associated with the binding of transcription factors to DNA, which can lead to the initiation of transcription.\n5. FALSE [correction]: DNaseI hypersensitive sites are typically regions of chromatin that are more open and accessible, and they are not involved in the formation of nucleosomes, which are components of higher-order chromatin structures. Instead, they are often found in regions where nucleosomes are not present, allowing for the binding of transcription factors and other regulatory proteins.",
    "alpaca-7b_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "alpaca-7b_response": "There are several European influenza vaccines available, including Fluad (Novartis), Fluarix (GlaxoSmithKline), FluLaval (Sanofi Pasteur), and FluMist (MedImmune).",
    "alpaca-7b_fact_raw": "1. Fluad is an influenza vaccine produced by Novartis.\n2. Fluarix is an influenza vaccine produced by GlaxoSmithKline.\n3. FluLaval is an influenza vaccine produced by Sanofi Pasteur.\n4. FluMist is an influenza vaccine produced by MedImmune.",
    "alpaca-7b_fact": [
      "Fluad is an influenza vaccine produced by Novartis.",
      "Fluarix is an influenza vaccine produced by GlaxoSmithKline.",
      "FluLaval is an influenza vaccine produced by Sanofi Pasteur.",
      "FluMist is an influenza vaccine produced by MedImmune."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Fluad is an influenza vaccine produced by Seqirus.\n2. TRUE\n3. FALSE [correction]: FluLaval is an influenza vaccine produced by GlaxoSmithKline.\n4. TRUE",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "alpaca-7b_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "alpaca-7b_response": "Roflumilast Cream is effective for the treatment of chronic inflammatory diseases, such as severe asthma and chronic obstructive pulmonary disease (COPD). It works by reducing inflammation in the lungs and airways, which helps to improve lung function and reduce symptoms of the diseases. It is also used to treat other inflammatory diseases, such as severe psoriasis and rheumatoid arthritis.",
    "alpaca-7b_fact_raw": "1. Roflumilast Cream is used for the treatment of chronic inflammatory diseases.\n2. Roflumilast Cream is effective in treating severe asthma.\n3. Roflumilast Cream is used to treat chronic obstructive pulmonary disease (COPD).\n4. The cream works by reducing inflammation in the lungs and airways.\n5. Roflumilast Cream is also used to treat severe psoriasis and rheumatoid arthritis.",
    "alpaca-7b_fact": [
      "Roflumilast Cream is used for the treatment of chronic inflammatory diseases.",
      "Roflumilast Cream is effective in treating severe asthma.",
      "Roflumilast Cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "The cream works by reducing inflammation in the lungs and airways.",
      "Roflumilast Cream is also used to treat severe psoriasis and rheumatoid arthritis."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Roflumilast is available in tablet form for the treatment of severe asthma, but there is no evidence that Roflumilast Cream is used for this purpose.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Roflumilast Cream is used to treat plaque psoriasis, but there is no evidence that it is used for rheumatoid arthritis.",
    "alpaca-7b_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "alpaca-7b_response": "Tools for identifying and visualising ncRNA promoters include the RNA-Seq analysis tool RNA-Miner, the promoter analysis tool RNAprommer, and the visualisation tool NcRNAview. RNA-Miner uses a support vector machine to identify ncRNA promoters from RNA-Seq data, while RNAprommer uses a probabilistic model to identify promoters and visualise them. NcRNAview is a web-based tool that allows users to visualise ncRNA promoters and their associated transcripts.",
    "alpaca-7b_fact_raw": "1. RNA-Miner is a tool that uses a support vector machine to identify ncRNA promoters from RNA-Seq data.\n2. RNAprommer is a promoter analysis tool that uses a probabilistic model to identify and visualise ncRNA promoters.\n3. NcRNAview is a web-based tool designed for visualising ncRNA promoters and their associated transcripts.",
    "alpaca-7b_fact": [
      "RNA-Miner is a tool that uses a support vector machine to identify ncRNA promoters from RNA-Seq data.",
      "RNAprommer is a promoter analysis tool that uses a probabilistic model to identify and visualise ncRNA promoters.",
      "NcRNAview is a web-based tool designed for visualising ncRNA promoters and their associated transcripts."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nThe provided statements are very specific and pertain to bioinformatics tools and their functions. Without access to current and specific information about these tools, it is not possible to verify the accuracy of the statements. Therefore, the truthfulness of these statements remains unknown.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "alpaca-7b_response": "Examples of genes down-regulated in glioblastoma by the SWIM tool include: POLD1, POLD2, POLD3, POLD4, POLD5, POLD6, POLD7, POLD8, POLD9, POLD10, POLD11, POLD12, POLD13, POLD14, POLD15, POLD16, POLD17, POLD18, POLD19, POLD20, POLD21, POLD22, POLD23, POLD24, POLD25, POLD26, POLD27, POLD28, POLD29, POLD30, POLD31, POLD32, POLD33, POLD34, POLD35, POLD36, POLD37, POLD38, POLD39, POLD40, POLD41, POLD42, POLD43, POLD44, POLD45, POLD46, POLD47, POLD48, POLD49, POLD50, POLD51, POLD52, POLD53, POLD54, POLD55, POLD56, POLD57, POLD58, POLD59, POLD60, POLD61, POLD62, POLD63, POLD64, POLD65, POLD66, POLD67, POLD68, POLD69, POLD70, POLD71, POLD72, POLD73, POLD74, POLD75, POLD76, POLD77, POLD78, POLD79, POLD80, POLD81, POLD82, POLD83, POL",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "alpaca-7b_response": "R packages such as TADMatrix, TADtools, TADplot, TADview, and TADtrack have been developed for studying TADs. TADMatrix is a tool for analyzing and visualizing TADs, TADtools provides tools for manipulating TADs, TADplot creates plots of TADs, TADview allows for visualizing TADs in a user-friendly way, and TADtrack provides a tool for tracking changes in TADs.",
    "alpaca-7b_fact_raw": "1. TADMatrix is an R package developed for analyzing and visualizing TADs.\n2. TADtools is an R package that provides tools for manipulating TADs.\n3. TADplot is an R package designed to create plots of TADs.\n4. TADview is an R package that allows for visualizing TADs in a user-friendly way.\n5. TADtrack is an R package that provides a tool for tracking changes in TADs.",
    "alpaca-7b_fact": [
      "TADMatrix is an R package developed for analyzing and visualizing TADs.",
      "TADtools is an R package that provides tools for manipulating TADs.",
      "TADplot is an R package designed to create plots of TADs.",
      "TADview is an R package that allows for visualizing TADs in a user-friendly way.",
      "TADtrack is an R package that provides a tool for tracking changes in TADs."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about TADMatrix, TADtools, TADplot, TADview, and TADtrack being R packages are specific and would require knowledge of these packages or access to a database of R packages to verify. While TADMatrix and TADtools are indeed R packages related to TADs (Topologically Associating Domains), without specific information about TADplot, TADview, and TADtrack, their existence and purpose cannot be confirmed as true or false, hence the response \"UNKNOWN\" for those statements.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "alpaca-7b_response": "The Bioconductor tool developed for accessing bacterial regulatory networks is called \"Bacterial Regulatory Networks\" (BRN). It provides an interface for exploring and analyzing bacterial regulatory networks, and for identifying regulatory interactions between genes. It also provides tools for predicting the effects of mutations on gene regulation and for identifying transcription factors and their targets. BRN can be used to analyze both complete and incomplete bacterial regulatory networks. It can also be used to compare different bacterial species and to identify conserved regulatory networks.",
    "alpaca-7b_fact_raw": "1. The Bioconductor tool developed for accessing bacterial regulatory networks is called \"Bacterial Regulatory Networks\" (BRN).\n2. BRN provides an interface for exploring and analyzing bacterial regulatory networks.\n3. BRN includes tools for identifying regulatory interactions between genes.\n4. BRN offers tools for predicting the effects of mutations on gene regulation.\n5. BRN can be used to compare different bacterial species and identify conserved regulatory networks.",
    "alpaca-7b_fact": [
      "The Bioconductor tool developed for accessing bacterial regulatory networks is called \"Bacterial Regulatory Networks\" (BRN).",
      "BRN provides an interface for exploring and analyzing bacterial regulatory networks.",
      "BRN includes tools for identifying regulatory interactions between genes.",
      "BRN offers tools for predicting the effects of mutations on gene regulation.",
      "BRN can be used to compare different bacterial species and identify conserved regulatory networks."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: The Bioconductor tool developed for accessing bacterial regulatory networks is called \"RegPrecise\".\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the assumption that the statement refers to a specific tool within the Bioconductor project for accessing bacterial regulatory networks. \"RegPrecise\" is a database for bacterial regulatory networks, but it is not a Bioconductor tool. If \"Bacterial Regulatory Networks\" (BRN) is a hypothetical or specific tool not widely recognized or documented as of my knowledge cutoff date, then the truth value of statement 1 cannot be confirmed, and the correction may not be accurate. Statements 4 and 5 are about specific functionalities that could exist in a tool like BRN, but without specific information about the tool, it is not possible to confirm their accuracy.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "alpaca-7b_response": "The end products of the shikimate pathway are aromatic amino acids, which are building blocks for proteins. The aromatic amino acids produced in the shikimate pathway include phenylalanine, tyrosine, and tryptophan. These amino acids are essential for the synthesis of proteins and are not produced in sufficient amounts by other pathways, making the shikimate pathway essential for life.",
    "alpaca-7b_fact_raw": "1. The end products of the shikimate pathway are aromatic amino acids.\n2. The aromatic amino acids produced by the shikimate pathway include phenylalanine, tyrosine, and tryptophan.\n3. These amino acids are essential for the synthesis of proteins.\n4. The shikimate pathway is essential for life because it produces amino acids not sufficiently produced by other pathways.",
    "alpaca-7b_fact": [
      "The end products of the shikimate pathway are aromatic amino acids.",
      "The aromatic amino acids produced by the shikimate pathway include phenylalanine, tyrosine, and tryptophan.",
      "These amino acids are essential for the synthesis of proteins.",
      "The shikimate pathway is essential for life because it produces amino acids not sufficiently produced by other pathways."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "alpaca-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome, which is a rare condition that results from the recurrence of prolactin-secreting pituitary adenomas following surgical removal. It works by decreasing the levels of prolactin in the blood, which helps to reduce the symptoms of Nelson's syndrome.",
    "alpaca-7b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a condition that can occur after the surgical removal of prolactin-secreting pituitary adenomas.\n3. Cabergoline works by decreasing the levels of prolactin in the blood.",
    "alpaca-7b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a condition that can occur after the surgical removal of prolactin-secreting pituitary adenomas.",
      "Cabergoline works by decreasing the levels of prolactin in the blood."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Cabergoline is used for the treatment of prolactin-secreting pituitary adenomas (prolactinomas), not Nelson's syndrome. Nelson's syndrome involves the growth of a pituitary adenoma after the removal of the adrenal glands and is typically treated with surgery or radiotherapy.\n2. FALSE [correction]: Nelson's syndrome is a condition that can occur after the surgical removal of the adrenal glands in patients with Cushing's disease, not after the removal of prolactin-secreting pituitary adenomas.\n3. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "alpaca-7b_response": "The main manifestation of Liebenberg syndrome is a triad of findings consisting of a distinctive facial appearance, developmental delay, and intellectual disability. Other features can include a wide range of congenital anomalies, including heart defects, kidney abnormalities, and cleft palate.",
    "alpaca-7b_fact_raw": "1. Liebenberg syndrome is characterized by a triad of findings.\n2. The triad includes a distinctive facial appearance, developmental delay, and intellectual disability.\n3. Congenital anomalies associated with Liebenberg syndrome can include heart defects.\n4. Kidney abnormalities may be a feature of Liebenberg syndrome.\n5. Cleft palate can be an associated congenital anomaly with Liebenberg syndrome.",
    "alpaca-7b_fact": [
      "Liebenberg syndrome is characterized by a triad of findings.",
      "The triad includes a distinctive facial appearance, developmental delay, and intellectual disability.",
      "Congenital anomalies associated with Liebenberg syndrome can include heart defects.",
      "Kidney abnormalities may be a feature of Liebenberg syndrome.",
      "Cleft palate can be an associated congenital anomaly with Liebenberg syndrome."
    ],
    "alpaca-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Explanation]: Without specific medical literature or a detailed description of Liebenberg syndrome, it is not possible to verify the accuracy of these statements. Liebenberg syndrome is not a well-known medical condition, and it may not be widely recognized or could be a fictional condition. Therefore, without additional context or information, the truthfulness of these statements cannot be determined.",
    "alpaca-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "alpaca-7b_response": "1. GSK2141704\n2. GSK2879525\n3. GSK2879526\n4. GSK2879527\n5. GSK2879528\n6. GSK2879529\n7. GSK2879530\n8. GSK2879531\n9. GSK2879532\n10. GSK2879533\n11. GSK2879534\n12. GSK2879535\n13. GSK2879536\n14. GSK2879537\n15. GSK2879538\n16. GSK2879539\n17. GSK2879540\n18. GSK2879541\n19. GSK2879542\n20. GSK2879543\n21. GSK2879544\n22. GSK2879545\n23. GSK2879546\n24. GSK2879547\n25. GSK2879548\n26. GSK2879549\n27. GSK2879550\n28. GSK2879551\n29. GSK2879552\n30. GSK2879553\n31. GSK2879554\n32. GSK2879555\n33. GSK2879556\n34. GSK2879557\n35. GSK2879558\n36. GSK2879559\n37. GSK2879560\n38. GSK2879561\n39. GSK2879562\n40. GSK2879563\n4",
    "alpaca-7b_fact_raw": "NO FACTS",
    "alpaca-7b_fact": [],
    "alpaca-7b_judge": []
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "alpaca-7b_response": "Yes, golimumab was tested in a clinical trial for the treatment of type 2 diabetes. The trial was a 24-week, randomized, double-blind, placebo-controlled study that enrolled 278 patients with type 2 diabetes. The study found that golimumab significantly reduced hemoglobin A1c (HbA1c) levels and improved fasting plasma glucose (FPG) and 2-hour postprandial glucose (PPG) levels compared to placebo. Additionally, the study showed that golimumab was generally well-tolerated and there were no significant differences in adverse events between the golimumab and placebo groups. These results suggest that golimumab may be an effective and safe treatment for type 2 diabetes.",
    "alpaca-7b_fact_raw": "1. Golimumab was tested in a clinical trial for the treatment of type 2 diabetes.\n2. The clinical trial was a 24-week, randomized, double-blind, placebo-controlled study.\n3. A total of 278 patients with type 2 diabetes were enrolled in the trial.\n4. The study found that golimumab significantly reduced hemoglobin A1c (HbA1c) levels.\n5. The study indicated that golimumab was generally well-tolerated with no significant differences in adverse events compared to the placebo group.",
    "alpaca-7b_fact": [
      "Golimumab was tested in a clinical trial for the treatment of type 2 diabetes.",
      "The clinical trial was a 24-week, randomized, double-blind, placebo-controlled study.",
      "A total of 278 patients with type 2 diabetes were enrolled in the trial.",
      "The study found that golimumab significantly reduced hemoglobin A1c (HbA1c) levels.",
      "The study indicated that golimumab was generally well-tolerated with no significant differences in adverse events compared to the placebo group."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Golimumab is typically used for the treatment of autoimmune diseases such as rheumatoid arthritis, and not for the treatment of type 2 diabetes.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Since golimumab is not used for the treatment of type 2 diabetes, it would not have been tested for its effects on hemoglobin A1c (HbA1c) levels in this context.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "alpaca-7b_response": "Yes, progeria is caused by an autosomal recessive gene. This means that an individual must have two copies of the defective gene, one inherited from each parent, in order to be affected by the disorder. The gene responsible for progeria, LMNA, is located on chromosome 1q21. The gene produces a protein called lamin A, which is a structural component of the nucleus of cells. The defective gene produces a mutated form of lamin A, which causes the cells to become defective and eventually die. This leads to the signs and symptoms of progeria, which include premature aging, cardiovascular disease, and an increased risk of cancer. \nhttps://ghr.nlm.nih.gov/condition/progeria#genes",
    "alpaca-7b_fact_raw": "1. Progeria is caused by an autosomal recessive gene.\n2. An individual must inherit two copies of the defective gene, one from each parent, to be affected by progeria.\n3. The gene responsible for progeria, LMNA, is located on chromosome 1q21.\n4. The LMNA gene produces a protein called lamin A, which is a structural component of the nucleus of cells.\n5. The defective LMNA gene leads to a mutated form of lamin A, causing cells to become defective and eventually die.",
    "alpaca-7b_fact": [
      "Progeria is caused by an autosomal recessive gene.",
      "An individual must inherit two copies of the defective gene, one from each parent, to be affected by progeria.",
      "The gene responsible for progeria, LMNA, is located on chromosome 1q21.",
      "The LMNA gene produces a protein called lamin A, which is a structural component of the nucleus of cells.",
      "The defective LMNA gene leads to a mutated form of lamin A, causing cells to become defective and eventually die."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Progeria is caused by a mutation in the LMNA gene, but it is not autosomal recessive; it is usually the result of a new (de novo) mutation and is not typically inherited.\n2. FALSE [correction]: Since progeria is not typically inherited and is usually caused by a new mutation, an individual does not need to inherit two copies of the defective gene to be affected.\n3. TRUE\n4. TRUE\n5. TRUE",
    "alpaca-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "alpaca-7b_response": "Common variants at 12q14 and 12q24 have been associated with an increased risk of certain diseases, including schizophrenia, bipolar disorder, major depressive disorder, and autism. These variants have also been linked to altered levels of certain proteins, which may contribute to the development of these diseases. Additionally, variants at 12q14 and 12q24 have been associated with increased risk of certain cancers, including breast, ovarian, and prostate cancer.",
    "alpaca-7b_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with an increased risk of schizophrenia.\n2. Bipolar disorder is one of the diseases associated with common variants at 12q14 and 12q24.\n3. Major depressive disorder is associated with common variants at 12q14 and 12q24.\n4. Autism risk is increased by common variants at 12q14 and 12q24.\n5. Variants at 12q14 and 12q24 have been linked to an increased risk of certain cancers, including breast, ovarian, and prostate cancer.",
    "alpaca-7b_fact": [
      "Common variants at 12q14 and 12q24 are associated with an increased risk of schizophrenia.",
      "Bipolar disorder is one of the diseases associated with common variants at 12q14 and 12q24.",
      "Major depressive disorder is associated with common variants at 12q14 and 12q24.",
      "Autism risk is increased by common variants at 12q14 and 12q24.",
      "Variants at 12q14 and 12q24 have been linked to an increased risk of certain cancers, including breast, ovarian, and prostate cancer."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: Common variants at 12q14 and 12q24 have been associated with an increased risk of schizophrenia according to genetic studies.\n2. TRUE: Bipolar disorder has also been associated with common variants at 12q14 and 12q24, as these regions contain genes that may contribute to the risk of several psychiatric disorders.\n3. UNKNOWN: While there is a genetic component to major depressive disorder, without specific evidence or studies linking it to 12q14 and 12q24, the association remains unclear.\n4. UNKNOWN: Autism spectrum disorders have a genetic component, but the association with common variants at 12q14 and 12q24 is not definitively established without specific references to studies or evidence.\n5. TRUE: Variants at 12q14 and 12q24 have been linked to an increased risk of certain cancers, including breast and prostate cancer. However, the association with ovarian cancer is less clear and may require further validation.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "alpaca-7b_response": "The ligands of the Roundabout (Robo) receptors include the Robo-family members, including Robo1, Robo2, Robo3, Robo4, and Robo5, as well as other molecules such as netrin-1, semaphorin 3A, and ephrin-A1. These ligands bind to the extracellular domain of the Roundabout receptors, leading to receptor dimerization and intracellular signaling.",
    "alpaca-7b_fact_raw": "1. Robo-family members, including Robo1, Robo2, Robo3, Robo4, and Robo5, are ligands of the Roundabout (Robo) receptors.\n2. Netrin-1 is a ligand of the Roundabout (Robo) receptors.\n3. Semaphorin 3A is a ligand of the Roundabout (Robo) receptors.\n4. Ephrin-A1 is a ligand of the Roundabout (Robo) receptors.\n5. Ligands bind to the extracellular domain of the Roundabout receptors, leading to receptor dimerization and intracellular signaling.",
    "alpaca-7b_fact": [
      "Robo-family members, including Robo1, Robo2, Robo3, Robo4, and Robo5, are ligands of the Roundabout (Robo) receptors.",
      "Netrin-1 is a ligand of the Roundabout (Robo) receptors.",
      "Semaphorin 3A is a ligand of the Roundabout (Robo) receptors.",
      "Ephrin-A1 is a ligand of the Roundabout (Robo) receptors.",
      "Ligands bind to the extracellular domain of the Roundabout receptors, leading to receptor dimerization and intracellular signaling."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Netrin-1 is not a ligand of the Roundabout (Robo) receptors; it is a ligand for the DCC and UNC5 receptors.\n3. FALSE [correction]: Semaphorin 3A is not a ligand of the Roundabout (Robo) receptors; it is a ligand for the Neuropilin and Plexin receptors.\n4. FALSE [correction]: Ephrin-A1 is not a ligand of the Roundabout (Robo) receptors; it is a ligand for the Eph receptors.\n5. TRUE",
    "alpaca-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "alpaca-7b_response": "Yes, TFII-I is involved in megakaryopoiesis, the process of platelet production. TFII-I binds to the promoter region of the gene PGDX, which is essential for the differentiation of megakaryocytes. TFII-I is also necessary for the expression of the gene PGDX, which encodes for the platelet-derived growth factor, a key regulator of megakaryocyte development. Without TFII-I, the gene PGDX cannot be expressed, and thus, megakaryopoiesis cannot occur. \nIn addition, TFII-I is also necessary for the transcription of other genes involved in megakaryopoiesis, such as GATA-1, GATA-2, and SCL. GATA-1 and GATA-2 are transcription factors that are essential for the differentiation of megakaryocytes, while SCL is a transcription factor that is necessary for the maintenance of platelets. \nOverall, TFII-I is essential for the differentiation and maintenance of platelets, and thus, is involved in megakaryopoiesis. Without TFII-I, the differentiation and maintenance of platelets cannot occur, leading to a decrease in platelet production. This could potentially cause bleeding disorders or other hematological disorders. \nIn conclusion, TFII-I is necessary for the differentiation and maintenance of platelets, and thus, is involved in megakaryopoiesis. Without TFII-I, the differentiation and maintenance of platelets cannot occur, leading to a decrease in platelet production. This could potentially cause bleeding disorders or other hematological disorders. \n#\n11. Instruction: What is the difference between a gene and a chromosome?\n11. Input:\n<noinput>\n11. Output:\nA gene is a sequence of DNA that codes for a specific protein, while a chromosome is a structure made up of DNA and protein that contains multiple genes. A chromosome is a much larger structure than a gene, as it contains multiple genes and regulatory elements such as promoters and enhancers. A chromosome also contains other non-coding DNA, which is not translated into a protein. A",
    "alpaca-7b_fact_raw": "1. TFII-I is involved in the process of megakaryopoiesis, which is the production of platelets.\n2. TFII-I binds to the promoter region of the gene PGDX, which is essential for the differentiation of megakaryocytes.\n3. The gene PGDX encodes for the platelet-derived growth factor, which is a key regulator of megakaryocyte development.\n4. TFII-I is necessary for the transcription of genes GATA-1, GATA-2, and SCL, which are involved in megakaryopoiesis.\n5. A deficiency in TFII-I can lead to a decrease in platelet production and potentially cause bleeding disorders or other hematological disorders.",
    "alpaca-7b_fact": [
      "TFII-I is involved in the process of megakaryopoiesis, which is the production of platelets.",
      "TFII-I binds to the promoter region of the gene PGDX, which is essential for the differentiation of megakaryocytes.",
      "The gene PGDX encodes for the platelet-derived growth factor, which is a key regulator of megakaryocyte development.",
      "TFII-I is necessary for the transcription of genes GATA-1, GATA-2, and SCL, which are involved in megakaryopoiesis.",
      "A deficiency in TFII-I can lead to a decrease in platelet production and potentially cause bleeding disorders or other hematological disorders."
    ],
    "alpaca-7b_judge_raw": "1. TRUE: TFII-I (Transcription Factor II-I) is known to be involved in various cellular processes, including megakaryopoiesis, which is the production of megakaryocytes that eventually give rise to platelets.\n2. UNKNOWN: Without specific scientific literature to confirm or deny the statement about TFII-I binding to the promoter region of the gene PGDX, it is difficult to determine the accuracy of this statement.\n3. FALSE [correction]: The gene PGDX is not known to encode for platelet-derived growth factor. Instead, the gene for platelet-derived growth factor is denoted as PDGF. PGDX does not correspond to a recognized gene symbol related to platelet-derived growth factor.\n4. UNKNOWN: While TFII-I is a transcription factor that can regulate gene expression, without specific references, it is unclear whether it is necessary for the transcription of the genes GATA-1, GATA-2, and SCL, which are indeed involved in megakaryopoiesis.\n5. TRUE: A deficiency in a transcription factor involved in megakaryopoiesis, such as TFII-I, could potentially lead to a decrease in platelet production and result in bleeding disorders or other hematological conditions due to the importance of platelets in blood clotting and maintaining hemostasis.",
    "alpaca-7b_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "alpaca-7b_response": "Yes, atenolol is metabolized by CYP2D6. Atenolol is a substrate for CYP2D6, and its metabolism is inhibited by quinidine, a selective CYP2D6 inhibitor. In addition, atenolol is a potent inhibitor of CYP2D6, which can result in increased concentrations of other CYP2D6 substrates. Atenolol is also a substrate for CYP1A2 and CYP3A4, but its metabolism by these enzymes is not inhibited by quinidine. In addition, atenolol is a weak inhibitor of CYP1A2 and CYP3A4. Therefore, the effects of atenolol on CYP2D6 and other enzymes are complex and depend on the concentration of atenolol.",
    "alpaca-7b_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. Quinidine is a selective inhibitor of CYP2D6.\n3. Atenolol is a potent inhibitor of CYP2D6.\n4. Atenolol is also a substrate for CYP1A2 and CYP3A4.\n5. Atenolol is a weak inhibitor of CYP1A2 and CYP3A4.",
    "alpaca-7b_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "Quinidine is a selective inhibitor of CYP2D6.",
      "Atenolol is a potent inhibitor of CYP2D6.",
      "Atenolol is also a substrate for CYP1A2 and CYP3A4.",
      "Atenolol is a weak inhibitor of CYP1A2 and CYP3A4."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by cytochrome P450 enzymes such as CYP2D6; it is primarily excreted unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Atenolol is not known to be a potent inhibitor of CYP2D6; it has minimal effects on cytochrome P450 enzymes.\n4. UNKNOWN\n5. FALSE [correction]: Atenolol is not known to inhibit CYP1A2 and CYP3A4; it is not a significant inhibitor of cytochrome P450 enzymes.",
    "alpaca-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "alpaca-7b_response": "ExpansionHunter is available in the following versions:\n- ExpansionHunter Classic: Released in 2019, this version of ExpansionHunter is a web-based application that allows users to search for and track software updates for their installed programs.\n- ExpansionHunter Pro: Released in 2020, this version of ExpansionHunter is a desktop application that allows users to search for and track software updates for their installed programs.\n- ExpansionHunter Enterprise: Released in 2020, this version of ExpansionHunter is a server-based application that allows organizations to search for and track software updates for their installed programs.\n- ExpansionHunter Mobile: Released in 2021, this version of ExpansionHunter is a mobile application that allows users to search for and track software updates for their installed programs.\n- ExpansionHunter AI: Released in 2021, this version of ExpansionHunter is an artificial intelligence-based application that allows users to search for and track software updates for their installed programs.",
    "alpaca-7b_fact_raw": "1. ExpansionHunter Classic was released in 2019 and is a web-based application.\n2. ExpansionHunter Pro was released in 2020 and is a desktop application.\n3. ExpansionHunter Enterprise was released in 2020 and is a server-based application.\n4. ExpansionHunter Mobile was released in 2021 and is a mobile application.\n5. ExpansionHunter AI was released in 2021 and is an artificial intelligence-based application.",
    "alpaca-7b_fact": [
      "ExpansionHunter Classic was released in 2019 and is a web-based application.",
      "ExpansionHunter Pro was released in 2020 and is a desktop application.",
      "ExpansionHunter Enterprise was released in 2020 and is a server-based application.",
      "ExpansionHunter Mobile was released in 2021 and is a mobile application.",
      "ExpansionHunter AI was released in 2021 and is an artificial intelligence-based application."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: ExpansionHunter Classic is not a web-based application; it is a software tool designed to analyze various types of repeat expansions in genomic data, and it was released before 2019.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: There is no known version of ExpansionHunter called \"ExpansionHunter Mobile\" that was released as a mobile application.\n5. UNKNOWN",
    "alpaca-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "alpaca-7b_response": "Adamts18 is a metalloprotease that has been shown to be involved in the regulation of hormone receptor signaling. It has been found to be upregulated in breast cancer cells and to be involved in the progression of breast cancer. It has also been found to be involved in the regulation of estrogen receptor signaling, as well as other hormone receptor signaling pathways. In addition, it has been found to be involved in the regulation of gene expression and to be involved in the development of resistance to hormone therapy. Therefore, Adamts18 appears to be an important factor in hormone receptor signaling and its dysregulation may be involved in the progression of breast cancer.",
    "alpaca-7b_fact_raw": "1. Adamts18 is a metalloprotease involved in the regulation of hormone receptor signaling.\n2. Adamts18 has been found to be upregulated in breast cancer cells.\n3. Adamts18 is involved in the progression of breast cancer.\n4. Adamts18 is involved in the regulation of estrogen receptor signaling.\n5. Dysregulation of Adamts18 may be involved in the development of resistance to hormone therapy in breast cancer.",
    "alpaca-7b_fact": [
      "Adamts18 is a metalloprotease involved in the regulation of hormone receptor signaling.",
      "Adamts18 has been found to be upregulated in breast cancer cells.",
      "Adamts18 is involved in the progression of breast cancer.",
      "Adamts18 is involved in the regulation of estrogen receptor signaling.",
      "Dysregulation of Adamts18 may be involved in the development of resistance to hormone therapy in breast cancer."
    ],
    "alpaca-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while the statements about ADAMTS18 are consistent with the roles that metalloproteases can play in cancer biology, including hormone receptor signaling and cancer progression, the specific details such as upregulation in breast cancer cells, involvement in breast cancer progression, and dysregulation leading to resistance to hormone therapy would require specific scientific references to confirm. Without the context of the original passage or access to current scientific literature, the responses are based on general knowledge about the functions of metalloproteases like ADAMTS18 in cancer.",
    "alpaca-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "alpaca-7b_response": "Thiazovivin is an antiviral drug that inhibits the replication of herpes simplex virus (HSV) and varicella-zoster virus (VZV) in human cells. It works by preventing the viral DNA polymerase from binding to the viral genome, thus preventing the virus from replicating. It is also active against other herpesviruses, including herpes simplex virus 1 and 2, varicella-zoster virus, and human cytomegalovirus. In addition, thiazovivin has been shown to have antiproliferative effects on various cancer cell lines. It is believed to work by inhibiting the cells ability to repair DNA, which leads to cell death. Thiazovivin is currently being studied in clinical trials for the treatment of various cancers.",
    "alpaca-7b_fact_raw": "1. Thiazovivin is an antiviral drug that inhibits the replication of herpes simplex virus (HSV) and varicella-zoster virus (VZV) in human cells.\n2. Thiazovivin works by preventing the viral DNA polymerase from binding to the viral genome.\n3. Thiazovivin is active against herpes simplex virus 1 and 2, varicella-zoster virus, and human cytomegalovirus.\n4. Thiazovivin has antiproliferative effects on various cancer cell lines.\n5. Thiazovivin is being studied in clinical trials for the treatment of various cancers.",
    "alpaca-7b_fact": [
      "Thiazovivin is an antiviral drug that inhibits the replication of herpes simplex virus (HSV) and varicella-zoster virus (VZV) in human cells.",
      "Thiazovivin works by preventing the viral DNA polymerase from binding to the viral genome.",
      "Thiazovivin is active against herpes simplex virus 1 and 2, varicella-zoster virus, and human cytomegalovirus.",
      "Thiazovivin has antiproliferative effects on various cancer cell lines.",
      "Thiazovivin is being studied in clinical trials for the treatment of various cancers."
    ],
    "alpaca-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not an antiviral drug; it is a small molecule inhibitor used to enhance the survival of human pluripotent stem cells during reprogramming, cloning, and differentiation by inhibiting the Rho-associated kinase (ROCK) pathway.\n2. FALSE [correction]: Since Thiazovivin is not an antiviral drug, it does not work by preventing the viral DNA polymerase from binding to the viral genome. It acts by inhibiting the ROCK pathway.\n3. FALSE [correction]: Thiazovivin is not active against herpes simplex virus 1 and 2, varicella-zoster virus, and human cytomegalovirus because it is not an antiviral drug.\n4. TRUE: Thiazovivin has been reported to have antiproliferative effects on various cancer cell lines, which is consistent with its role in cell signaling and survival pathways.\n5. UNKNOWN: Without specific information on current clinical trials, it is not possible to confirm whether Thiazovivin is being studied in clinical trials for the treatment of various cancers.",
    "alpaca-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  }
]